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ABSTRACT 
Successful delivery of pharmaceuticals orally requires a firm understanding of how dosage forms 
behave during their passage through the gastrointestinal (GI) tract. In this study, the GI transit time 
and absorption of amphotericin B (AmB) solid lipid nanoparticles (SLN) were investigated in rats, 
using paracetamol (PAR) and sulphapyridine (SP) as indirect markers. A high encapsulation 
efficiency of 91.2% was obtained for the AmB SLNs. The SLNs were exhaustively characterised 
with regards to size, zeta potential (ZP), viscosity, density, migration propensity within agarose 
gel, in vitro drug release and morphology, to ensure similar disposition in the GI tract after 
simultaneous oral administration. Freeze-drying did not significantly alter the size or ZP of the 
AmB SLNs, and in vitro drug release from fresh and freeze-dried SLNs were identical. AmB, PAR 
and sulphasalazine (SSZ) (the latter being the prodrug of SP) were individually formulated into 
SLNs using beeswax and theobroma oil as the lipid matrix. The z-averages, polydispersity indices 
and ZPs of the SLNs ranged from 206.5-224.8 nm, 0.161-0.218 and |61.90|-|71.90| mV, 
respectively. Gel electrophoresis studies indicated a similar movement propensity among the three 
SLNs as their migration distances were identical (22.2-22.4 mm) within agarose gel. Scanning 
electron and atomic force microscopy studies revealed that all three SLNs were spherical in 
morphology and with similar surface characteristics. The SLNs were assessed for changes in size 
and surface charge on exposure to simulated GI fluids using dynamic light scattering (DLS) and 
nanoparticle tracking analysis (NTA). On contact with the fluids, the particles had a slight increase 
in size due to ingress of the dissolution media. NTA results were found to be more beneficial than 
DLS as the latter was biased towards larger particles that were present possibly due to aggregation. 
After incubation in simulated gastric fluid followed by simulated intestinal fluid (mimicking 
gastric emptying), all the SLNs were found to be less than 350 nm in size and neutral in charge, 
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which are optimal attributes for intestinal absorption. Time-of-flight secondary ion mass 
spectroscopic (ToF-SIMS) analyses revealed minimal drug amounts on the surfaces of the particles 
indicating that drug location was in the core of the SLNs. A developed and validated high-
performance liquid chromatography (HPLC) method for simultaneous assay of the drugs in rat 
plasma using piroxicam as internal standard was found to be sensitive, accurate and precise, with 
drug recovery from plasma exceeding 92% in each case. A pilot GI transit study conducted in rats 
showed that the HPLC method was appropriate for the study. In the main study, the effects of food 
on the transit and absorption of the AmB SLNs were investigated. The presence of food slowed 
the transit of the SLNs in the GI tract. The gastric transit time of the AmB SLNs was estimated 
indirectly using PAR and was obtained as 1.71-2.25 hr. Caecal arrival time (CAT) of the AmB 
SLNs was estimated using SP detection in plasma as SSZ metabolism to produce SP occurs 
predominantly by the activity of colonic flora. In both fasted and fed states, CAT was 1.80-1.90 
hr whereas transit time through the small intestine was 1.65-1.79 hr. A delayed rate of AmB 
absorption was observed in the fed state however, the extent of absorption was not affected by 
food. The percentage AmB absorption during the fasted state in the stomach, small intestine and 
colon were not significantly different from absorption within the respective regions in the fed state. 
In both states however, absorption was highest in the colon and appeared to be a summation of 
small intestinal absorption plus absorption proper within the colon. The study indicated that AmB 
SLNs irrespective of food status were slowly but predominantly taken up by lymphatic absorption, 
and the small intestine was the most favourable site for their absorption. The data indicate that it 
is possible to enhance the bioavailability of AmB through its incorporation into SLNs. Further 
enhancement of AmB bioavailability can be achieved through appropriate formulation 
interventions aimed at slowing transit of the SLNs in the small intestine. Finally, being a lipid-
based system, the SLNs may have a potential to reduce the nephrotoxic effects of AmB.
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
1.1 General overview 
Amphotericin B (AmB) is a broad-spectrum antifungal drug, chiefly used for treating life-
threatening systemic fungal infections. Its therapeutic efficacy is however limited due to poor 
aqueous solubility, and serious side effects mainly nephrotoxicity [Nahar et al., 2008; Kleinberg, 
2006]. A micellar suspension of the sodium deoxycholate salt of AmB (Fungizone®) is currently 
the conventional formulation that is used clinically [Wong-Beringer et al., 1998].  
Lipid-based drug delivery is a favourable approach used to enhance the absorption and 
bioavailability of poorly water-soluble drugs [Wagnera et al., 2001; Pouton and Porter, 2008; 
Jawahar et al, 2012]. Three lipid formulations of AmB are currently available on the market, 
following persistent efforts aimed at formulating to improve its tolerability and increase its 
efficacy. These are AmB lipid complex (ABLC), (Abelcet®); AmB colloidal dispersion (ABCD), 
(Amphocil®); and liposomal AmB (L-AmB) (AmBisome®). These formulations are all 
administered intravenously but are still associated with serious side effects such as fever, chills, 
rigors, malaise, headache, generalised aches, nausea, vomiting and hypoxia [Kleinberg, 2006; 
Patel, 2000].  
One lipid-based delivery system receiving much attention lately is the solid lipid nanoparticle 
(SLN), which is used to improve the oral bioavailability of hydrophobic drugs. In addition, studies 
have shown that the side effects imposed by AmB are potentially minimised when administered 
as a lipid-based oral formulation [Risovic et al., 2003; Gershkovich et al., 2009; Jain et al., 2012]. 
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An oral SLN formulation of AmB is therefore a sensible approach for the delivery of AmB. 
However, it is imperative that the absorption behaviour of the SLN formulation within the GI tract 
is studied to ensure that the formulation manifests maximum therapeutic efficacy. 
A review of literature indicates that a huge amount of work has been done on the development of 
nanoparticulate drug delivery systems, aimed at addressing the issue of poor efficacy/absorption. 
However, not much work is directed towards establishing the uptake mechanisms or transit 
properties of these nanoparticles after oral administration.  
Monitoring the absorption and gastrointestinal (GI) transit of pharmaceuticals provides vital 
information on their design and development. GI transit studies give an indication of a drug’s 
‘absorption window’, which is the optimal site of absorption of orally administered dosage forms. 
For the design and delivery of therapeutic agents that are known to have poor bioavailability, this 
information is vital. Gamma scintigraphy is a useful technique that may be used. However, the 
gamma camera is rather expensive and suitable radionuclides may not be readily available. Indirect 
methods which employ suitable marker drugs may be used in obtaining data on gastric emptying 
and orocaecal transit properties of dosage forms in lieu of gamma scintigraphy [Peh and Yuen, 
1996; Rahman et al., 2005]. 
The absorption of paracetamol (PAR) (which is preferential in the small intestine) is related to the 
rate of gastric emptying after oral delivery [Heading et al., 1973; Clements et al., 1978]. Its rate 
of appearance in blood is therefore useful as a measure of the gastric emptying rate of 
simultaneously administered dosage forms. After oral administration, sulphasalazine (SSZ) is 
hydrolysed by the large bowel flora to produce sulphapyridine (SP) and 5-aminosalicylic acid. The 
SP is rapidly absorbed from the large bowel thus, measuring SP in the blood can be used to 
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determine the arrival of an SSZ-containing dosage form at the large bowel and hence, the orocaecal 
transit time can be estimated [Kellow et al., 1986; Staniforth et al., 1987]. These two compounds 
therefore provide a cheaper alternative to gamma scintigraphy in monitoring the GI transit 
behaviour of a drug formulation [Peh and Yuen, 1996; Rahman et al., 2005].  
In this study, it was aimed to use PAR and SP (SP to be released from SSZ hydrolysis in the large 
intestine) as marker drugs to monitor the GI transit behaviour of AmB SLNs in relation to its 
absorption. The three drugs (AmB, PAR and SSZ) were therefore formulated into individual SLNs. 
The SLNs were evaluated for similarities in their physical properties and then subjected to a pilot 
GI transit study using Sprague-Dawley rats as the animal model. The pilot study provided the basis 
for a main transit study in which the effect of food on the oral absorption of AmB-containing SLNs 
was studied.  
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1.2 Amphotericin B 
AmB is a fungicidal agent that was initially isolated from Streptomyces nodosus. It has a broad 
spectrum of activity and is efficacious in candidiasis, cryptococcosis, aspergillosis, histoplasmosis, 
blastomycosis, coccidioidomycosis, zygomycosis, sporotrichosis, fusariosis and 
phaeohyphomycosis [Klepser, 2011]. Some fungi including rare pathogens such as Trichosporon 
spp., Aspergillus terreus, Scedosporium spp. and Malassezia furfur are intrinsically resistant to 
AmB. AmB is also effective against the protozoan parasite Leishmania donovani [Walsh et al., 
1990; Walsh et al., 1992].  
 
1.2.1 Physicochemical properties  
AmB is a mixture of antifungal polyenes (polyunsaturated organic compounds) produced by 
growing certain strains of Streptomyces nodosus. AmB (C47H73NO17 = 924.1; structure shown in 
Figure 1.1) is a yellow to orange powder which gradually decomposes above 170°C [Moffat et al., 
2005]. It is practically insoluble in water, ethanol, chloroform and ether, but it is soluble in 
dimethylformamide (1 in 200), dimethyl sulphoxide (1 in 20) and propylene glycol. It has a pKa 
value of 5.5.  
 
1.2.2 Pharmacokinetics  
Due to its hydrophobicity, AmB is poorly absorbed after oral, intramuscular or subcutaneous 
administration [Moffat et al., 2005]. It is slowly excreted in the urine (about 40%), and less than 
10% of the administered dose is excreted unchanged in 24 hr with traces still detectable in urine 
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several days after treatment has ended. AmB has a plasma half-life about 24 to 48 hr and a volume 
of distribution of about 4 L/kg. In plasma, about as high as 90 to 97% of the drug is protein bound. 
AmB is a class IV drug according to the Biopharmaceutics Classification System, which means 
that, it has low solubility and low membrane permeability. These two properties in addition to its 
poor stability in acidic media are the key factors that contribute to the poor oral bioavailability of 
AmB. Generally, class IV compounds have poor bioavailability and are minimally absorbed over 
the intestinal mucosa with high variability. The low stability of AmB in acidic media can be 
addressed through enteric-coating of orally destined formulations but the poor aqueous solubility 
and membrane permeability remain significant challenges to oral delivery [Amidon et al., 1995; 
Gershkovich et al., 2009]. 
 
Figure 1.1 Chemical structure of AmB 
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1.2.3 Mechanism of action 
In the presence of ergosterol in fungal cell membrane, AmB monomers nucleate to form an AmB 
multimeric pore with the lipophilic polyene chains arrayed on the outside of the multimer in 
contact with the fungal membrane lipids [Kleinberg, 2006]. The hydrophilic polyhydroxyl chains 
of AmB form the inner walls of an aqueous pore. These pores increase the permeability of the 
fungal membrane to small intracellular cations such as potassium, which are necessary for cell 
metabolism, thereby promoting their leakage. The rapid depletion of these ions finally results in 
fungal cell death. Although AmB has a slightly higher affinity for ergosterol in the fungal cell 
membrane, it can also bind to the cholesterol in mammalian cell membranes due to the structural 
similarity of the two sterols (Figure 1.2); this is the cause of the cytotoxicity associated with AmB 
therapy. A study by Baginski et al. (2002) showed that the channels/pores formed by AmB 
interaction with ergosterol were larger in size with a more prominent pattern of stable 
intermolecular hydrogen bonds compared with those formed with cholesterol, resulting in higher 
ion conductance in fungi than in mammals [Baginski et al., 2002]. 
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Figure 1.2 Structural similarities between cholesterol and ergosterol  
 
1.2.4 Toxicity  
Although AmB has broad-spectrum antifungal activity, its clinical use is limited by its toxicity. It 
shows two main toxicities, acute or infusion-related toxicity and chronic (end organ) toxicity 
[Patel, 2000]. The latter essentially affects the kidneys (nephrotoxicity) and may lead to permanent 
renal impairment especially when AmB is co-administered with other nephrotoxic drugs. The 
infusion-related adverse events are characterised by fever, thrombophlebitis, chills, rigors, malaise, 
headache, generalised aches, nausea, vomiting and hypoxia [Ellis et al., 1992; Khoo et al., 1994; 
Patel, 2000]. Hypotension/hypertension, hypothermia, cardiac arrhythmia and pulmonary 
infiltrates have also been reported when AmB is administered with leukocyte transfusions. Some 
strategies used to reduce the nephrotoxicity include saline loading, slowing the infusion rate, 
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alternate-day dosing and dose reduction; however, the two latter strategies are inappropriate if a 
patient is suffering a life-threatening infection.  
The toxic reactions to AmB may be related to the induction of pro-inflammatory cytokines 
produced by AmB and the release of TNF-alpha from macrophages [Chia and McManus, 1990; 
Arning et al., 1995]. Premedication with analgesics, antihistamine drugs and low-dose 
hydrocortisone may help decrease these effects [Khoo et al., 1994]. 
The AmB-associated nephrotoxicity causes lengthy hospitalisation and increased mortality (49-
65%) especially in patients requiring haemodialysis [Deray, 2002]. There is attendant duplication 
of baseline creatinine levels; vasoconstriction which leads to ischemic injury and direct interaction 
with epithelial cell membranes causing tubular dysfunction. Risk factors for AmB nephrotoxicity 
include high daily average and total cumulative doses, dehydration, abnormal baseline renal 
function (e.g. compromised glomerular filtration rate (GFR) in very ill and elderly patients), 
simultaneous use of nephrotoxic drugs (e.g. cyclosporine and vancomycin) and patients in a high-
risk category such as bone marrow transplant patients [Wingard et al., 1999; Deray, 2002]. A 25% 
increase in creatinine values (i.e. a 50% decrease in GFR) results in nephrotoxicity except the drug 
is stopped; but this may not be probable if large cumulative doses (> 4 g) have already been given. 
High doses of AmB (up to 2 mg/kg/day) can be tolerated by continuous infusion but AmB has a 
concentration-dependent mode of action therefore, the adverse effects may be more pronounced 
[Deray, 2002; Imhof et al., 2003]. 
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1.2.5 Available formulations of amphotericin B 
Due to the toxicities from AmB therapy highlighted above, efforts have been directed towards 
reformulations to improve tolerability and increase efficacy [Vyas and Gupta, 2006]. Fungizone®, 
which is a micellar dispersion of AmB with sodium deoxycholate (AmBD) has been available 
since 1958 and is usually referred to as the classical AmB formulation. However, its use is 
associated with a number of the aforementioned acute side effects in about 80% of patients, with 
about 30% of patients also experiencing renal malfunction [Torrado, 2008; Baginski, 2009]. 
Fungizone® extensively associates with low-density lipoproteins (LDL) and is then taken up by 
LDL receptors in the kidneys. This process is believed to be the cause of its dose-dependent 
nephrotoxicity. 
Three parenteral lipid formulations of AmB have been approved by the FDA: AmB lipid complex 
(ABLC), composed of AmB complexed with dimyristoylphosphatidylcholine and 
dimyristoylphosphatidylglycerol (Abelcet®); AmB colloidal dispersion (ABCD), which is formed 
from AmB complexed with cholesteryl sulphate (Amphocil®); and liposomal AmB, L-AmB 
(AmBisome®), which is composed of AmB complexed with hydrogenated soy 
phosphatidylcholine, distearoyl, phosphatidylglycerol and cholesterol [Kleinberg, 2006]. These 
formulations are used only intravenously as intramuscular administration of AmB is not ideal 
because of irritation and poor absorption from the intramuscular route [Khoo et al., 1994]. 
These lipid formulations differ in various aspects such as their lipid composition, shape/design, 
physicochemical properties, pharmacokinetic parameters and clinical efficacy; nonetheless, they 
are less nephrotoxic than conventional AmB, which was the purpose of their development. They 
also show different accumulation rates in various tissue components [Herbrecht, 2003]. 
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ABLC is used at a dosage of 5 mg/kg/day in patients of all ages. It offers equal or better efficacy 
compared with AmBD, coupled with improved tolerability. There are no differences in efficacy or 
mortality compared with L-AmB, and it can be given safely to patients with existing renal failure 
(including that caused by AmBD use) to improve renal function [Walsh et al., 1998; Martino, 
2004]. 
ABCD is used at a dosage of 3-4 mg/kg/day. It is the least studied lipid formulation however, it 
has equal efficacy with the other formulations. It is much less nephrotoxic (50% less) than AmBD 
but associated with more frequent infusion-related toxicity (i.e. chills and fever) [White et al., 
1998; Bowden et al., 2002].  
L-AmB is a single-bilayer liposomal drug-delivery system used for treating infections refractory 
to AmBD, or used in patients in whom renal impairment or unacceptable toxicity precludes the 
use of AmBD [Ostrosky-Zeichner et al., 2003; Antoniadou and Dupont, 2005]. L-AmB 
accumulates well in the kidneys but it is the least nephrotoxic of the lipid formulations however, 
dose-limiting renal toxicity may still be observed. Its approved dosage is 3 mg/kg/day for empiric 
therapy in neutropenic patients, 6 mg/kg/day for cryptococcal meningitis in patients with HIV 
infection and 3-5 mg/kg/day for systemic fungal infections. 
 
1.3 Nanoparticle formulations 
Nanoparticles range from 10 to 1000 nm in diameter and may be formulated using polymers or 
lipids, in which a therapeutic agent can be entrapped, adsorbed, or chemically coupled with 
[Panyam and Labhasetwar, 2003; Sahoo and Labhasetwar, 2003]. Their submicron size offers 
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several advantages over microparticles such as having a relatively higher intracellular uptake. For 
instance, a study indicated that nanoparticles of size 100 nm showed 2.5-fold greater intracellular 
uptake compared to 1-μm sized particles, and a 6-fold higher uptake compared to 10-μm particles 
in a Caco-2 cell line [Desai et al., 1997]. Similar data was obtained using a rat in situ intestinal 
loop model, in which the uptake of 100 nm sized particles was 15- to 250-fold more than that of 1 
and 10 μm sized particles [Desai et al., 1996]. 
The selection of a suitable delivery system for a drug is based on the physicochemical properties 
of the drug, the disease state and the location of the disease in the body [D’mello et al., 2009]. The 
size and mode of delivery of a drug can affect the therapeutic outcomes of a disease; this is because 
permeability and passive membrane diffusion are effected for drugs with small size. Therefore, 
entrapping a drug in a nanoparticle could result in better cellular uptake or drug targeting to specific 
tissues in addition to possibly controlling the drug release.  
The use of nanoparticles may however be limited by physical instability (e.g. aggregation) and/or 
chemical instability (e.g. hydrolysis of the drug carrier, drug leakage and chemical reactivity) when 
they are stored for a long time [Auvillain et al., 1989; Chacon et al., 1999] but these can be 
controlled or avoided by optimising the formulation parameters. 
 
1.4 Lipid nanoparticles 
Lipid nanoparticles are colloidal nanoparticles made from solid lipids or a combination of solid 
and liquid lipids [Müller et al., 2002]; these are known as solid lipid nanoparticles (SLNs) and 
nanostructured lipid carriers (NLCs), respectively. The key difference between them is the 
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composition and physical state of the lipids, which serve as the core of their structures [Saupe et 
al, 2005].  
In SLNs, the drug is incorporated between the voids in the crystal lattice of the solid lipid [Müller 
et al., 2000] while in NLCs, the liquid lipids added to solid lipids offer flexibility in controlling 
drug encapsulation and drug release [Sauto and Müller, 2007]. The solid-liquid lipid matrix of 
NLCs has more imperfections and could make higher drug encapsulation possible depending on 
the drug and lipid properties [Müller et al., 2007]. Drug location in the core or shell of the lipid 
nanoparticle depends on the lipid nature, drug properties, drug solubility in the lipid and the 
method of nanoparticle preparation employed [Sauto and Müller, 2007]. 
Lipid nanoparticles have superior physical stability as compared with other disperse systems such 
as liposomes [Saupe et al., 2005]. In liposomes and emulsions, the drug can diffuse and partition 
between the oil and the aqueous phase unlike in lipid nanoparticles where the solid lipid shell 
prevents this, thus reducing drug leakage and degradation [Müller et al., 2000; Sauto and Müller, 
2007]. Lipid nanoparticles offer benefits over other lipid carriers. For example, because of the 
increased surface area from the lipids in a nanoparticulate system for transdermal drug delivery, 
adhesiveness to the skin is improved. In addition, an occluding film is formed on the skin, which 
increases skin hydration and penetration of the drug. The lipids in the nanoparticle can also interact 
with the lipids in the skin and act further as penetration enhancers [Wissing et al., 2001; Sauto and 
Müller, 2007]. 
Lipid nanoparticles can also be used to control drug release through gradual drug diffusion out of 
the lipid matrix [Müller et al., 2000]. As a result of this, drug release can be moderated by altering 
the composition of the lipids [Lippacher et al., 2001; Sauto and Müller, 2007].  
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1.5 Solid lipid nanoparticles (SLNs) 
SLNs are composed of physiological lipids usually dispersed in an aqueous surfactant solution 
(Figure 1.3) and are solid at room temperature. Consequently, mobility of the incorporated drug is 
reduced, which is favourable for controlled drug release [Müller and Lucks, 1996; zur Mühlen et 
al., 1998]. SLNs are an alternative to polymeric particulate systems and are suitable carriers for 
hydrophobic drugs, peptides, proteins and antigens; however, for hydrophilic drugs, a high 
encapsulation efficiency into the hydrophobic matrix is not usually achieved [Almeida and Souto, 
2007].  
The unique properties of small size (large surface area) and high drug loading capacity give SLNs 
the potential to enhance the performance of lipophilic pharmaceuticals [Saupe and Rades, 2006; 
Uner and Yener, 2007]. 
 
Figure 1.3 Typical SLN structure 
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1.5.1 Influence of formulation and processing variables on SLN quality  
1.5.1.1 Lipids and emulsifiers 
The ingredients used in preparing SLNs include biocompatible/biodegradable solid lipid(s), 
emulsifier(s), coemulsifier(s) and water. The lipids used are safe (reducing the risk of acute and 
chronic toxicity), inexpensive and can be obtained in high purity; they include triglycerides (e.g. 
tristearin), partial glycerides (e.g. Imwitor), fatty acids (e.g. stearic acid), steroids (e.g. cholesterol 
and cholesterol butyrate) and waxes (e.g. cetyl palmitate, carnauba wax, beeswax, emulsifying 
wax) among others [Loxley, 2009; Severino et al., 2012]. The choice of the lipid is based on the 
assessment of its polymorphic nature, crystallinity, miscibility/solubility in solvents and 
physicochemical properties.  
All classes of emulsifiers (with respect to charge and molecular weight) can be used to stabilise 
the lipid dispersion [Mehnert and Mäder, 2001]. A blend of emulsifiers prevents particle 
agglomeration more efficiently but the choice depends on the route of administration for instance, 
using the parenteral route requires careful selection and limited use of emulsifiers due potential 
toxicity. Surfactant/surfactant mixture concentration can strongly affect the SLN particle size. 
Generally, smaller particle sizes are obtained when a higher surfactant to lipid ratio is employed 
and vice versa [zur Mühlen, 1996].  
It has also been investigated that when a blend of ‘same-class’ surfactants are used than either 
surfactant used alone at the same concentration, they seem to compete for interface sites [Tan et 
al., 2010]. This competition leads to a relatively thinner Helmholtz layer, resulting in a higher zeta 
potential and hence, a higher colloidal stability. In addition, the electrostatic repulsion produced 
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from using ionic surfactants is more vital in imparting stability to lipid nanoparticles during storage 
as compared with the stearic hindrance from non-ionic surfactants.  
In the hot homogenisation method of preparing SLNs, particle size increases with higher melting 
lipids. Other factors linked to the type of lipid and SLN quality are the velocity of lipid 
crystallisation, lipid hydrophilicity (which influences self-emulsifying properties) and the shape 
of the lipid crystals [Siekmann and Westesen, 1992; Siekmann and Westesen, 1994; zur Mühlen, 
1996]. Increasing SLN lipid content over 5-10% produces larger particles with a broader size 
distribution in most cases, which is undesirable. 
  
1.5.1.2 Particle size 
Particle size can considerably affect the physical stability of the formulation, the biofate of the 
particles, as well as the release profile of the loaded drug. Therefore, particle size must be well 
controlled; ideally, size distribution must be narrow and in the submicron range [Siekmann and 
Westesen, 1994; Mehnert and Mäder, 2001]. The final particle size of lipid nanoparticles is 
affected by several factors such as the constituents of the formulation (i.e. surfactant/surfactant 
mixture, lipid properties and the drug), production methods and variables (such as time, 
temperature, pressure, number of cycles and equipment) and other procedures like sterilisation and 
lyophilisation (freeze-drying) if required. For example, larger particle sizes are achieved at lower 
processing temperature. Additionally, the hot homogenisation technique produces SLNs of smaller 
sizes (< 500 nm) with a narrow size distribution as compared with cold homogenisation however, 
high temperature is not suitable for thermolabile drugs or lipids/carriers. Again, mean particle size 
and polydispersity index increase with increasing homogenisation pressure (beyond 1500 bar) and 
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number of homogenisation cycles (beyond 3-5 cycles) due to the increased kinetic energy of the 
particles. 
 
1.5.2 Advantages of SLNs over other particulate drug delivery forms 
 Their small size makes them suited for intravenous drug delivery and for the crossing of 
biomacromolecules into the lymphatic system after oral delivery.  
 In some production methods of SLNs, the use of organic solvents could be avoided.  
 They can be produced on a large scale with excellent reproducibility.  
 Drug release can be controlled if desired. 
 Drug targeting to specific areas in the body by coating/attaching ligands to their surfaces 
can be achieved. 
 SLN formulations can be optimised to have increased stability of several months.  
 The lipids used are biodegradable; therefore, SLNs have a better biocompatibility.  
 Higher drug loading, as well as high bioavailability of entrapped drugs.  
 Chemical protection of incorporated drugs is offered by the solid lipid core. 
[Müller et al., 2000; Gohla and Dingler, 2001; Mehnert and Mäder, 2001; Lockman et al., 2003; 
Saupe and Rades, 2006; Mukherjee et al., 2009] 
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1.5.3 Methods of preparing SLNs 
1.5.3.1 High pressure homogenisation (HPH) 
HPH is a reliable method for preparing SLNs, in which scaling up presents no problems as the 
other techniques do [Lippacher et al., 2000]. In HPH, homogenisers are operated at high pressures 
(100-2000 bar), which causes acceleration of fluids to a very high velocity (over 1000 km/h) 
resulting in particle size reduction to the submicron range. The lipid content in the formulation is 
usually 5-10% but higher amounts of up to 40% can also be used.  
There are two approaches for the homogenisation step in the production of SLNs by HPH, cold 
and hot. In each case, the primary step requires drug incorporation into the molten lipid. 
 
1.5.3.1.1 Hot homogenisation  
This is carried out at temperatures above the melting point of the lipid used [Lander et al., 2000]. 
A pre-emulsion is produced from the drug-loaded lipid melt and an aqueous solution of the 
emulsifier (both at the same temperature) with the aid of a high-shear mixing device, followed by 
HPH. It is necessary to obtain a pre-emulsion of good quality and with droplet size in the range of 
only a few micrometres to produce a final product of high quality. When smaller particle sizes are 
desired, higher temperatures are employed to decrease the viscosity of the inner phase but this 
could also increase the rate of degradation the drug and/or the lipid carrier. More than one cycle 
of homogenisation (about 3-5 cycles at 500-1500 bar) can be done, noting that HPH by itself 
increases the sample temperature by about 10°C for 500 bar [Jahnke, 1998].  
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The primary product of the hot homogenisation process is a nanoemulsion. Solid particles are then 
formed by cooling the hot nanoemulsion to room temperature or below. Due to the small particle 
size and the presence of emulsifiers, the chances of lipid crystallisation occurring is highly slowed, 
enabling the sample to remain intact for several months [Bunjes et al., 1998].  
 
1.5.3.1.2 Cold homogenisation  
Cold homogenisation on the other hand is carried out with the lipid in the solid state. Good 
temperature control is needed to ensure the unmolten state of the lipid because there is temperature 
increase during homogenisation [Jahnke, 1998]. This technique overcomes some problems 
associated with the hot homogenisation technique such as temperature-induced drug degradation, 
drug distribution into the aqueous phase during homogenisation and complexity of the 
crystallisation step of the nanoemulsion (which leads to some alterations and/or supercooled melts) 
[zur Mühlen, 1996]. 
The first step is the same as in the hot homogenisation technique, which is dissolving or dispersing 
the drug in the melted lipid [zur Mühlen, 1996]. The drug-containing lipid melt is then cooled 
rapidly (using either dry ice or liquid nitrogen), which favours the homogenous distribution of the 
drug within the lipid matrix. The solid lipid-drug complex thus obtained is ball or mortar milled 
into microparticles (50-100 µm). The cooling step increases the brittleness of the lipid thereby 
favouring particle comminution. The microparticles are then dispersed in a chilled emulsifier 
solution and subjected to high pressure homogenisation at or below room temperature. 
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Compared with hot homogenisation, larger particle sizes and a broader size distribution are 
obtained [zur Mühlen, 1996]. In addition, thermal exposure of the sample is decreased, but not 
evaded due to the initial step of melting the lipid [Mehnert and Mäder, 2001]. 
 
1.5.3.2 High speed stirring and/or ultrasonication  
Ultrasonicators and stirring equipment are common in the laboratory but both instruments have 
the disadvantage of producing particles with a broad particle size distribution that ranges into the 
micrometre range [Mukherjee et al., 2009]. This results in physical instabilities like particle growth 
upon storage. There may also be metal contamination from the probe due to the ultrasonication 
step. In order to make a stable formulation, a high stirring speed and ultrasonication are used in 
combination at a high temperature in making the pre-emulsion for formulating the SLNs. 
The large-sized particles obtained by this method are not a problem for oral drug delivery however, 
if the formulation is intended for intravenous administration, a high concentration of emulsifiers 
can be used for particle size reduction, but this may also increase the risk of toxicity [Mehnert and 
Mäder, 2001]. 
 
1.5.3.3 Emulsification solvent diffusion 
This method (summarised in Figure 1.4) was first described by Quintanar-Guerrero et al. (1996) 
in preparing polymeric nanoparticles. In this technique, the organic solvent (partially water-
miscible) is saturated with water to achieve preliminary thermodynamic equilibrium between the 
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two liquids. The organic solvent containing the dissolved carrier (polymer/lipid) and the drug is 
emulsified in an aqueous surfactant solution using a high-speed homogeniser (a stabilising agent 
may be added) at the melting point of the lipid (or about 5°C higher). Excess water is then added 
to the oil-in-water (o/w) emulsion formed with continuous stirring thus causing phase 
transformation and outward diffusion of the solvent from the internal phase to the external phase. 
This leads to the precipitation of the polymer/lipid and the formation of colloidal nanoparticles. 
The solvent is then removed by vacuum or steam distillation or evaporation. The concentration 
and the nature of the lipid and surfactant, stirring rate and the processing temperature are critical 
variables in this technique [Quintanar-Guerrero et al., 1996; Trotta et al., 2003]. 
 
Figure 1.4 Schematic diagram for preparing nanoparticles using emulsification solvent 
diffusion method [modified from Jelvehgari and Montazam, 2012]. 
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1.5.3.4 Emulsification solvent evaporation 
This method involves obtaining nanoparticles by precipitation from o/w emulsions. The lipophilic 
material (that is the drug and the lipid) is dissolved in a water-immiscible organic solvent (e.g. 
cyclohexane, ethyl acetate) and then emulsified in an aqueous phase using mechanical stirring 
[Mehnert and Mäder, 2001]. The solvent is then evaporated causing precipitation of the lipid 
nanoparticles in the aqueous medium. 
Sjöström and Bergenståhl (1992) used this method to obtain a mean particle size of 25 nm using 
cholesterol acetate as model drug and a lecithin/sodium glycocholate blend as emulsifier. The lipid 
concentration in the organic phase determines the mean particle size; that is, very small particles 
are obtained with low lipid content (about 5%). In addition, as the lipid content increases, the 
efficiency of the emulsification declines because the viscosity of the dispersed phase increases. 
The avoidance of any heat stress is beneficial in this procedure over cold homogenisation while 
the main drawback is the use of organic solvents [Mehnert and Mäder, 2001]. 
 
1.5.3.5 Supercritical fluid (SCF) method  
There are several procedures in SCF technology for producing micro/nanoparticles. These include 
rapid expansion of supercritical solution (RESS), particles from gas-saturated solutions (PGSS), 
gas/supercritical antisolvent (GAS/SAS), aerosol solvent extraction system (ASES) and solution 
enhanced dispersion by supercritical fluids (SEDS) [Jung and Perrut, 2001; Jovanoviæ et al., 2004; 
Rodrigues et al., 2004].  
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SCF technology is a useful alternative for producing solvent-free particulate drug carriers. Carbon 
dioxide (CO2) is almost exclusively the solvent employed for reasons such as its low toxicity, 
relatively low critical temperature and moderate critical pressure and low cost [Sellers et al., 2001]. 
The advantages of this method are the mild processing conditions, possible sterilising properties 
of supercritical CO2, possibility of producing nanoparticles as dry powders and the feasibility of 
scaling-up [Jovanoviæ et al., 2004]. 
A modified PGSS process has been used to produce insulin SLNs, where the drug was dissolved 
in dimethyl sulphoxide (DMSO) and the solution incorporated into a melted mixture of tristearin, 
phosphatidylcholine and dioctyl sulphosuccinate [Caliceti et al., 2006]. The lipid matrix was 
mixed with compressed CO2 and atomised to produce SLNs < 500 nm in size. The formulation 
had sustained release properties and preserved the biological activity of the insulin. However, the 
use of the DMSO compromised the aim of solvent-free SCF processing, especially as the particles 
were intended for parenteral purposes.   
 
1.5.3.6 Microemulsion-based method 
This is based on the dilution of a microemulsion, where the lipid nanoparticles are prepared by 
stirring an optically transparent mixture comprising of a low melting fatty acid (e.g. stearic acid), 
an emulsifier (e.g. polysorbate 20), co-emulsifiers (e.g. butanol) and water at 65-70°C. The hot 
microemulsion produced is then diluted in cold water (2-3°C) in a ratio range of 1:25 to 1:50, 
respectively, with stirring, which causes the lipid droplets in the microemulsion to solidify into 
lipid nanoparticles [Gasco, 1993; Cavalli et al., 1996; Joresa et al., 2004]. The temperature 
gradient and pH define the quality of the product obtained but the former facilitates rapid lipid 
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crystallisation thus preventing particle aggregation. The dilution stage considerably lowers the 
lipid content as compared with SLNs produced by the HPH method. The possibility of scaling up 
from laboratory size to industrial size batch is an advantage of this method as there is no need for 
high shear machinery. 
Major drawbacks include high production costs and sensitivity to minor changes in the formulation 
composition or thermodynamic variables, which can result in phase transitions [Gasco, 1993]. In 
addition, the dilution step reduces particle concentration to below 1%, requiring a large amount of 
water to be removed for processing to a final dosage form. Lastly, a high concentration of 
surfactant is used which can cause toxicity but the excess can be removed by ultracentrifugation, 
ultrafiltration or dialysis. 
 
1.5.3.7 Double emulsion method 
This is based on the emulsification solvent evaporation method for preparing SLNs for hydrophilic 
drugs [Cortesi et al., 2002]. The drug and a stabiliser (e.g. gelatin, poloxamer-407) are 
encapsulated in the internal water phase of a w/o/w double emulsion to avoid drug partitioning 
into the external water phase during solvent evaporation. This is then emulsified in melted lipid to 
give a primary emulsion, which is then dispersed in another aqueous phase containing a 
hydrophilic emulsifier (e.g. PVA). The double emulsion thus obtained is stirred and isolated by 
filtration. SLNs containing sodium cromoglycate (a hydrophilic compound) have been prepared 
using this method. Prior to this, the solvent evaporation method was employed which gave a low 
encapsulation efficiency (2%w/w); which was increased to 50% w/w when the w/o/w double 
emulsion technique was used except that larger-sized particles were obtained. 
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1.5.3.8 Film-ultrasound dispersion method 
In this method, the lipid and the drug are dispersed in an appropriate organic solution(s). A lipid 
film is obtained by rotating the organic solution in a suitable vessel and evaporating the solvent, 
after which an aqueous solution containing the emulsifier is added [Ekambaram et al., 2012]. SLNs 
with small and uniform particle sizes are then produced with the aid of an ultrasound probe. Wang 
et al. (2007) used this technique to produce oleanolic acid SLNs with mean diameter of 62 nm and 
encapsulation efficiency of 98.29%. 
 
1.5.4 Characterisation of SLNs 
1.5.4.1 Particle size 
(I) Photon correlation spectroscopy (PCS) and laser diffraction (LD) are the dominantly 
employed techniques for routine particle size measurements [Sinha et al., 2010]. PCS is based on 
dynamic laser light scattering (DLS) due to Brownian motion of particles in a solution/suspension, 
and is suitable for assessing particle sizes from 3 nm to 3 µm. PCS diameters (hydrodynamic 
diameters) are obtained by measuring the fluctuation of scattered light from particles. The PCS 
device comprises a light source, a temperature-controlled sample cell and a photomultiplier for 
detecting the scattered light. PCS uses the scattered light and diffusion data from the Brownian 
motion of particles in the Stokes-Einstein equation to give the radius of a particle (average particle 
size) along with the size distribution in a fairly dilute sample [Sinha et al., 2010]. An improvement 
of PCS for higher concentrated/opaque samples (e.g. emulsions) is photon cross-correlation 
spectroscopy (PCCS).  
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Laser diffraction (LD) alternatively measures particle size in the range of 0.1-180 µm and is based 
on the dependence of diffraction angle on particle size (Fraunhofer spectra); that is, smaller 
particles cause more intense scattering at higher angles than larger particles [Sinha et al., 2010].  
Phase sensitive-intensity-difference-scattering technology has very much enhanced the sensitivity 
of LD to smaller particles however, it is advisable to use PCS with LD. PCS and LD are however 
not very useful in analysing samples comprising various populations of different sizes [Garti and 
Sato, 1988; Müller et al., 2000]. 
Nanoparticle formulations are usually polydisperse systems, so polydispersity index (PDI) is used 
as a measure of the particle size distribution. Ideally, the PDI for a monodisperse system is zero 
whereas for polydisperse systems PDI must be less than 0.5 because, a value greater than the latter 
indicates a very broad particle size distribution system [Jawahar et al., 2012]. 
 
(II) Nanoparticle tracking analysis (NTA) is a commercialised equipment by NanoSight Ltd 
(Amesbury, UK) and provides visualisation of samples in real time. NTA measures the absolute 
size distribution of particles with diameters ranging from 50 nm to 1 µm. The particles suspended 
in a suitable dispersion medium are illuminated by a laser beam and they scatter light or exhibit 
fluorescence. A dark-field microscope is then used to determine the position of single particles in 
constant motion due to Brownian motion. The movements of each particle are tracked and the 
mean squared velocity, which depends on the particle diameter is calculated. An absolute size 
distribution of the particles in suspension can be obtained after the system has been calibrated with 
beads of known concentration. NTA can be used to determine the zeta potential as well by applying 
an electric field across the suspension and measuring the velocity of single particles due to 
electrophoresis [Carr et al., 2008; Dragovic et al., 2011].  
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 (III) Field flow fractionation (FFF) is another technique that is used in particle size 
characterisation [Jawahar et al., 2012]. FFF is centered on the elution of small particles in a 
parabolic flow profile. The scattering signal produced by the eluted components are then evaluated 
by multi-angle light scattering (MALS) with the aid of a photometer which records and computes 
the size-weighed radius within the range of 10 nm to 1 μm. Flow FFF is the most sensitive of the 
available FFF techniques as it can measure particle size as small as 1 nm. Small particle size 
differences could be very well resolved using FFF unlike in PCS. Additionally, FFF can be used 
for separating particles for further characterisation.  
Samples have to be diluted well for FFF analysis like most other nanoparticle analytical procedures 
but this may alter some sample properties (e.g. removal of surfactants from the particle surface) 
and result in erroneous data [Mehnert and Mäder, 2001]. 
 
(IV) Acoustic spectroscopy is useful for obtaining data on particle size using relevant equations 
and measuring the attenuation of sound waves [Garud et al., 2012]. The oscillating electric field 
produced by moving charged particles under the influence of acoustic energy could also be used 
to obtain information on the surface charge of particles. 
Laser diffraction is the commonly used technique for determining particle size in suspensions, 
emulsions, dry powders and aerosols, but it requires light transmission, which limits its application 
to dilute samples [Alba et al., 1999]. Sound waves interact with particles in a similar fashion to 
light but the former has the benefit of being able to travel through concentrated samples. Sound-
based particle size analysis has been in existence for years but it is limited in size ranges and only 
works well with dense, rigid particles. Acoustic attenuation spectroscopy overcomes these 
restrictions. It employs ultrasonic transducer technology and digital signal processing which are 
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centred on classical acoustical principles to permit analysis of highly concentrated particle systems 
with sizes in the range of 0.01 µm to 1000 µm. 
 
1.5.4.2 Zeta potential (ZP) 
A nanoparticle having a net surface charge attracts a layer of oppositely charged ions which moves 
with the nanoparticle [Escubed Ltd., 2015]. There is however a point beyond which the attracted 
ions do not move with the particle which is called the ‘slipping plane’. The layer of both the surface 
charge and oppositely charged ions is referred to as the electrical double layer (EDL). The EDL 
consists of an inner region of strongly bound ions known as the ‘stern layer’ and an outer layer of 
loosely associated ions called the ‘diffuse layer’ (depicted in Figure 1.5).  
 
Figure 1.5 Diagrammatic representation of the distribution of ions around a charged 
nanoparticle in a dispersion [Escubed Ltd., 2015] 
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Zeta potential (electrokinetic potential) is a measure of the potential difference between the 
medium in which the particle is dispersed and the layer of fluid containing the oppositely charged 
ions [Escubed Ltd., 2015; Nanocomposix, 2015]. ZP is therefore, the electric potential at the EDL 
boundary. Particles with ZP bind to oppositely charged surfaces. The magnitude of ZP (usually 
ranging from -100 mV to +100 mV) gives information on the stability of a colloidal dispersion. 
Nanoparticles with higher ZP values exhibit increased electrostatic repulsion (from ionic 
surfactants) and are therefore stable over time while those with lower magnitudes ultimately 
aggregate due to van der Waals inter-particle attractions. This is however not applicable to 
formulations containing steric stabilisers because the latter reduce particle aggregation by 
adsorption onto the particle surface and decrease ZP in the process [Müller, 1996]. This indicates 
that a formulation containing a steric stabiliser will show good stability despite having a low ZP 
magnitude. The following ZP values (absolute) give an indication of the stability behaviour of 
colloidal dispersions according to Riddick (1968):  
 0-3 mV : Maximum agglomeration and precipitation  
 3-5 mV : Strong agglomeration and precipitation 
 10-15 mV : Threshold of agglomeration 
 16-30 mV : Threshold of delicate dispersion  
 31-40 mV : Moderate stability 
 41-60 mV : Fairly good stability 
 61-80 mV : Very good stability  
 81-100 mV : Extremely good stability 
It is worth noting that the magnitude of charge on the surface of a nanoparticle is affected by the 
pH of the dispersion medium. The net charge on a nanoparticle can be reduced to zero at its 
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isoelectric point however, this may not be desired as the dispersion becomes highly unstable at 
this point with a high probability of flocculation. 
ZP is usually measured in a cell that has two gold electrodes [Nanocomposix, 2015]. Voltage is 
applied to the electrodes to cause the particles to move towards the oppositely charged electrode 
and particle velocity is then measured as a function of voltage. The particles move through a laser 
beam passing through the cell and the intensity of scattered light fluctuates at a frequency 
proportional to the particle speed. The latter is measured at multiple voltages and the data obtained 
is used to calculate the ZP. 
 
1.5.4.3 Particle shape, morphology and topography  
(I) Electron microscopy 
Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) are examples 
of direct methods for physical characterisation of SLNs [Liu et al., 2007]. Electron microscopy 
employs electrons instead of light for visualising particles in the nanometre range. SEM detects 
scattered electrons from the surface of the particles and visualises the surface while TEM detects 
electrons transmitted through the sample. 
When performing TEM on nanoparticles, it must be considered that they can be vulnerable to the 
high energetic electron beam [Bentley et al., 2005] so for susceptible samples, a low electron beam 
current should be used. TEM however is costly, and there may be image overlapping during 
analysis [Smith, 2007]. Sample preparation is also a bit tedious and time-consuming, involving 
dehydration, staining and conductive coating steps, which may cause changes that could affect the 
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resulting shape of the nanoparticles [Liu et al., 2007]. High-resolution TEM (HRTEM) uses 
electron beam interference by the sample rather than the absorbance of the beam as with ordinary 
TEM, thereby giving a higher resolution.  
SEM is also used for shape and morphological examination of nanoparticles by using a high-
energy electron beam however, the beam is scanned over the sample surface and the backscattering 
of the electrons is looked at [Jawahar et al., 2012]. The sample has to be under a vacuum (like 
TEM) and electrically conductive (non-conductive samples can be sputter-coated for conductivity) 
at the surface.  
 
 (II) Atomic force microscopy (AFM)  
AFM employs the force acting between a sample surface and a probing tip to provide qualitative 
and/or quantitative information about the physical properties of nanoparticles such as size, 
morphology, surface texture and roughness (topography) [Drake et al., 1989; Kirby et al., 1995]. 
The benefit of AFM is that the sample is easily prepared by placing a drop of dilute 
solution/dispersion on a clean microscope slide or a mica substrate, and the sample may be dried 
prior to analysis. In addition, vacuum is not a requirement, the sample does not need to be 
conductive and images are obtained rapidly.  
Submicron particles move rapidly, as such preparatory steps such as solvent removal may be 
crucial depending on the analysis being conducted however, this may also cause significant 
modifications in the molecular structure of the sample [Kumar and Randhawa, 2013]. Sample 
dehydration may result in changes such as cluster formation, particle shrinkage and lipid 
crystallisation, all of which can affect the results obtained. 
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1.5.4.4 Crystallinity of lipid and drug  
Studying the degree of lipid crystallinity and modification in lipid nanoparticles is essential as 
these are highly related to drug incorporation and release rates. Differential scanning calorimetry 
(DSC) and X- ray scattering are commonly used for this purpose. 
DSC is based on the fact that various modifications (such as polymorphs) of a lipid have different 
melting points and enthalpies [Müller et al., 2000]. It gives data on the nature, melting and 
crystallisation characters of both the solid and liquid constituents of a sample by providing data on 
their glass transition temperatures, as well as their melting points and enthalpies. Thermodynamic 
stability and lipid packing density are both inversely related to drug incorporation rates but the 
extent depends on the particular modification/polymorphic form (supercooled melt, alpha (α)-
modification, beta prime (β’)-modification and beta (β)-modification) of the lipid. The main 
polymorphic forms have been reported to be in the following order of increasing stability, melting 
point and packing density: α < β’ < β. A supercooled melt is formed when lipid 
crystallisation/solidification (initiated by crystallisation nuclei) does not occur although a lipid in 
its liquid/molten state is stored below its melting point. Crystallisation is a size dependent process 
so the tendency to form supercooled melts increases with decreasing particle size. After 
crystallisation, triglycerides tend to pack into very specific structural arrangements with 
characteristic symmetries, and the latter depends on the type of unit cell present in the crystals. 
The packing arrangement of atoms within the crystal defines the type of unit cell structure present 
in the crystal [Boistelle, 1988; Müller et al., 2000; Marangoni, 2011].  
Polymorphism is mainly a property of triacylglycerols and other lipids, and is their ability to 
crystallise into different crystal types but essentially maintaining their chemical composition 
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[Marangoni, 2011]. It is a form of physical degradation that can affect the stability of dosage forms 
because although chemically identical, polymorphs may have different thermodynamic properties 
such as melting point, X-ray diffraction pattern, infrared spectral signature, Raman spectra and 
solubility characteristics [Martin et al., 1983; Marangoni, 2011]. It is therefore important to 
understand the particular polymorphic shifts of both lipids and drugs in a drug product, if any. 
It is however worth noting that, because emulsifiers are included in SLN preparation, lipid 
crystallisation and changes due to lipid modifications are greatly slowed [Suresh et al., 2007; 
Vivek et al., 2007; Jawahar et al., 2012]. 
X-ray diffraction (XRD) is used to evaluate the length of the long and short spacings of a lipid 
lattice but it is necessary to analyse the whole SLN dispersion instead of only the lipid. This is 
because solvent removal may lead to changes in the sample [Westesen et al., 1993].  
Both single crystals and polycrystalline materials can be analysed using XRD, which involves 
evaluation of the interference of scattered x-rays from the atoms in a sample using Bragg’s Law. 
XRD dimensions are stated in angstroms (1 Å = 0.1 nm). XRD is very beneficial but it can be 
time-consuming and also, a large amount of sample is usually required. 
 
1.5.4.5 Drug localisation within SLNs  
The amount of drug incorporated in SLNs may affect the characteristics of drug release. The 
amount of encapsulated drug in an SLN can be ascertained after the free drug and the lipid(s) have 
been separated from the aqueous medium. This separation can be achieved through 
ultracentrifugation, centrifugation, filtration or gel permeation chromatography. The amount of the 
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drug is then determined by a suitable standard analytical technique such as spectrophotometry, 
spectroflurophotometry, high-performance liquid chromatography (HPLC) or liquid scintillation 
counting [Magenheim and Benita, 1991]. In this regard, the selected analytical method must be 
sensitive, selective and precise for the drug. 
Factors influencing drug loading in a lipid are drug solubility in/miscibility with the melted lipid, 
chemical/physical structure of the solid lipid matrix and the polymorphic state of the lipid. For 
adequate drug loading, drug solubility in the lipid melt must be sufficiently high, which can 
generally be achieved by using mono- and diglycerides. Complex lipids like mixtures of mono-, 
di- and triglycerides and also lipids with fatty acids of different chain lengths form less perfect 
crystals, which offer voids to contain the drugs to enhance drug loading [Mehnert et al., 1997; 
Müller et al., 2000]. 
The incorporation of drugs into SLNs has been summarised (Figure 1.6) to be by one of the 
following models: 
(I) Solid solution: This model is produced during the initial stages of cold homogenisation. 
After dissolution in the molten lipid, the drug becomes molecularly dispersed within the 
lipid matrix when the drug-lipid mixture is rapidly cooled [zur Mühlen et al., 1998].  
(II) Core-shell model, drug-enriched shell: This model results from hot homogenisation, as the 
drug repartitions into the SLN shell (superficial layers) during the cooling stage of SLN 
preparation.  
(III) Core-shell model, drug-enriched core: This is formed when a drug is dissolved in the lipid 
melt at or close to its saturation solubility and it precipitates before the lipid recrystallises 
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during the cooling stage of preparing the nanoemulsion. The cooling results in 
supersaturation and crystallisation of the drug preceding lipid crystallisation, which leads 
to the formation of a drug-enriched core surrounded by a lipid shell.  
[Schwarz, 1995; zur Mühlen, 1996; Mehnert et al., 1997; zur Mühlen and Mehnert, 1998] 
(IV) Drug particles could also be attached/adsorbed onto the surface of the SLN [Svilenov and 
Tzachev, 2013]. Several techniques such as electron spectroscopy (e.g. X-ray 
photoelectron spectroscopy (XPS)), ion-based techniques (e.g. secondary ion mass 
spectrometry (SIMS)), and scanning probe microscopy (SPM) (e.g. AFM and scanning 
tunnelling microscopy (STM)) are available for the characterisation of SLN surfaces. Any 
of these can be useful in studying the presence of drug particles on the surface of a particle.  
 
 
Figure 1.6 Possible drug localisation in SLNs [Svilenov and Tzachev, 2013] 
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1.5.4.6 Drug release from SLNs 
Drug release is a key factor worth considering before and after preparing a successful SLN system 
[Dhawan et al., 2004]. The rate of drug release depends on the solubility characteristics of the 
drug, desorption of surface-bound/adsorbed drug, drug diffusion through the SLN and 
erosion/degradation of the SLN matrix. If drug diffusion occurs faster than erosion of the matrix, 
then the drug release mechanism is largely by diffusion. 
Some in vitro and in vivo data on SLNs have shown prolonged drug release up to 80 hr [Reddy et 
al., 2006; Li et al., 2009; Dodiya et al., 2011; Dwivedi et al., 2014]. An in vitro study conducted 
on prednisolone SLNs showed drug release up to 35 days [zur Mühlen and Mehnert, 1998]. It is 
possible to modify drug release profiles based on the lipid, type and amount of surfactant, as well 
as the production parameters (e.g. temperature) [zur Mühlen and Mehnert, 1998; zur Mühlen et 
al., 1998] used in formulating SLNs. However, sufficient hydrophobicity of the drug is also 
necessary to keep the latter preferentially entrapped within the lipid matrix to achieve a prolonged 
release. All the aforementioned factors are key in determining the shape/outline of the release 
profiles of drugs from carrier systems. 
A problem of ‘burst release’ (initial high drug release) is sometimes observed with lipid 
nanoparticulate systems when particles with drug-enriched shells are produced [zur Mühlen et al., 
1998]. This property can be exploited to deliver an initial high dose if desired or avoided if 
prolonged drug release is desired. Differences in lipid melting and homogenisation temperatures 
are considered as the main parameters that determine the structure of the SLN matrix and hence, 
how drug release may occur. 
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Drug release profiles for SLNs can be explained by drug partitioning between the lipid and aqueous 
surfactant phases, especially during the production stage [Müller et al., 2000]. For instance during 
hot homogenisation, varying amounts of the drug partitions into the aqueous phase. This 
partitioning and the extent to which it happens depend on the drug’s solubility characteristics, 
temperature of the aqueous phase and the surfactant concentration. High drug solubility, high 
temperature and increasing surfactant amount result in higher drug partitioning into the aqueous 
phase. On cooling the o/w nanoemulsion, drug solubility in the water phase decreases causing re-
partitioning of the drug back into the lipid phase. Due to the decreasing temperature, solid lipid 
cores also start forming thereby encapsulating the drug until they become crystallised/solidified. 
As a result, the remaining drug concentrates in and/or on the outer shell of the SLNs and is 
subsequently released in the form of a ‘burst’, while the drug within the SLN core is released 
gradually over an extended period [zur Mühlen and Mehnert, 1998; Müller et al., 2000]. 
A good way to avoid undesired burst release is to prepare SLNs at a low temperature, and either 
with a low concentration of surfactants or with surfactants which do not solubilise the drug, to 
keep the drug within the lipid matrix [zur Mühlen and Mehnert, 1998; Müller et al., 2000]. 
 
1.5.5 Oral absorption and bioavailability of SLNs 
1.5.5.1 Dosage forms for oral SLNs 
SLNs can be orally administered as an aqueous dispersion or in the traditional solid dosage form 
such as tablets, pellets, capsules or powders. An aqueous SLN formulation can be used as the 
granulation fluid for making tablets or it can be spray-dried or lyophilised into powder form and 
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added as part of the powder mix for tableting. SLNs can also be administered as pellets by using 
the former as a wetting agent in the extrusion process [Pinto, 1999]. SLN powders or pellets can 
as well be filled into hard gelatin capsules for oral delivery. Alternatively, SLNs can be formulated 
in liquid PEG 600 and filled into soft gelatin capsules for use [Yang, 1999]. 
 
1.5.5.2 Mechanisms of oral absorption of SLNs  
There are two possible mechanisms of uptake of SLNs as illustrated in Figure 1.7. 
(I) Microfold (M) cells of Peyer’s patches in the gut (Figure 1.8): 
This is an intracellular uptake route by which drugs are transported into systemic circulation, 
through the intestinal lymphatics and the thoracic lymph duct [Aprahamian et al., 1987]. The 
intercellular junctions between endothelial cells of lymphatic capillaries are more open as 
compared to blood capillaries, which results in molecular sieving of nanoparticles of large sizes 
directly into lymphatic vessels. M cell uptake of nanoparticles is therefore size-dependent (i.e. the 
smaller the size, the higher the uptake). Thus, nanoparticulate systems can effectively improve 
drug bioavailability to enhance therapeutic efficacy. Lymphatic delivery is helpful not only for 
absorption of poorly soluble drugs but also for targeting drug carriers to the lymphatics.  
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Figure 1.7 Summary of SLN absorption after oral administration:  
A. Intercellular/paracellular pathway, B. M cell uptake via Peyer’s patches, and C. 
chylomicron-assisted enterocyte absorption [SLN models: SS-Solid solution; 
CSM-DES-Core-shell model, drug-enriched shell; CSM-DEC-Core-shell model, 
drug-enriched core] [Harde et al., 2011] 
 
(II) Intercellular/paracellular uptake: 
Paracellular uptake transports SLNs directly into blood through capillary vessels or between 
intestinal epithelial cells [Aprahamian et al., 1987]. Nanoparticles have been found in intercellular 
spaces and in larger defects of the mucosa 10 to 15 min after intraluminal injection into the 
intestines of anaesthetised beagle dogs. The nanoparticles were subsequently found in the small 
capillaries near the intestinal epithelium and then finally in the capillaries of the core of the villus. 
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After 30 min, the nanoparticles were quite numerous at the inner surface of the vascular epithelium 
where they generally formed clusters.  
In addition to M cell and paracellular uptake of SLNs, lipase-mediated chylomicron formation 
followed by lymphatic absorption can enhance SLN absorption. Chylomicrons are physiological 
carriers (lipoproteins) that transport lipids from the intestines to the lymph [Bargoni et al., 1998; 
Sanjula et al., 2009]. Lipase-mediated chylomicron formation aids in the dissolution and 
assimilation of hydrophobic drugs in the lipid core of SLNs to promote drug absorption. 
Involvement of chylomicrons and transport via the Peyer’s patches offer SLNs a direct transport 
into the lymphatic system, which allows for drug targeting to lymph [Bargoni et al., 1998]. 
 
Figure 1.8 Diagram showing an M cell of a Peyer’s patch [Mowat, 2003]  
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1.5.5.3 Bioavailability of SLNs 
The oral bioavailability of drugs depends on their solubility/dissolution rate and degradation in the 
GI tract, absorption across transmembrane barriers and transporters such as P-gp [Cai et al., 2010]. 
Lipid-based drug delivery systems such as SLNs enhance the oral bioavailability of hydrophobic 
drugs by keeping the drugs in a solubilised state. In addition, triglycerides of SLNs are digested 
by lipases to produce surface-active mono- and diacylglycerols, which induce the secretion of 
endogenous phospholipids and bile salts to facilitate the formation of mixed micelles and thereby 
improve oral absorption of poorly soluble drugs [Müller et al., 2006; Porter et al., 2007]. SLNs of 
several drugs have shown significant improved oral bioavailability compared with their respective 
drug suspensions [Li et al., 2009; Sanjula et al., 2009; Hu et al., 2010; Varshosaz et al., 2010(a, 
b); Luo et al., 2011; Zhang et al., 2012; Xue et al., 2013; Dwivedi et al., 2014]. 
A factor that contributes to the absorption enhancing property of SLNs is their small size, which 
considerably increases their surface area and results in ample and steady absorption from the GI 
tract [Hanafy et al., 2007]. Because very fine particles are generally adhesive, SLNs can adhere to 
the gut wall to prolong their residence time thereby enhancing their oral absorption [Tarr and 
Yalkowsky, 1989; Müller et al., 2000; Müller et al., 2006]. Again, SLNs can enhance lymphatic 
delivery of drugs (Section 1.5.5.2) contributing to their bulk oral bioavailability. Lipids can 
stimulate lipoprotein formation and intestinal lymphatic lipid flux to increase the extent of 
lymphatic drug transport, but this is influenced by the type of lipid [Paliwal et al., 2009] and the 
amount of surfactants [Sanjula et al., 2009] used in preparing the SLNs. For instance, a study by 
Paliwal et al. (2009) revealed that Compritol® 888 ATO-based SLNs showed better drug loading 
and release characteristics, better oral bioavailability and higher concentration of methotrexate in 
the lymph, as compared with the stearic acid-, glycerol monostearate- or tristearin-based SLNs. 
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Sanjula et al. (2009) have also reported that increasing the concentration of the surfactant 
poloxamer 188 resulted in a decreased bioavailability of carvedilol SLNs, after intraduodenal 
administration of the SLNs to rats.  
Uptake of intact SLNs via M cells and the lymphatic route plays an important role in SLN 
absorption, as evidenced by some studies. TEM analyses of blood and lymph after duodenal 
administration of SLNs to rats have shown the presence of intact SLNs. It was also observed that 
the size of the SLNs prior to administration and that found later in the lymph were about the same 
[Bargoni et al., 1998; Cavalli et al., 2003]. Yuan et al. (2007) also used fluorometry to confirm 
that about 77.9% of fluorescein isothiocyanate-labelled stearic acid SLNs were absorbed into 
systemic circulation through the lymphatic route after oral administration of the SLNs to rats. 
 
1.5.5.4 Metabolism of SLNs 
The solid lipids in SLNs are degraded enzymatically by pancreatic lipases after oral administration 
however, the rate of degradation is affected by the type of lipid matrix as well as the type and 
amount of surfactant [Müller et al., 1996]. In an in vitro lipase assay, it was found that using bile 
salts in low concentrations promoted SLN degradation while poloxamer 188 inhibited SLN 
degradation due to steric stabilisation. The rate of lipase degradation of long fatty acid chains was 
also slower than that of shorter ones. Again, larger SLNs (≥ 800 nm) were degraded slowly as 
compared with smaller particles (180-330 nm) [Olbrich et al., 2002(a,b)]. 
Due to the improved lymphatic transport of SLNs, incorporated drugs avoid first-pass metabolism. 
As a result, lower doses of drugs affected by first-pass metabolism can be administered in the form 
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of SLNs, which serves to improve tolerance to drugs with narrow therapeutic windows. The 
bioavailability of drugs loaded into SLNs is therefore further enhanced via evading first-pass effect 
due to lymphatic transport, adding on to the aforementioned mechanisms of improved absorption 
[Hu et al., 2010; Varshosaz et al., 2010(a)].  
 
1.5.6 Potential of SLNs in reducing toxicity and side effects of drugs 
The encapsulation of drugs into SLNs and the resulting controlled drug release from the particles 
reduce direct exposure of the encapsulated drugs to the body, which to an extent decreases drug-
induced systemic toxicities. Some studies have compared the toxic effects of lipid-based 
formulations of AmB with those of aqueous suspensions containing only the drug. The results 
indicated that the lipid formulations, compared to the free drug, showed significantly lesser renal 
toxicity in rats [Risovic et al., 2003; Gershkovich et al., 2009; Jain et al., 2012], as well as reduced 
in vitro haemolysis [Jain et al., 2012; Gupta et al., 2013] in mammalian cells. In the former set of 
studies, renal toxicity was assessed based on changes in plasma creatinine levels after drug 
administration compared with baseline values. 
Triptolide has limited clinical use due to its poor aqueous solubility and oral bioavailability. It also 
causes hepatotoxicity. However, oral administration of triptolide SLNs to rats led to an improved 
bioavailability and reduced toxicity of triptolide [Mei et al., 2005; Zhang et al., 2013]. An in vitro 
study by Ezzati et al. (2014) on alendronate sodium also indicated that loading the drug into SLNs 
resulted in a considerably lower cytotoxicity as compared with the free drug. SLNs therefore serve 
as a promising system for reducing drug-related toxicities. 
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1.6 Gastrointestinal transit of pharmaceutical dosage forms 
The small intestine is considered the main site of drug absorption in man due to its high and 
effective surface area [Davis et al., 1986]. If any, drug absorption from the stomach is minimal, 
and some drugs may be absorbed to a limited extent from the large intestine. The general 
consideration therefore is that drugs should be formulated so they can be principally absorbed from 
the small intestine. 
Ho et al. (1977) and Higuchi et al. (1981) introduced the 'reserve length' concept for drug 
absorption, which is the anatomical length over which complete drug absorption occurs. The 
reserve length depends on physiological factors such as bulk flow rate, spreading of the dosage 
form in the small intestine and drug permeability through the intestinal mucosa. 
Factors such as particle size, stress, posture, calorific value of meals and specific effects of 
fats/lipids have been shown to affect gastric emptying of markers, food and dosage forms [Kelly, 
1981; Dubois and Castell, 1984; Fell and Digenis, 1984; Fara, 1985]. For instance, smaller-sized 
drug [Sugito et al., 1992] and food [Olausson et al., 2008] particles are emptied from the stomach 
faster than larger ones in human subjects. Some studies have also indicated that lying down may 
slow down peristalsis [Steingoetter et al., 2006] and delay gastric emptying [Gruber et al., 1958]. 
In a study by Zheng et al. (2009), gastric emptying was found to be delayed when rats were acutely 
stressed (single stress), and then completely restored after chronic stress (repeated single stress for 
5 consecutive days) was applied using a restraint stress model. The presence of lipids in the 
duodenum [Hölzer et al., 1994] and consumption of meals of high caloric values [Calbet and 
MacLean, 1997] have also been found to delay gastric emptying.  
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Several methods are available to measure intestinal transit time of orally administered 
formulations. These include radiography, the use of metabolisable markers (hydrogen breath test) 
and gamma scintigraphy, with each having its benefits and shortcomings. The nature of the method 
employed, such as the use of a high osmolarity preparation (lactulose solution) in the hydrogen 
breath test [Read et al., 1980], or the present condition of the subject, such as intubation [Read et 
al., 1983], may alter the normal physiological processes in a subject. Gamma scintigraphy has 
mostly been used over the years for investigating the transit pattern (movement and disintegration) 
and intestinal transit time of dosage forms [Wilson et al., 1984; Christensen et al., 1985; Billa et 
al., 2000; Honkanen et al., 2004]; however, this procedure requires the use of expensive 
equipment, radionuclides and harmful radiation. Figure 1.9 illustrates how the position of a 
radiolabelled dosage form in the GI tract was monitored in gamma scintigraphy; noting that, the 
times of arrival of the dosage form at various points of the GI tract could also be estimated. 
 
Figure 1.9 Typical gamma scintigraphic images from a GI transit study in a human volunteer 
[Reference markers: Firmly attached to the skin at left lobe of liver and lower left 
costal margin to aid repositioning of the volunteer for image acquisition]  
[Billa et al., 2000] 
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1.7 Aim of the study 
To formulate and characterise an amphotericin B-containing solid lipid nanoparticulate 
formulation, and to study the gastrointestinal transit behaviour and absorption of the formulation 
in rats. 
 
1.8 Specific objectives 
1. To formulate and optimise an AmB-containing solid lipid nanoparticle (SLN) 
formulation. 
2. To formulate paracetamol (PAR) SLNs and sulphasalazine (SSZ) SLNs.   
3. To characterise the formulated SLN preparations to ensure similarities in their 
physicochemical properties. 
4. To develop and validate a high-performance liquid chromatography method to 
assay AmB, PAR and sulphapyridine (SP) simultaneously in rat plasma, using a 
suitable internal standard. 
5. To investigate the gastrointestinal transit behaviour and absorption of the AmB-
loaded SLNs using rats as the animal model. 
6. To study the effect of food on the absorption of the AmB SLNs. 
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CHAPTER 2 
FORMULATION AND CHARACTERISATION OF AMPHOTERICIN B, 
PARACETAMOL AND SULPHASALAZINE SOLID LIPID NANOPARTICLES 
2.1 Introduction  
Hydrophobic drugs such as AmB are poorly absorbed from the GI tract when administered orally; 
therefore, such drugs have to be administered in appropriate carrier systems to address the 
constraint of poor absorption in order to enhance their therapeutic efficacy. One main system 
proposed is the lipid-based delivery system (LBDS). Lipids increase drug absorption and thereby 
improve oral bioavailability by: facilitating the formation of solubilised species via particle size 
reduction, producing a solid-state solution within the carrier [Humberstone and Charman, 1997; 
Porter and Charman, 2001; Pouton and Porter, 2008; Jawahar et al., 2012]; changing drug uptake, 
efflux and disposition by modifying enterocyte-based transport [Wilson and Mahony, 1997; 
Pramod et al., 2010]; and enhancing lymphatic drug transport [Charman et al., 1997; Driscoll, 
2002; Porter et al., 2007]. 
After oral delivery, nanoparticles as well as microparticles less than 5 µm in size have the potential 
to traverse the Peyer’s patches along the GI tract, which drain into lymph and then eventually 
empty loaded drugs into systemic circulation [Jani et al., 1989; Jani et al., 1994; Shakweh et al., 
2005]. There is also evidence that lipid-based AmB formulations improve the oral bioavailability 
of AmB [Patel and Patravale, 2011; Jain et al., 2012] and minimise its side effects, chiefly the 
nephrotoxicity [Risovic et al., 2003; Gershkovich et al., 2009; Jain et al., 2012]. The triple-benefit 
of improved oral bioavailability, reduced renal toxicity and preclusion of infusion-related toxicity 
give oral AmB-containing SLN preparations a promising future in clinical use.   
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Adequate and proper characterisation of SLN dispersions is a prerequisite for the control of their 
quality. Characterisation of SLNs is however met with challenges due to their small size and the 
complexity and dynamic nature of the delivery system. The important parameters of SLNs that are 
usually evaluated include but are not limited to particle size, size distribution, zeta potential, degree 
of crystallinity and lipid properties, drug content, in vitro drug release and surface morphology 
[Mehnert and Mäder, 2001]. 
As the sizes of particles decrease to the submicron scale, their physicochemical properties begin 
to differ from those associated with their bulk forms/individual components [Baer et al., 2010]; 
thus, particle size is usually the first feature that is determined after SLNs are prepared. In addition, 
the surface layers of nanoparticles, whether deliberately or accidentally formed may have 
important effects on formulations so there is the need to understand and characterise the particle 
surface [Grainger and Castner, 2008]. Nanoparticles may also be coated with surfactants or 
contaminants hence, it is necessary that these are adequately identified and characterised as their 
composition and structure may affect the properties and performance of the formulation as a whole, 
especially during storage or after environmental exposure [Baer et al., 2010]. 
Many analytical tools cannot be used for direct measurement of freshly prepared undiluted SLN 
dispersions. Consequently, there is the possibility of changes within a sample prior to its 
characterisation, due to sample preparation procedures such as dilution, which results in the 
removal of emulsifiers from the particle surface. Additionally, removal of water during sample 
drying may induce crystallisation and lipid modifications [Mehnert and Mäder, 2001]. The 
aforementioned factors therefore have to be taken into consideration during characterisation of 
SLNs and other nanoparticulate systems. 
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In this chapter, the preparation and characterisation of individual SLN formulations containing 
AmB, PAR or SSZ are described. The characterisation studies precede a GI transit study in rats in 
the subsequent chapters, in which the PAR and SSZ (from which SP is released in vivo) serve as 
markers for estimating the gastric emptying and orocaecal transit times respectively, of the AmB 
SLNs. The exhaustive characterisation of all three SLNs is to ensure similarity in their 
physicochemical properties with the assumption that, when administered simultaneously via the 
oral route, they would respond similarly to the hydrodynamics within the GI tract.   
 
2.2 Materials  
Beeswax (Acros Organics, Morris Plains, NJ, USA), theobroma oil (JB Cocoa Sdn Bhd, Gelang 
Patah, Johor, Malaysia), amphotericin B (Nacalai Tesque, Inc., Kyoto, Japan), sulphasalazine 
(Tokyo Chemical Industry Co. Ltd., Tokyo, Japan) and agarose (1st Base Laboratories Sdn Bhd, 
Seri Kembangan, Selangor, Malaysia) were purchased from the respective companies. 
Paracetamol, trehalose and phosphate-buffered saline (pH 7.4) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Lecithin soy and sodium cholate were obtained from MP 
Biomedicals (Illkirch, France). Chloroform, ethyl acetate, methanol and hydrochloric acid were 
purchased from Fisher Scientific (Loughborough, UK). SYBR® Green and loading buffer were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). All reagents and solvents used 
were of analytical and HPLC grades, respectively. Water used was Milli-Q 18.2 MΩ·cm at 25°C 
(Millipore Corp., Bedford, USA). 
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2.3 Methods 
2.3.1 Formulation of AmB, PAR and SSZ SLNs  
The SLNs were prepared as previously described by Tan et al. (2010) but without oleic acid (liquid 
lipid). Briefly, the drug (AmB, PAR or SSZ) and lecithin soy (LS) were first dissolved in a mixture 
of chloroform-methanol at a 2:1 ratio, along with theobroma oil (TO) and beeswax (BW) as 
indicated in Table 2.1. The solvent mixture was evaporated off using a Rotavapor® R-200/205 
(Büchi Labortechnik AG, Flawil, Switzerland) at 50°C, leaving the drug embedded within the lipid 
matrix. The lipid matrix was melted in 10 mL of ethyl acetate (previously equilibrated with water 
for 10 min) at 70°C. At the same time, 20 mL of a 5%w/v sodium cholate (SC) solution was heated 
to the same temperature. Both phases were homogenised using a high-speed homogeniser (Ika-
Turrax T 25®, IKA®, Staufen im Breisgau, Germany) at 9 500 rpm for 10 min. 80 mL of water at 
70°C was then added slowly to the mixture with continuous stirring for a further 20 min. The 
organic solvent was then evaporated off using the rotary evaporator at 70°C. 
 
Table 2.1 Composition of the SLNs 
Drug Amount of 
drug (mg) 
Theobroma 
oil (mg) 
Beeswax 
(mg) 
Lecithin 
soy  (mg) 
Sodium cholate      
(mg/20 mL) 
Water 
(mL) 
AmB, PAR 
or SSZ 
50 200 200 120 1000 80 
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2.3.2 Scanning electron microscopy (SEM)  
The surface topography and morphology of the SLNs were determined using a Quanta 400 FE-
SEM (FEI, Hillsboro, OR, USA). Prior to analysis, the samples were diluted with Milli-Q water. 
They were then placed on carbon tape and air-dried for 24 hr. Samples were then mounted on the 
stage and viewed under low vacuum mode at 20 kV. 
 
2.3.3 Optimised procedure for preparing AmB, PAR and SSZ SLNs 
The SLNs were prepared according to the procedure described in Section 2.3.1 with the following 
modifications. The chloroform-methanol mixture was used at a ratio of 1:1. The concentration of 
the SC solution was reduced to 2.5%w/v. The volumes of ethyl acetate and SC solution used, each 
at 70°C, were 20 mL and 40 mL, respectively. Homogenisation of the lipid and aqueous phases 
was done at 10 000 rpm for 6 min. The final steps were addition of 60 mL of water at 70°C to the 
nanoemulsion formed, followed by stirring the mixture for 20 min and then evaporation of the 
organic solvent. 
 
2.3.4 Characterisation of the optimised SLNs 
2.3.4.1 Relative density and viscosity determinations 
The densities and viscosities of freshly prepared SLN dispersions were investigated using a density 
bottle and a viscometer (DV-I Prime, Brookfield Engineering Laboratories Inc., Middleboro, MA, 
USA), respectively. For the relative density determination, the mass of each formulation was 
divided by the mass of an equal volume of deionised water. The viscosity values on the other hand 
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were obtained directly from the viscometer readings. All determinations were made in triplicate 
and results expressed as mean ± standard deviation (SD). 
 
2.3.4.2 Gel electrophoresis 
In order to gain an insight into the relative movement propensities of the three SLNs within a 
milieu as may be encountered in the GI tract, a gel electrophoresis was set up (Figure 2.1) and the 
distances travelled by the three SLNs, constrained within agarose gel were measured. Agarose was 
completely dissolved in 1×TBE (89 mM Tris base, 89 mM boric acid and 2 mM EDTA) buffer 
solution at a concentration of 1%w/v using microwave heating. The solution was allowed to cool 
slightly (before gelation), followed by the addition of 30 µL of SYBR® Green dye. The mixture 
was poured into a casting plate and a gel comb was inserted to form wells. The gel was left to set 
at room temperature for 30 min. The running buffer, 1×TBE, was then poured into the gel tank to 
submerge the gel. A 10-µL aliquot of each SLN sample was mixed separately with 2 µL of the 
loading buffer (containing glycerol, bromophenol blue as dye and water) and then loaded into the 
wells within the gel in triplicates. The gel electrophoresis unit was run at 45 V for 45 min and 
then 39 V for 15 min. The migration of the SLNs within the gel was viewed under UV light (Bio-
Rad, Hercules, CA, USA) and the distances travelled were measured using a calibrated ruler. 
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Figure 2.1 Gel electrophoresis set-up 
 
2.3.4.3 Photon correlation spectroscopy (PCS)  
PCS studies were carried out on the SLNs using a Zetasizer Nano ZS® (Malvern, UK) equipped 
with a 4 mW He-Ne laser (633 nm). The parameters measured were z-average, zeta potential and 
polydispersity index (PDI). Particle size analysis using PCS is evaluated using the intensity 
distribution of the particles; therefore, the z-average is the mean intensity diameter of the particle 
population. PDI, also known as heterogeneity index describes the width of variation within the 
sample size distribution. The zeta potential is the measurement of the net surface charge of the 
SLNs. 
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All SLN samples were diluted with Milli-Q water before analyses using a clear disposable zeta 
cell. Each analysis was carried out at 25°C and performed in triplicate. The data obtained were 
expressed as mean ± SD. 
 
2.3.4.4 SEM analyses 
SEM analyses were performed as described in Section 2.3.2. 
 
2.3.4.5 Atomic force microscopy (AFM)  
AFM images were obtained from freshly prepared SLN samples using a scanning probe 
microscope (NTEGRA Prima, NT-MDT, Moscow, Russia). Prior to analysis, 50 µL of each 
sample was diluted with 1 mL deionised water. A 40-µL aliquot of this dilution was placed on a 
mica disc and air-dried after removing excess liquid with filter paper. Images were recorded in 
tapping mode using silicon cantilevers coated with aurum at a resonance frequency of 220 kHz.  
 
2.3.4.6 Fourier transform infrared spectroscopy (FTIR)  
This analysis was conducted to verify the possibility of interaction between the drugs and other 
components within the SLN formulations. Infrared spectra were obtained using an FTIR 
spectrophotometer (Spectrum RX I, Perkin Elmer, Waltham, MA, USA). To record the spectra, 
samples were ground with an appropriate amount of potassium bromide until a homogenous mix 
was obtained. A well-formed disc of the mixture was obtained by compressing the mixture at a 
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pressure of 5 tons for 5 min using a pellet press (Model 4350, Carver Inc., Wabash, IN, USA). The 
spectra were obtained over a wavenumber range of 4000-400 cm-1. 
 
2.3.4.7 Differential scanning calorimetry (DSC)  
DSC thermograms of the drugs, bulk lipids and SLNs were obtained using a DSC Q2000 (TA 
instruments, New Castle, DE, USA) equipped with a TA Universal Analysis 2000 software. 
Approximately 5 mg of sample was placed in a standard aluminium pan, hermetically sealed and 
subjected to the analyses at a scan rate of 5°C/min from -20 to 250°C. The melting enthalpies of 
the samples were obtained by integration of their melting peaks with the TA Universal Analysis 
2000 software. Analyses were run under a gentle stream of nitrogen (50 mL/min), using an empty 
pan as the reference.  
 
2.3.4.8 HPLC method for in vitro analyses 
A Perkin Elmer HPLC system (Series 200 auto-sampler, Series 200 UV/VIS detector) configured 
to TotalChrom® Navigator software was used with an Eclipse Plus® C18 (250 x 4.6 mm, 5 μm) 
column (ZORBAX, Agilent, Santa Clara, CA, USA). The mobile phase was filtered through a 
0.45 μm membrane filter before use and comprised of acetate buffer (pH 4) [A], prepared by 
mixing 847 mL of 0.1 M acetic acid and 153 mL of 0.1 M sodium acetate trihydrate [Lambert and 
Muir, 1955]; and acetonitrile [B]. The mobile phase was run at a flow rate of 1 mL/min in gradient 
mode as follows: 100% A at 0-0.5 min; 60% A at 0.5-7 min; 20% A at 7-9 min; 60% A at 9-12 
min and 100% A at 12-15 min. A wavelength of 254 nm was used to detect PAR and SSZ, and 
405 nm used to detect AmB. Calibration curves for AmB, PAR and SSZ dissolved in a mixture of 
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methanol and dimethyl sulphoxide at ratios of 1:3, 3:1 and 1:1, respectively, were plotted (peak 
area against drug concentration) over a concentration range of 0.25-50 µg/mL for each drug. The 
coefficients of determination (R2) and line equations were determined for each calibration curve. 
 
2.3.4.9 Encapsulation efficiency (%EE) 
The %EE of AmB, PAR or SSZ within the SLNs was determined following a slightly modified 
method [Tan et al., 2010]. Briefly, a few drops of a 0.1 M HCl solution were added to 1 mL of 
SLN dispersion to precipitate the nanoparticles, followed by centrifugation at 14 000 rpm for 45 
min using a microcentrifuge (Microfuge® 16, Beckman Coulter Inc., Brea, CA, USA). The 
supernatant was decanted and the precipitate washed with PBS (pH 7.4) to remove any free drug. 
The precipitate was then dissolved in 1 mL of a mixture of methanol and DMSO at a ratio of 1:3, 
3:1, and 1:1 for AmB, PAR and SSZ SLNs, respectively. The above mixtures were heated to 70°C 
and then cooled to room temperature, followed by centrifugation at 14 000 rpm for 10 min to 
separate the lipid. The amount of drug in the solvent was determined using HPLC (Section 2.3.4.8). 
The %EE was calculated using the following equation: 
%EE =  
Amount of drug in precipitate 
Amount of drug used in formulation
 × 100%   ………………Equation 2.1 
 
2.3.4.10 Drug release studies 
Cumulative in vitro drug release studies on both freshly prepared and freeze-dried (Alpha1-2 
LDPlus freeze-dryer, Osterode am Harz, Germany) SLNs were conducted using PBS (pH 7.4) as 
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the dissolution medium. SLNs containing 0.5 mg of drug were dispersed in the dissolution medium 
and incubated at 37°C in a WiseCube WIS-20® shaking incubator (PMI-Labortechnik GmbH, 
Grafstal, Switzerland) operated at 100 rpm. At predetermined time intervals (0, 1, 2, 4, 8 hr), 1 mL 
samples were withdrawn and the volume taken was replenished with the dissolution medium. The 
nanoparticles were then precipitated with 0.1 M HCl, followed by centrifugation at 14 000 rpm for 
10 min using a microcentrifuge and the supernatant decanted. A 20-µL aliquot of the supernatant, 
containing the released drug was then injected onto the HPLC (Section 2.3.4.8) and the cumulative 
amount of drug released with time calculated. The data obtained are expressed as mean ± SD from 
triplicate measurements. The same procedure was followed for each SLN formulation. 
The in vitro release of the SLNs was further evaluated up to 30 hr on individual seeded tubes and 
not cumulatively as described above. Several replicas of 100 μL SLNs (either freshly prepared or 
a suspension of freeze-dried sample in deionised water) were placed in separate microcentrifuge 
tubes containing 1 mL of PBS (pH 7.4) and subjected to the same conditions (temperature and 
speed) as described above. The analyses were conducted for drug released in each tube. At 
predetermined times (0, 1, 2, 4, 8, 18 and 30 hr), a seeded tube was taken and subjected to the same 
procedure of SLN precipitation, centrifugation and analysis of supernatant as described above. 
 
2.3.4.11 Determination of drug release kinetics 
The release kinetics of the drugs from the SLNs were determined by fitting the in vitro release data 
into the equations presented in Table 2.2. The zero order kinetics corresponds to the percentage 
cumulative drug release versus time data. Values of the coefficients of determination (R2) were 
calculated from the linear curves obtained by regression analyses of the plot for each formulation. 
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The kinetic model that best fitted the release data was then evaluated by comparing the R2 values 
from using the various models. For the Korsmeyer-Peppas model, the value of n was also obtained.  
 
Table 2.2 Models for drug release kinetics 
Model Expression 
Zero order Q = Kt … … … … … … . . . . Equation 2.2 
First order 
log QR =
Kt
2.303
… … … . . Equation 2.3 
Higuchi 
Q = K(t)
1
2 … … … … … … . Equation 2.4 
Hixson-Crowell 
Q0
1
3⁄ − Qt
1
3⁄ = Kt … … . . . Equation 2.5 
Korsmeyer-Peppas log Q = log K + nlog t … Equation 2.6 
 
Where: Q - percentage cumulative release; QR - percentage drug remaining; t - time in hours; K - 
constant (according to the respective models); n - release/diffusional exponent. 
 
2.3.4.12 Statistical analyses 
The properties of the AmB SLNs, PAR SLNs and SSZ SLNs were compared where appropriate 
using GraphPad Prism 5 software. Paired t-test was used to analyse statistical differences between 
freshly prepared and freeze-dried SLN samples. In all cases, statistical significance was indicated 
when p value < 0.05. 
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2.4 Results and discussion 
2.4.1 Physical appearance of the SLNs 
Figure 2.2 shows the appearances of the freshly prepared SLNs. The arrows in the diagram point 
to a small amount of sediment at the bottom of the AmB SLN vial, and areas of different opacities 
in the PAR and SSZ SLNs. The latter is clearly indicative of creaming phenomenon. Many 
emulsion-based formulations cream on standing [Attwood, 2001]. This is caused by the dispersed 
phase either rising to the top or sinking to the bottom of the preparation depending on its density 
relative to that of the continuous phase. The nanoparticles in the creamed layers of the SLNs did 
not coalesce, thus they were easily redispersed upon shaking however, creaming is not desirable 
as it increases the tendency of particle aggregation. One way of preventing creaming is to reduce 
the particle size of the dispersed phase, which can be achieved by homogenisation at an optimum 
speed and for an optimum time. This is because, although homogenisation results in particle size 
reduction, the kinetic energy imparted to the particles can result in particle collisions and cause 
aggregation and increase in particle size instead.  
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Figure 2.2 Physical appearance of the SLNS 
 
2.4.2 SEM analyses of the SLNs 
The images obtained from the SEM analyses of all the three SLNs as presented in Figure 2.3 
showed that mostly spherical microparticles were formed instead of nanoparticles. These images, 
together with the physical appearance of the SLNs (Figure 2.2) necessitated that the SLNs be 
reformulated.  
After optimisation, homogenisation at a speed of 10 000 rpm for 6 min was deemed favourable for 
formulating the SLNs to achieve particle size reduction to the submicron range. 
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Figure 2.3 SEM images of the SLNs 
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2.4.3 Physical appearance of the optimised SLNs  
The modified procedure stated in Section 2.3.3 was used in preparing the SLNs shown in Figure 
2.4. The SLNs were easy to differentiate from each other as the final products took the colours of 
the incorporated drugs; yellow for the AmB SLNs, white for the PAR SLNs and bright yellow for 
the SSZ SLNs. The preparations were uniform in appearance without any signs of physical 
instability such as creaming, flocculation, coalescence or particle sedimentation. 
 
Figure 2.4 Physical appearances of the optimised SLNS 
 
2.4.4 Relative density and viscosity 
The mean values of relative densities were 1.00, 1.01 and 1.01 for AmB, PAR and SSZ SLNs 
respectively; and were not significantly different from each other (p > 0.05 in all cases). The mean 
viscosity values were 1.14±0.16 cPs, 1.21±0.06 cPs and 1.04±0.12 cPs for AmB, PAR and SSZ 
SLNs respectively; also being not statistically different from each other (p > 0.05). Viscosity and 
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density play a significant role in the GI transit of dosage forms because generally, low viscosity 
liquid dosage forms offer advantages of elimination of fed-fasted effects, rapid drug absorption 
and increased bioavailability [Amidon et al., 1991; Clarke et al., 1993; Tuleu et al., 1999; Bosch 
et al., 2003]. It is therefore probable that the three SLNs would respond similarly to the 
hydrodynamics imposed by the GI tract due to the similarities in viscosity and density.  
 
2.4.5 Gel electrophoresis 
In order to further ascertain the relative propensities of the three SLNs to move within a milieu, 
the SLNs were subjected to gel electrophoresis and the distances migrated by each type of SLN 
towards the positive electrode were measured. The agarose gel matrix contains pores that are 
formed from random packing of the polymer, which consists of repeating agarobiose units. 
Agarobiose is a disaccharide derived from D-galactose and 3,6-anhydro-L-galactopyranose. 
Although the pores in the gel are small and the gel is stationary in contrast to what would be 
expected in the GI tract, the analyses nonetheless give an indication of the mobility propensities 
of the SLNs within a matrix such as chyme. Figure 2.5 illustrates images of the agarose gel before 
and after the application of voltage, and clearly show that the SLNs travelled similar distances 
along the gel. The distances migrated by the three types of SLNs were 22.2±0.0 mm for AmB; 
22.4±0.4 mm for PAR and 22.3±0.1 mm for SSZ, with the values not differing from each other 
significantly (p > 0.05). This study along with the density and viscosity data further suggest the 
possibility of similar dispositions amongst the three SLNs in response to GI hydrodynamics. 
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Figure 2.5 Agarose gel (a) before and (b, c) after voltage application [b-normal photograph; c-
image obtained from viewing the gel under UV light] 
 
2.4.6 PCS studies 
The particle size distribution profiles for all three SLNs were mostly unimodal with negligible 
proportions of the particles having sizes above 1000 nm as depicted in Figure 2.6. From Table 2.3, 
it can be seen that there were no statistically significant differences among the z-averages of the 
three SLNs (p > 0.05), albeit a slightly higher value for SSZ (224.8±3.3 nm) and PAR (210.1±1.4 
nm) compared with AmB (206.5±1.7 nm) SLNs. All the PDI values obtained were well below 0.5, 
ranging from 0.16±0.03 to 0.22±0.01, which indicates a mostly narrow particle size distribution. 
This is also evidenced by the narrow widths of the particle size distribution profiles.  
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The ZP values for all three SLNs showed that the surfaces of the particles were negatively charged. 
This is attributable to the use of sodium cholate, which is an anionic surfactant, in preparing the 
SLNs. The magnitude of ZP can be used to predict colloidal stability, with values greater than |60 
mV| indicating very good stability resulting from high inter-particle electrostatic repulsion, which 
is of great importance during storage [Riddick, 1968]. The ZP for the three SLNs ranged from -
61.9±1.0 mV to -71.9±0.9 mV indicating that particle aggregation during storage owing to van der 
Waals inter-particle attractions can be expected to be low.  
 
Table 2.3 Z-averages, PDIs and ZPs of freshly prepared SLN formulations 
 
Sample Z-average            
(nm) 
PDI ZP                        
(-mV) 
AmB 210.1±1.4 0.22±0.01 61.9±1.0 
PAR 206.5±1.7 0.16±0.03 71.9±0.9 
SSZ 224.8±3.3 0.19±0.08 70.7±0.6 
p value * * * 
* p > 0.05 - the mean values do not significantly differ from each other statistically 
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Figure 2.6 Particle size distribution by intensity of the freshly prepared SLNs (n = 3) 
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2.4.7 SEM analyses 
The images obtained from the SEM are presented in Figure 2.7. All three SLNs showed uniform 
spherical particles with fairly smooth morphologies and generally appeared identical in outlook, 
with a tendency for agglomeration. The SEM images show homogenous particle sizes and 
corroborate the size data obtained in the PCS analysis. None of the images of the SLNs showed 
the presence of drug crystals. 
It can also be seen that the particle sizes from the SEM data are lower than the z-average values 
obtained from the PCS analyses. The particle sizes in the SEM seem to be at the lower end of the 
size distribution profiles for all three SLNs, which is consistent with the findings of Dubes et al. 
(2003) who observed a similar pattern. This is because PCS measurements are based on DLS, and 
measure the hydrodynamic diameter of particles. DLS measurements depend on additional surface 
structures attached to particles due to the double layer of solvated ions that move with the particles 
when the latter are in Brownian motion in a liquid. Therefore, the sizes measured in PCS are 
relatively larger than those obtained from microscopic techniques since the latter do not use DLS. 
In addition, any hydration layers around the particles are removed during the drying step of sample 
preparation prior to analysis, if drying is required [Tscharnuter, 2000; Svilenov and Tzachev, 
2013]. 
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Figure 2.7 SEM images of the optimised SLNs 
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2.4.8 AFM studies 
AFM analyses were done to further study the size, morphology and surface texture or roughness 
of the SLNs. Figures 2.8-2.10 show the phase, topographic and 3D images of the SLNs. The 
sample surface topographic and phase images for all three SLN formulations showed discrete 
particles, which were somewhat spherical in shape, and with sizes corroborating those obtained 
from the PCS and SEM analyses. The phase images showed that the SLNs have a homogenous 
appearance without a crystalline or rough appearance to suggest significant drug adsorption on the 
particle surfaces. The 3D images further reveal that the particles from all the formulations studied 
had somewhat smooth surfaces. Comparing the height of the particles (z-axis) with the 
width/diameter dimensions on the x- and y-axes, it was observed that the heights were below 50 
nm with the diameters being up to about 200 nm.  This indicates that the particles may be disc-like 
or platelet-like in shape or that they may have lost their sphericity during the sample preparation 
process however, non-spherical particles are seen in the topographic images as well. As with the 
particle sizes in the SEM images, it can be seen that the particle sizes obtained from the AFM 
analyses are smaller as compared with the z-average sizes obtained in the PCS analyses. This is 
because the SLN samples were air-dried prior to the analyses as was done for the SEM analyses, 
thereby removing any solvent layers, which contribute to the hydrodynamic particle diameters in 
PCS analyses. The disc-like shape and the difference between the diameter and height of the SLNs 
are in line with the findings of zur Mühlen et al. (1996) and Dubes et al. (2003). Dubes et al. 
(2003) also attributed smaller particle sizes from SEM analyses compared with PCS sizes to 
possible shrinking of particles during sample drying. 
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Figure 2.8 AFM (a) surface topographic (b) phase and (c) 3D images of AmB SLNs 
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Figure 2.9 AFM (a) surface topographic (b) phase and (c) 3D images of PAR SLNs 
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Figure 2.10 AFM (a) surface topographic (b) phase and (c) 3D images of SSZ SLNs 
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2.4.9 FTIR analyses  
Figure 2.11 shows the chemical structures of AmB, PAR and SSZ.   
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Chemical structures of AmB, PAR and SSZ 
 
FTIR was used to identify possible changes in the drugs (AmB, PAR and SSZ) after incorporating 
them into the SLN formulations. Such changes may result from interactions between the lipids, 
drug and the other excipients, which were sodium cholate and lecithin soy, used in the 
formulations. In general, the FTIR spectra of the pure drugs and their respective SLNs showed no 
AmB 
PAR 
SSZ 
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significant chemical interactions between the drugs and the excipients as characteristic drug peaks 
were still seen in the corresponding SLN spectra, indicating compatibility between the drugs and 
the excipients in the formulations.   
Theobroma oil (TO) is an edible vegetable fat composed mainly of triglycerides of palmitic 
acid, stearic acid and oleic acid. TO has C-H and C=H stretching vibrations at approximately 719 
and 1464 cm-1; and between 2800-3000 cm-1, respectively. The O-C=O ester bond vibration found 
in triglycerides is also located 1177 and 1736 cm-1 [Goodacre and Anklam, 2001]. 
Beeswax (BW) is a wax formed from several compounds. Its main components 
are palmitate, palmitoleate and oleate esters of cerotic acid and long-chain (30-32 
carbons) aliphatic alcohols such as triacontanyl alcohol. BW shows hydrocarbon vibrations at 
approximately 2918 and 1464 cm-1. It has bands of esters (O-C=O) at about 1700 cm-1 and alcohols 
(O-H) at 1047 cm-1. There have also been peaks detected at approximately 1338 cm-1 for amides 
and at 1219 and 728 cm-1 for amines [Zimnicka and Hacura, 2006]. 
Lecithin on the other hand is composed largely of phosphoric acid, choline, fatty 
acids, glycerol, glycolipids, triglycerides and phospholipids [Nzai and Proctor, 1998]. The 
phosphate stretches are evident at 1177, 1078 and 1047 cm-1 while the quaternary amine group is 
characterised by asymmetrical and symmetrical stretchings at 1046 and 1078 cm-1, respectively. 
There is also a band between 1765-1720 cm-1 corresponding to a strong C=O stretching vibration 
in the phospholipid and a (CH3)3N stretching band at 983 cm
-1. 
Cholic acid is a bile acid. Sodium cholate shows characteristic bands for O-H stretching at about 
3394 cm-1 and C-H vibrations at 2939 and 2863 cm-1. There are also bands showing vibrations for 
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C-H in-plane bending, C=O and C-O-H at about 1403 cm-1; and C-C-O at 1082 cm-1 [Yang et al., 
2005]. 
It is evident from the above that a number of functional groups exist in the excipients in the SLN 
formulations. Some of the bands representing characteristic functional groups in the drugs were 
slightly shifted to lower or higher frequencies or showed differing band intensities or both, in their 
respective SLN spectrum. Other peaks also seem absent or merged with adjacent peaks to form 
larger bands. These are due to the many functional groups from both the drugs and excipients, 
resulting in the possibilities of merging of bands closely located in the spectra; as well as possible 
interactions between drug and lipid/excipients such as intermolecular hydrogen bonding. 
Figure 2.12 shows the FTIR spectra for pure AmB and AmB SLN. The pure drug shows 
characteristic bands at 1692, 1570 and 1010 cm-1 due to C=O stretch band and N-H2 in-plane bend, 
polyene C=C stretch band, and C-H bend out-of-plane bend, respectively. The peak at 1040 cm-1 
is also characteristic of the bending of N-H2 out-of-plane and C-O-C symmetric stretching 
vibration due to the pyranose ring. The 1177 cm-1 band also represents a C-O-C asymmetric stretch 
for the β-glycosidic linkage. The C-H bend in the pyranose ring vibration is also represented by 
the 851 cm-1 peak. Comparing the spectra for AmB and AmB SLN, it can be seen that the majority 
of the aforementioned peaks are still present in the SLN except for the carbonyl-stretching band at 
1692 cm-1 which seems to have merged with the peak at 1736 cm-1 in the SLN spectrum [Asher 
and Schwartzman, 1977; Nahar and Jain, 2009; AL-Quadeib et al., 2015]. 
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Figure 2.12  FTIR spectra for pure AmB and AmB SLN 
 
Figure 2.13 shows FTIR spectra for PAR and PAR SLN. The main absorption bands for pure PAR 
are those at: 3326 cm-1, which represents the N-H stretching vibration; 3162 cm-1 for the O-H 
group stretching vibration; 1655 cm-1 for the C=O group; 1564 cm-1 for the N-H in-plane bending; 
1610, 1506 and 1442 cm-1 for the aromatic ring; and 1327 cm-1 for O-H bending vibration [Wang 
et al., 2002]. There is also a peak at 1260 cm-1 for the C-N stretching vibration. All these peaks 
are found present in the spectrum for PAR SLN except those at 3326 cm-1 and 3162 cm-1. Instead, 
there is a single band at 3401 cm-1 in the SLN, which is characteristic of the O-H functional group 
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in PAR, BW and sodium cholate; and which also points to a possible intermolecular hydrogen 
bonding of the O-H group with the N-H group in PAR. 
 
Figure 2.13 FTIR spectra for pure PAR and PAR SLNs 
 
Figure 2.14 shows the FTIR spectra for pure SSZ and SSZ SLN. The spectrum for pure SSZ shows 
a medium broad band at 3438 cm-1, which is attributed to the phenolic O-H and carboxylic O-H 
groups [Soliman et al., 2005]. Other characteristic peaks are those at 1280, 1427 and 1618 cm-1, 
representing the C=O bond in the phenolic group, and symmetric and asymmetric stretching 
vibrations of the carboxylate moiety, respectively.  
77 
 
 
Figure 2.14 FTIR spectra for pure SSZ and SSZ SLNs 
 
The peak located at 1587 cm-1 represents the stretching of the N=N group; while those at 1359 cm-
1 and 1173 cm-1 represent asymmetric and symmetric stretching vibrations of the O=S=O group, 
respectively [Soliman et al., 2005]. In-plane bending of O-H group occurs at 1394 cm-1. The bands 
at 1618 and 1587 cm-1 assigned to the carbonyl and azo groups, respectively, are not apparent in 
the spectrum for the SSZ SLN, which is attributable to interactions with other functional groups 
in the formulation resulting in merged and broader bands shifted to 1635 and 1563 cm-1, 
respectively. These two latter peaks are present at similar positions in the spectra for AmB SLN 
and PAR SLN as well so it cannot be established if a significant interaction had occurred between 
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SSZ and the excipients in the formulation. However, it could rather be explained that the two bands 
are largely due to functional group interactions in the excipients as neither peak points directly to 
a characteristic band in any of the excipients. Again, it can be observed that the peaks at 1635 and 
1563 cm-1 are of higher intensities in the spectra for all three SLNs as compared with peaks at 
similar positions in the pure drugs, which further supports the preceding statement. 
Figure 2.15 illustrates the FTIR spectra for the three SLNs only. The resemblance among the 
spectra is clearly seen, which is due to the same vibrations in the lipids and other excipients, as the 
SLNs were similarly formulated. The circled band in the spectrum for PAR SLN at 1515 cm-1 is 
the most visible peak clearly absent from the other spectra. The other main differences in the 
spectra are the shifts in frequencies and differences in shape and intensities of similar peaks, which 
clearly emphasise the effect of the different molecular vibrations in the three different drugs; and 
also the various interactions that may have occurred among the excipients or between the drugs 
and the excipients.  
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Figure 2.15 FTIR spectra for AmB SLNs, PAR SLNs and SSZ SLNs 
[Circled band represents the most distinct peak in the PAR SLN, possibly due to the aromatic ring 
in PAR; and which is absent from the spectra for the AmB and SSZ SLNs] 
 
2.4.10 DSC studies 
DSC analyses were carried out in order to identify any interactions between the components of the 
SLN formulations, chiefly between the lipids and drugs, and to investigate the melting behaviour 
of the lipids. Figure 2.16 shows the DSC thermograms of the excipients (bulk lipids, lecithin soy 
and sodium cholate) overlaid on the thermograms of the various SLN formulations while Figure 
2.17 shows thermograms of the pure drugs and the SLNs containing them.  
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Figure 2.16 DSC thermograms of theobroma oil (TO), beeswax (BW), lecithin soy (LS), sodium cholate (SC), drug-free (DF) SLN 
and the drug-loaded SLNs 
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Figure 2.17 DSC thermograms of pure drugs and their respective SLN formulations
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Table 2.4 also lists the melting temperatures and enthalpies of TO and BW in their bulk forms as 
well as within the SLNs. 
 
Table 2.4 Melting peaks and enthalpies of TO and BW in the bulk lipids and the SLNs  
 
 
Sample 
 
 
TO  
 
BW 
Melting 
point 
(°C) 
Melting 
enthalpy 
(J/g) 
Melting 
point 
(°C) 
Melting 
enthalpy 
(J/g) 
Bulk lipid 35.1 156.1 63.3 176.7 
Drug-free SLNs 33.1 13.32 61.8 3.47 
AmB SLNs 33.1 5.95 61.5 3.76 
PAR SLNs 32.9 8.55 61.9 4.07 
SSZ SLNs 33.4 6.32 61.3 3.68 
 
Overall, it can be seen that the melting peaks of TO and BW occurred at slightly lower 
temperatures (32.9-33.4°C for TO and 61.3-61.9°C for BW) in all the SLNs compared with that 
of their bulk counterparts (35.1°C for TO and 63.3°C for BW). It is also observed that the melting 
peaks corresponding to TO and BW in the SLN thermograms are broadened while those for the 
bulk lipids are sharper. These are largely due to the increased surface area resulting from the 
nanocrystalline size of the lipids in the SLNs as compared with the larger size and smaller surface 
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area of their bulk forms. The peak broadening is essentially due to the polydisperse nature of the 
particles, which causes different fractions to melt at slightly different temperatures [Westesen and 
Bunjes, 1995; Unruh et al., 1999; Bunjes et al., 2000]. It is clear from the results that the properties 
of the lipid cores in all the SLN formulations remained essentially the same as their bulk forms. 
This is because, any changes in the crystalline properties of the lipids after formulating the 
nanoparticles would have manifested as substantial changes in their melting temperatures; which 
would indicate that a polymorphic transformation has occurred. 
Melting enthalpy is another indication of the crystal orderliness in lipids, aside melting point [Hou 
et al., 2003]. Generally, substances in their less ordered crystal or amorphous state require less 
energy to melt as compared with their perfect crystalline forms, which need higher amounts of 
energy to overcome crystal lattice forces. The melting enthalpies of the bulk TO and BW were 
156.1 and 176.7 J/g respectively; this suggests ordered lattice arrangements unlike in the SLNs in 
which they exist as their amorphous forms, resulting in lower melting enthalpies ranging 5.95-
13.32 J/g and 3.47-4.07 J/g, respectively. 
The melting peaks for the drugs: 153.7°C for AmB, 169.6°C for PAR and 245.9°C for SSZ, were 
absent from the thermograms of the respective SLNs containing them. This suggests that the drugs 
are dispersed in their amorphous forms within the SLNs and not in their crystalline states as in the 
bulk forms. This change in form occurred during preparation of the SLNs when the drugs were 
dissolved in the solvent-mix and the melted lipids, resulting in a homogenous distribution of the 
drugs in the latter. Again, the sodium cholate serving as surfactant keeps the drugs solubilised in 
the SLN structure; this prevents the drugs from crystallising out and keeps them in their amorphous 
states [Cavalli et al., 1997; Cavalli et al., 1999; Venkateswarlu and Manjunath, 2004]. These 
results are in line with other DSC studies in which drug peaks were absent from the respective 
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SLN thermograms but present when physical mixtures of the drugs and excipients were analysed 
[Yang and Zhu, 2002; Venkateswarlu and Manjunath, 2004; Reddy et al., 2006; Zhang et al., 2012; 
Yasir and Sara, 2014]. 
 
2.4.11 HPLC analyses 
The amount of AmB, PAR and SSZ encapsulated within the respective SLNs as well as the 
amounts of each drug released from the particles during the in vitro studies were determined using 
HPLC, employing external standard calibration. A standard curve was constructed for each analyte 
from peak responses against known concentrations of standard solutions. The equations generated 
from the curves were then used in calculating unknown amounts of the respective analytes. 
Identification and assignment of the peaks for the various analytes were done by repeatedly 
injecting standard solutions of the respective drug solutions under the same chromatographic 
conditions. In most HPLC analyses, quantitative calculations are done using peak areas; however, 
equivalent results can be achieved with peak heights for most cases [Crawford Scientific, 2015(a)]. 
The use of peak area is more suitable if there is peak tailing because the latter results in variations 
in peak heights while peak area values generally remain constant and are therefore more 
reproducible. Calculations using peak heights are usually preferred for trace analysis, in which the 
peaks of interest are very small owing to very low analyte concentrations [Lindholm, 2004; 
Crawford Scientific, 2015(a)]. In the present study, drug assays were conducted using peak areas. 
Figure 2.18 shows representative individual chromatograms obtained from separately injecting 
solutions of AmB, PAR and SSZ under the same chromatographic conditions.  
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Figure 2.18 Representative chromatograms for AmB at 405 nm, and PAR and SSZ at 254 nm [50 µg/mL each in a pure solution] 
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It can be seen that all the peaks obtained are very well resolved without any interfering peaks. The 
retention times were obtained as 11 min for AmB at 405 nm; and as 6.6 min and 9.7 min for PAR 
and SSZ, respectively, at 254 nm. The calibration curves were found to be linear over the 
concentration range of 0.25-50 µg/mL for each drug (Figure 2.19). The coefficients of 
determination (R2) were obtained to be 1, 1 and 0.9997, for AmB, PAR and SSZ, respectively, 
indicating very good linearity. The simple HPLC method and mobile phase system used can be 
applied in assaying AmB, PAR or SSZ in pharmaceutical formulations and the clear retention 
times of the analytes from each other also allows for their simultaneous assay.  
There are several published data on the individual detection and assay of AmB, PAR and SSZ in 
various pharmaceutical dosage forms, chiefly for quality control and stability testing purposes. In 
an HPLC method for analysing SSZ, a retention time and run time of 14 min and 18 min, 
respectively, were obtained by Saini and Bansal (2014), which are both longer than those obtained 
in this study; 9.7 min and 15 min, respectively. Several HPLC studies on PAR [Chandra and 
Sharma, 2013; Chandra et al., 2013; Gangishetty and Verma, 2013] and AmB [Wilkinson et al., 
1998; Eldem and Arican-Cellat, 2000; Balamuralikrishna and Syamasundar, 2010] as separate 
entities have produced shorter retention and run times than those obtained in the present work as 
only one compound was analysed in each case. In the current study however, a single HPLC 
method for analysing all three compounds is preferred for simplicity and rapidity in terms of 
instrumentation, mobile phase composition and other chromatographic conditions, as well as to 
make a simultaneous assay of the analytes possible since both PAR and SSZ were detected at the 
same wavelength of 254 nm. 
 
87 
 
 
 
     
 
Figure 2.19 Standard calibration curves for pure solution of (a) AmB, (b) PAR and (c) SSZ  
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2.4.12 Encapsulation efficiency (%EE)  
The %EEs of the freshly prepared AmB, PAR and SSZ SLNs were found to be 91.2±3.04%, 
60.7±0.26% and 78.4±0.16%, respectively, and are illustrated in Figure 2.20. The higher 
encapsulation efficiency of AmB is attributable to its relatively high lipophilicity, being 
compatible with the lipid matrices. On the other hand, the %EE for PAR was the lowest and this 
can be linked to its hydrophilic nature. Nonetheless, the %EE for all three drugs were appreciably 
high and suggest that the emulsification solvent diffusion technique used in preparing the SLNs is 
suitable for encapsulating AmB and the marker drugs. 
A search through literature does not reveal solid lipid nanoparticulate formulations of PAR or SSZ; 
due to the former’s good oral bioavailability of about 70-90%, and the latter is partially although 
irregularly absorbed after oral administration [Moffat et al., 2005]. AmB on the other hand is 
poorly absorbed orally; hence, there are various proposed formulations to help improve its 
absorption. Percentage encapsulation efficiencies of 34.5%, 50.6% and 75.9% have been achieved 
for AmB in poly (lactide-co-glycolide) [Italia et al., 2009(a)], gelatin-coated [Jain et al., 2012] and 
phospholipid-cholesterol [Jung et al., 2009] nanoparticles, respectively. In the initial two studies, 
the drug loading in the formulations were 10%w/w and 6%w/w of the lipid/polymer weight, 
respectively. In the present study however, drug loading in each SLN formulation was 12.5%w/w 
of the total lipid used. Two SLN formulations of AmB have been prepared by Patel and Patravale 
(2011) (AmbiOnp) and Gupta et al. (2013) for which the drug loading and %EE were 12.5%w/w 
and 99.99%, and 1%w/w and 69.8%, respectively. The AmbiOnp formulation however had a PDI 
greater than 1 and required further treatments such as probe sonication and dialysis, to obtain 
smaller sized particles with a reduced PDI of 0.12. As a result, the whole procedure lasts longer 
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than 6 hr and is expensive. The AmB SLNs produced in this study however follows a simpler 
process and requires a shorter formulation time. 
 
 
Figure 2.20 Encapsulation efficiencies of AmB, PAR and SSZ in their respective SLNs (n = 3) 
 
2.4.13 Drug release studies 
Cumulative drug release studies were conducted on both freshly prepared and freeze-dried SLNs 
and the results are illustrated in Figure 2.21. The data show that for the freshly prepared SLNs, 
only 11.80±0.4% of AmB was released within the 8 hr study period, whereas the maximum amount 
of SSZ released was 31.40±1.95%.  In contrast, 65.90±0.04% of PAR was released within the 
study period.  
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Figure 2.21 Cumulative release profiles of AmB, PAR and SSZ in PBS (pH 7.4) from their respective freshly prepared and  
freeze-dried SLNs 
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The percentage cumulative drug release from the freeze-dried AmB, PAR and SSZ SLNs were 
11.4%±0.4%, 76.04±0.21% and 31.6±0.33%, respectively. The differences in the amounts of drug 
released at the last time point, between each respective pair (fresh and freeze-dried SLNs) were 
not statistically significant (using t-test); 0.3894, 0.3351 and 0.0678 for AmB, PAR and SSZ, 
respectively. As such, whether as a fresh or freeze-dried formulation, drug release would remain 
essentially identical for all three SLNs. 
The low drug release from AmB and SSZ SLNs relative to PAR SLNs are consistent with the 
biopharmaceutics classification system (BCS) for AmB and SSZ as class IV drugs, with low 
permeability and aqueous solubility. PAR has been assigned to either class I or III in several reports 
due to its high aqueous solubility and relatively good permeability. Essentially, both class I and III 
drugs have high aqueous solubility however, class I drugs have higher permeability. The 
implications of the in vitro release study is that, most of the PAR is likely to be released from the 
nanoparticles prior to absorption of the intact SLNs. On the other hand, there is likely to be a 
significant retention of AmB and SSZ within the SLNs prior to absorption in the GI tract; this is 
because of the higher logP values of AmB (1.16) and SSZ (2.67) relative to PAR (0.48). One of 
the  significant advantages of SLNs is the fact that prolonged (slow) drug release is inherent 
because the particles are solid at room temperature hence, drug diffusion/mobility within the lipid 
matrix and then out of the particle is minimal [Reddy et al., 2006]. Drug release is normally 
preceded by ingress of the dissolution medium into the carrier, followed by dissolution of the drug 
and then outward diffusion of the drug. In this context, the slow ingress of water into the lipid 
matrix becomes rate-limiting. 
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It is also likely that due to the slow release of AmB from the SLNs as observed in Figure 2.21, 
AmB is incorporated within the SLN as a drug-enriched matrix model. In this case, drug molecules 
must diffuse across a distance from within the lipid matrix to the outer shell, which further slows 
the drug release process. The slow in vitro drug release from the SLNs is therefore desirable 
because, a higher proportion of the drug is retained within the SLNs prior to uptake of the intact 
particles by M cells of the Peyer’s patches and via the paracellular route. The drug-rich particles 
can also by digested and the drug incorporated into chylomicrons for uptake by the enterocytes. 
Since SLNs are reputed to be taken up principally by the Peyer’s patches along the GI tract, a 
sustained drug release is desirable.  
An extended drug release study was conducted on the respective pair of SLNs (freshly made and 
freeze-dried) up to 30 hr as depicted in Figure 2.22. In this study, the amount of drug released at 
each time point was assayed respectively hence, the plots are not cumulative. The release profiles 
of each of the three drugs from the pair of SLNs were identical as observed previously, albeit 
higher for the fresh formulation in each case. The statistical differences between drug release from 
freshly made and freeze-dried SLNs were mostly insignificant as the p values were > 0.05 at all 
the sampling points, except at the 2-hr time point for AmB where p = 0.0468, which although 
borderline, still indicates statistical significance.  
In the case of AmB, there was a slight dip in release from the freeze-dried SLNs at 2 hr but 
thereafter, release remained essentially identical to the fresh sample until 30 hr. The release of 
PAR was largely sustained up until 8 hr after which there was a slight dipping. This dip in PAR 
release might signal some changes to the physical integrity of the SLNs after the freeze-drying 
process, so that the matrices are more tortuous. Tortuosity refers to the structure (such as curviness) 
of pores and channels in a matrix. High tortuosity will therefore impede diffusion of drug payloads 
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from such matrices. Substances that are soluble in the GI tract are sometimes used as channelling 
agents in waxy matrices so that, as they dissolve and leach into the GI fluids, tortuous capillaries 
are created to aid drug diffusion [Collett and Moreton, 2001]. Since PAR has good aqueous 
solubility, it could have acted as a channelling agent with its effect being higher in the freeze-dried 
formulation and hence, the observed drug release pattern. SSZ release from the SLNs followed a 
typical diffusion-limited profile, with a peak at 2 hr and a somewhat sustained trough thereafter. 
Comparing the profiles, it is noted that PAR being more hydrophilic than the other two drugs is 
expected to show increased drug release with time. Moreover, the pattern of AmB release is 
indicative of a gradually eroding matrix, which means that for an intact SLN, the path length 
followed via diffusion remains fairly constant.  
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Figure 2.22 Drug release profiles of AmB, PAR and SSZ from their respective SLNs 
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2.4.13.1 Drug release kinetics 
In order to shed more light on drug release from the lipid matrices, the kinetics of release from 
each SLN was investigated. Drug release refers to the process by which a drug solute migrates 
from an initial position in a delivery system to the outer surface and then into the surrounding 
release medium [Langer, 1990]. This may seem as a simple process however, it is affected by 
several complex factors such as the physicochemical properties of the drug, the structural 
characteristics of the delivery system, the release environment and possible interactions among 
these factors. Generally, solute diffusion as well as swelling and degradation of the delivery system 
are the main driving forces for solute transport from drug containing matrices [Langer, 1990; 
Artifin et al., 2006]. 
The coefficient of determination (R2) values obtained from the various equations generated using 
the release models are shown in Table 2.5. It can be seen that the values are highest for the Higuchi 
model for each formulation. Only the PAR freeze-dried sample gave an R2 value for first-order 
release that was close to that for the Higuchi model albeit slightly higher for the latter; however, 
the model which best fits the release data by giving the highest R2 value is selected. It could 
therefore be said that drug release from the SLNs followed the Higuchi model. 
The mechanisms of drug release from dosage forms are conveniently used to categorise controlled 
release systems as diffusion-controlled, swelling-controlled or chemically-controlled [Siepmann 
and Peppas, 2011]. When the release data for a formulation fits well (very high R2 value) with the 
Higuchi model, it indicates that drug release is diffusion-controlled [Higuchi, 1961].  
According to the Higuchi model, the release of a solid drug from a matrix involves simultaneous 
penetration of the surrounding liquid, dissolution of the drug and leaching out of the drug through 
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interstitial channels or pores [Higuchi, 1961]. The model is based on several hypotheses. These 
include the following: initial drug concentration in the matrix is much higher than the drug’s 
solubility, drug diffusion occurs only in one dimension and edge effect is negligible, drug particles 
are much smaller than the thickness of the carrier system, matrix swelling and dissolution are 
negligible, drug diffusivity is constant, and perfect sink conditions exists in the release 
environment. 
 
Table 2.5 Nonlinear fits of AmB, PAR and SSZ released from the respective SLNs 
 
SLN      
formulation 
 R2   n value 
First order Higuchi Hixson-
Crowell 
Korsmeyer-Peppas 
AmB fresh  0.8997 0.9889 0.8964 0.9704  0.5960* 
AmB freeze-dried  0.9206 0.9826 0.9174 0.9606  0.6740* 
PAR fresh  0.9360 0.9858 0.9077 0.9728  0.4963 
PAR freeze-dried  0.9820 0.9825 0.9592 0.957  0.6392 
SSZ fresh  0.9631 0.9743 0.9559 0.9563  0.7565* 
SSZ freeze-dried  0.8932 0.9765 0.8821 0.9297  0.6035* 
* - data not applicable as drug release < 60% during the study period 
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Venkateswarlu and Manjunath (2004), Kushwaha et al. (2013), and Yasir and Sara (2014) also 
found the in vitro release of clozapine, raloxifene and haloperidol, respectively, from their SLNs 
to follow Higuchian release kinetics.  
The value of n from the Korsmeyer-Peppas equation characterises the drug transport/release 
mechanism in the following manner: n = 0.43 signifies Fickian (case I) diffusion, 0.43 < n < 0.85 
signifies anomalous (non-Fickian) diffusion, n = 0.85 means a case II transport, and n > 0.85 
indicates a super case-II transport. Fick’s laws of diffusion postulate that a drug solute will move 
from a region of high concentration to a region of low concentration across a concentration 
gradient; and the change in concentration with time in a particular region is proportional to the 
change in concentration gradient at that point.  
The value of n is however valid only when applied to the initial 60% of drug release, which makes 
it useful only for the release data obtained for the PAR SLNs. The n values for fresh and freeze-
dried PAR SLNs were found to be 0.4963 and 0.6392, respectively, both of which designate non-
Fickian diffusion. 
In Fickian diffusion, drug release is diffusion-controlled whereas in case II, release is controlled 
by relaxation of the matrix. Anomalous diffusion behaviour is intermediate between Fickian and 
case II, in which the rates of drug diffusion and relaxation of the matrix are comparable, which 
indicate that drug release from the PAR SLNs were controlled by both mechanisms. In the present 
study, relaxation relates to possible changes in the volume-to-surface ratio of the lipid matrix of 
the SLNs due to permeability of the matrices to the release medium [Langer, 1990; Artifin et al., 
2006]. 
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2.4.14  Stability of the SLNs after freeze-drying and storage 
2.4.14.1 Freeze-drying of the SLNs 
A study by zur Mühlen (1996) indicated that SLN formulations may be generally stable from 12 
to 36 months however, various factors such as initial processing parameters, handling and storage 
may cause increase in particle size over a short period of time if not optimised. Freeze-drying is 
one way to improve the physical and chemical stabilities of SLNs. Freeze-drying also makes the 
incorporation of SLNs into solid dosage forms possible however, both the freezing and drying 
steps exert mechanical stresses on the particles and reduce the protective effects of surfactants. 
Cryoprotectants are therefore usually added to SLN dispersions at concentrations of 10-15% (of 
the total formulation) prior to freeze-drying to reduce the chances of particle aggregation as well 
as to ease redispersion of the freeze-dried product. Cryoprotectants prevent particle aggregation 
by preventing direct contact between adjacent lipid particles and by interacting with the polar 
groups of surfactants to act as a pseudo-hydration shell [Mobley and Schreier, 1994]. 
Cryoprotectants are usually sugars or polymers but the commonly used ones are mannitol, sorbitol, 
trehalose, glucose and polyvinylpyrrolidone. Trehalose has been described as the most efficient 
cryoprotectant for SLN formulations [Cavalli et al., 1997; Schwarz and Mehnert, 1997; Heiati et 
al., 1998; Mehnert and Mäder, 2001] and was used at a concentration of 10% in the present study. 
The AmB, PAR and SSZ SLNs were freeze-dried without trehalose prior to the FTIR and DSC 
analyses in Section 2.3.4. In vitro release studies were conducted on the freeze-dried SLN samples 
in order to assess possible differences in drug release from freshly prepared SLN suspensions and 
the freeze-dried ones. Figure 2.23 shows images of the freeze-dried SLN powders. All three SLN 
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formulations produced fluffy powders, which tended to stick onto surfaces such as weighing paper, 
so they required very careful and swift handling during weighing and transfer into containers.  
 
 
Figure 2.23 Images of the freeze-dried SLNs 
 
Figure 2.24 illustrates the size distribution of the freeze-dried nanoparticles. It can be seen that 
only the AmB SLNs showed a more unimodal distribution. PAR and SSZ SLNs showed mostly 
bimodal size distribution profiles. The z-average diameters and PDIs for AmB, PAR and SSZ 
SLNs were 265.0±40.7 nm and 0.40±0.13, 333.6±56.8 nm and 0.53±0.06, and 283.6±63.5 nm and 
0.56±0.10, respectively. This shows that the freeze-drying procedure did not significantly alter the 
size of the nanoparticles. In general, the z-average values remained below 340 nm. Only the freeze-
dried PAR SLNs showed more than a 100 nm increase in mean particle size, which could be due 
to the presence of the aggregates seen in its SEM image in Figure 2.25. 
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Figure 2.24 Particle size distribution by intensity of the freeze-dried SLNs (n = 3) 
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Figure 2.25 SEM images of the freeze-dried SLNs 
[The arrow points to a large aggregate of the PAR SLNs] 
 
102 
 
The ZP values were obtained as -66.8±2 mV, -70.8±11.0 mV and -61.5±13.0 mV for AmB, PAR 
and SSZ SLNs, respectively, indicating good colloidal stability [Riddick, 1968], and not differing 
much from the values obtained for the fresh samples. Figure 2.25 shows the SEM images of the 
freeze-dried SLNs in which the particles appear similar in outlook with those of the freshly 
prepared SLNs (Figure 2.7) except for some few aggregates in the former. 
Polymorphic modifications of lipids may result from sample dehydration, as occurs in freeze-
drying [Svilenov and Tzachev, 2013]. These can cause changes in particle shape and conformation 
with various consequences such as particle growth, since surfactant molecules can no longer offer 
sufficient coverage to newer surfaces formed; and changes in drug incorporation and release rates. 
These may have further effects on bioavailability and obvious changes in the aesthetic appearance 
of the formulation [Reddy et al., 2006]. The results from the DSC experiments (Section 2.4.10), 
which were conducted on freeze-dried formulations indicated that the melting temperatures of the 
lipids in their bulk forms as well as within the SLNs remained relatively unchanged. The maximum 
difference in melting point observed was 2.2°C for TO in the PAR SLNs. This is a good indication 
that no polymorphic changes had occurred during the freeze-drying process, pointing to the 
stability of the dispersions.  
 
2.4.14.2 Storage temperature and light conditions 
Storage temperature can affect the stability of SLNs as well as drug formulations in general. Drug-
loaded SLNs have been found to be more stable when stored at low temperatures such as 
refrigerated or room temperatures (15-25°C). Storage at much higher or lower temperatures is 
associated with instabilities such as increase in particle size and PDI due to particle aggregation, 
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lipid modifications and high drug expulsion rates [Reddy et al., 2006; Harde et al., 2011; Kakkar 
et al., 2011]. Again, it is important to store SLNs at temperatures lower than the melting point of 
the lipid to ensure that the latter remains in solid state to keep the drug encapsulated. Refrigerated 
temperature (4-8°C) was therefore selected as the storage temperature for both freshly prepared 
and freeze-dried AmB, PAR and SSZ SLNs; also because the freeze-dried SLNs were found to 
stick together and to their containing vessels when kept at room temperature, causing difficulty in 
handling.  
Figure 2.26 shows the particle size distribution profiles of the three SLNs after storage at 
refrigerated temperature for 24 months. It can be seen that the profiles are similar with those 
obtained for the freshly prepared SLNs (Figure 2.6). The z-average diameters and PDIs for AmB, 
PAR and SSZ SLNs were obtained as 262.0±3.5 nm and 0.20±0.03, 307.7±2.7 nm and 0.25±0.02, 
and 256.6±2.9 nm and 0.27±0.03, respectively. The ZP values obtained were -63.7±5.4 mV, -
67.8±0.8 mV and -68.3±0.9 mV for AmB, PAR and SSZ SLNs, respectively. It is apparent that 
these agree very much with the PCS data obtained for the freshly prepared SLNs as presented in 
Section 2.4.6. Since the particle sizes and ZPs of the AmB, PAR and SSZ SLNs remained relatively 
same after storage, it can be said that storage of the AmB, PAR and SSZ SLNs in the refrigerator 
was appropriate and maintained the stability of the SLNs. 
The particle aggregation due to storing SLN dispersions at relatively high temperatures is 
attributed to increased particle kinetic energy from the input energy, which favours particle 
collisions and the resultant aggregation. Increasing temperatures may also cause changes in the 
protective film properties of surfactants on particles and result in particle aggregation [Reddy et 
al., 2006]. At the storage temperature of the SLNs (4-8°C), it can be said that the particles were 
not energetic enough to undergo rapid Brownian motion to result in aggregation induced by 
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particle collisions. Again, with the melting points of TO and BW which form the protective solid 
lipid cores of the particles being at about 33°C and 61°C, respectively, for all three SLNs according 
to Table 2.4, it is convincing that the nanoparticles would be remain solid to keep the drugs 
encapsulated within the lipid matrices during refrigerated storage. 
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Figure 2.26 Particle size distribution by intensity of the SLNs after 24 months of storage       
(n = 3) 
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Figures 2.27 and 2.28 compare the z-average diameters, PDIs and ZPs of the freshly prepared, 24 
months-stored and freeze-dried SLNs. It can be seen from the graphs that for all three SLNs, 
freeze-drying resulted in a slight increase in particle size (up to about 1.6-fold) and up to a 3-fold 
increase in PDI. Storage for 24 months also caused up to a 1.5-fold increase in the mean sizes of 
all three SLNs, and up to a 1.5-fold increase in the PDIs for PAR and SSZ SLNs, while the PDI 
for AmB remained almost unchanged. The ZP values however remained relatively the same with 
that of the freshly prepared SLNs, irrespective of storage time or freeze-drying. As stated in 
Section 1.5.4.2, ZP values > |60 mV|, as obtained for all three SLNs indicate high colloidal 
stability. The results therefore clearly point to all three SLN dispersions being very stable systems 
irrespective of storage or freeze-drying. Also, there is the likelihood that the freeze-dried product 
will have a much longer shelf life given that it is a solid formulation, and hence hydrolysis of either 
the drugs or the excipients are checked. 
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Figure 2.27 Z-averages and PDIs of the fresh SLNs, after storage for 24 months, and after 
freeze-drying (n = 3) 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
0
50
100
150
200
250
300
350
400
P
D
I
Z
-a
v
er
a
g
e 
 (
n
m
)
SLN formulation
Fresh SLNs
After storage
After freeze-drying
Z-average PDI
SSZAmB PAR 
108 
 
 
 
Figure 2.28 ZPs of the fresh SLNs, after storage for 24 months, and after freeze-drying (n = 3)  
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Another stability consideration of SLN formulations is the effect of light. In the present study, the 
storage containers for the AmB, PAR and SSZ SLNs were wrapped in aluminium foil to serve as 
a barrier against light. Coupled with being stored in the refrigerator, direct exposure to light was 
avoided to a large extent.  
A study by Reddy et al. (2006) showed more than a 4-fold increase in mean particles size of 
tamoxifen citrate-loaded SLNs after exposure of the dispersion to artificial light (40 W) and 
daylight. The high energy of light radiations cause an increase in the kinetic energy of particles in 
the same way that high temperature does, which causes increase in particle collisions resulting in 
particle growth. The study by Reddy et al. (2006) showed that daylight caused gelation in the 
dispersions and resulted in a higher destabilising effect (faster particle growth) than artificial light, 
which is not unusual due to the higher energy of UV radiations in natural light. These findings 
were in line with those of Freitas and Müller (1998) who also found that exposure of a Compritol 
SLN formulation to light resulted in gelation while storage of the SLNs in siliconised glass vials 
in darkness at 8°C prevented any particle growth. With the aforementioned conditions, they 
achieved an aqueous SLN dispersion which was stable (as regards measured particle size and ZP) 
over 3 years [Freitas and Müller, 1998; Reddy et al., 2006]. The results from the present study 
clearly indicate that storage of the SLNs in the refrigerator at 4-8°C was appropriate and prevented 
any physical or chemical instabilities in the formulations.  
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2.5  Conclusions 
In conclusion, individual SLN formulations containing AmB, PAR or SSZ were successfully 
formulated using an identical method and good encapsulation efficiencies were obtained. The 
SLNs had matching physical characteristics as regards particle size, shape, morphology, surface 
charge, in vitro drug release and mobility propensities, which indicate the suitability of employing 
the PAR and SSZ SLNs as markers in the GI absorption study to be conducted on the AmB SLNs 
(Chapters 5 and 6). Storing the SLNs for up to 24 months at 4-8°C, as well as freeze-drying did 
not significantly change the physical characteristics of the SLNs or the chemical nature of the drug 
load. High ZP values of magnitudes > 60 mV were obtained for all the SLNs, which show that 
very stable formulations had been prepared. AmB SLNs exhibited low in vitro drug release, which 
is favourable in pursuit of an AmB formulation with improved tolerability and free from systemic 
toxicity. A slow AmB release also assures that the drug load may be significant during GI transit 
and subsequent uptake by Peyer’s patches along the gut, all of which point to an improved oral 
bioavailability. The similarities in the properties of the three SLNs indicate the suitability of the 
preparation method for formulating SLNs containing drugs with different physicochemical 
properties. 
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CHAPTER 3 
STABILITY OF THE SOLID LIPID NANOPARTICLES AND SURFACE CHEMISTRY 
ANALYSES IN SIMULATED GASTROINTESTINAL FLUIDS 
3.1 Introduction 
Estimating the stability of nanoparticulate formulations in biological media can provide critical 
information for optimising such preparations that are meant for systemic delivery. Stability studies 
conducted in appropriate simulated gastrointestinal (GI) media may give information on the fate 
of formulations after oral administration. Generally, the stability of nanoparticulate formulations 
can be assessed with reference to their chemical and pharmaceutical/storage stabilities [Muthu and 
Feng, 2009]. The latter has been discussed in the preceding chapter. 
After oral administration, dosage forms must initially overcome the physical and chemical 
dynamics within the GI tract. The drug must traverse the intestinal epithelium efficiently in order 
to register any meaningful bioavailability. Lipid-based delivery systems comprising biodegradable 
materials are susceptible to digestion/degradation by gastric and intestinal enzymes, prior to their 
absorption. They can be absorbed by enterocytes as micelles, a process which serves to improve 
the absorption of hydrophobic drugs [Müller et al., 1996; Pouton, 2000; Subramanian and Ghosal, 
2004; Roger et al., 2009]. In addition, the nanometre dimension of SLNs gives them a large surface 
area; therefore, they are prone to aggregation, which may reduce particle interaction with the 
intestinal mucosa [Jani et al., 1990].  
The slow and controlled drug release characteristics exhibited by SLN systems assure evasion of 
gastric and intestinal degradation of susceptible drugs; however, these may depend on the rate of 
degradation of the particles, which is also governed by the type of stabiliser and lipid used in 
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formulating the SLNs [Damgé et al., 1990; Olbrich et al., 2002(a,b)]. A study by Zhang et al. 
(2013) revealed that the use of SLNs averted the gastric irritation caused by triptolide, which 
indicates the intactness of the delivery system in the stomach; however, the composition of the 
lipid matrix varies among formulations hence each SLN formulation must be tested. In the 
following, the various techniques that were used in this study to investigate the stability of AmB, 
PAR and SSZ SLNs when challenged by various simulated GI media are reviewed. 
Dynamic light scattering (DLS), also referred to as photon correlation spectroscopy (PCS) is a 
technique used for measuring particle size in the submicron region up to 10 µm, as well as the size 
distribution of particles. Useful applications of DLS include characterising particles, emulsions or 
molecules that are suspended or dissolved in a liquid. In DLS, the Brownian motion of particles in 
suspension causes scattering of laser light at different intensities, which is analysed using the 
Stokes-Einstein relationship (below) to obtain particle size.  
Stokes-Einstein equation: 
(𝑥, 𝑦)2 ̅̅ ̅̅ ̅̅ ̅̅ ̅ =  
2𝑘𝐵𝑇
3𝑟ℎ𝜋𝜂
 … … … … . … … . . Equation 3.1 
Where: kB is the Boltzmann constant,  (𝑥, 𝑦)2 ̅̅ ̅̅ ̅̅ ̅̅ ̅ is the mean squared speed of a particle with a 
hydrodynamic radius rh, at a temperature T, and in a medium of viscosity η. 
Electrophoretic light scattering (ELS) is a technique that measures the migration of suspended 
particles having a net charge, towards an oppositely charged electrode within an electric field. The 
velocity of the particles is known as their electrophoretic mobility and this is related to their zeta 
potential [Malvern Instruments, 2015].  
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Nanoparticle tracking analysis (NTA) uses both light scattering and Brownian motion to achieve 
the size distributions of particles in a suspension. In NTA, a laser beam is passed through a sample 
chamber and particles in the path of the beam scatter light so that they can be easily visualised 
through a magnification microscope, onto which a charge-coupled device (CCD) video camera is 
mounted. The camera captures a video file of the particles undergoing Brownian motion to provide 
real-time monitoring of changes in the characteristics of the particle populations. The NTA 
software is then used to track particles individually and using the Stokes-Einstein equation, the 
hydrodynamic diameter of a sample is computed. A fluorescence mode could also be used in the 
analysis to obtain data for specifically labelled particles. NTA can be used for analysing particles 
with sizes ranging from 30 to 1000 nm [Filipe et al., 2010; Malvern Instruments, 2015].   
Time-of-flight secondary ion mass spectroscopy (ToF-SIMS) is a technique in which ion beams 
are used to extract molecular information about functional groups on particle surfaces, as well as 
the composition of materials. SIMS can therefore be used to obtain information regarding 
contamination on samples. ToF-SIMS analyses basically involve bombarding a substrate with 
primary ion beams of Ga+, Ar+, O2 
+, Cs+, C60 
+, Au+, Bi+ or other atomic, molecular or cluster ions 
with energies between 3 and 20 keV. This results in the ejection of secondary atomic and molecular 
ions, which are drawn into a tube for mass analyses [Postawa et al., 2004; Shimizu, 2005; Baer et 
al., 2010].  
ToF-SIMS has a depth profiling capability, in which the surface of a sample is eroded away by 
rastering a high primary ion dose across the surface to create a flat-bottomed crater. Mass spectral 
data giving information on the variation in the composition of a sample with depth below its 
immediate surface is then obtained as a function of sputtering time. Spectroscopy and imaging in 
SIMS are performed in static mode whereas depth profiling makes use of dynamic SIMS [Briggs 
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and Seah, 1992]. Dynamic and static SIMS are distinguished by the dose of the primary ions used 
during an analysis; the latter involves low density and low total dose of ions with minimal surface 
damage and sample alteration. Depth profiling on the other hand is a destructive technique and 
results in significant surface damage therefore, spectral or image data for a particular sample area 
must be performed, if needed, prior to running the instrument in dynamic mode [Briggs and Seah, 
1992; Ratner et al., 2009; Vickerman and Gilmore, 2009; Nolan, 2013]. 
Specifically, PCS, NTA and ToF-SIMS were used to characterise and estimate the stability of 
AmB, PAR and SSZ SLNs in various simulated salt solutions mimicking GI fluids as regards pH 
and temperature. 
 
3.2 Materials  
The same materials and solvents listed in Section 2.2 were used in formulating the SLNs. 
Simulated gastric fluid and simulated intestinal fluid were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and appropriately diluted with deionised water to obtain the media at pH 1.2 
and pH 6.6, respectively. 
 
3.3 Methods 
3.3.1 Preparation of drug-free, AmB, PAR and SSZ SLN formulations 
The AmB, PAR and SSZ SLNs were prepared according to the procedure described in Section 
2.3.3. The drug-free formulation was similarly prepared as the other SLNs except that no drug was 
added to the formulation. 
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3.3.2 Stability of the SLNs in simulated GI fluids 
All the SLN formulations were evaluated for stability in simulated gastric fluid (SGF) and 
simulated intestinal fluid (SIF), at 37°C. A 1-mL sample of each formulation was added to SGF-
only and SIF-only, each in a separate tube to produce a 1 in 250 dilution, which was incubated for 
2 hr. In a parallel study, the formulations were incubated in SGF for 2 hr followed by transfer into 
SIF and incubation for an additional 2 hr to mimic gastric emptying (SGF+SIF). All the samples 
were diluted with the appropriate GI fluid or deionised water to obtain a final dilution of 1 in 500. 
The samples were then evaluated using PCS and NTA. ToF-SIMS was used to qualitatively 
evaluate the surface chemistries of the fresh particles, as well as to observe changes in the relative 
drug intensities at the surface of the particles after the various treatments. 
 
3.3.3 PCS studies  
PCS studies on the SLNs were carried out using a Zetasizer Nano ZS® (Malvern, UK) and the 
parameters measured were z-average diameter, zeta potential (ZP) and polydispersity index (PDI). 
Sample analyses were done using a clear disposable zeta cell. Each analysis was carried out at 
37°C and performed in triplicate. The data obtained have been expressed as mean ± standard 
deviation (SD). 
 
3.3.4 NTA studies 
The NTA measurements were performed using a NanoSight LM10 (NanoSight, Amesbury, United 
Kingdom) equipped with a sample chamber and a 640-nm laser. The samples were injected into 
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the sample chamber using sterile syringes, until some sample drops reached the tip of the exit 
nozzle to ensure the chamber was completely filled with the sample. All measurements were done 
at 37°C. Each video was captured at 30 frames/sec for 1 min 30 sec and analysed using the NTA 
software version 3.1 Build 3.1.46. Triplicate measurements were performed for each sample and 
the data obtained expressed as mean ± SD.  
 
3.3.5 ToF-SIMS analyses 
Surface chemistry analyses were carried out on the samples using a ToF-SIMS (ION-ToF GmbH, 
Münster, Germany) equipped with a liquid metal bismuth ion gun (LMIG). Prior to analyses, the 
SLNs were washed by centrifuging 1 mL samples at 13 000 rpm for 60 min, after which the 
supernatants were discarded and deionised water added to the samples. The washing was done to 
exclude ions from the simulated GI media from the particles, as the ions can affect signals in the 
spectra; and to remove traces of unassociated drug. The precipitated particles were resuspended in 
water by shaking and the centrifugation process was repeated thrice. The washed SLNs were 
redispersed in deionised water and about 40 µL samples placed on labelled silicon wafers and air-
dried prior to analyses. The analyses were carried out using 25 keV Bi3
+ primary ions. Depth 
profiles for the fresh SLNs were obtained by sputtering a 2.5 KeV Ar-cluster beam randomly on a 
200 μm × 200 μm area over a sputter time of 500 s. Data analyses were performed on the negative 
ion spectra for each sample using the Ion-ToF software.  
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3.4 Results and discussion 
3.4.1 PCS analyses 
The z-average values obtained from PCS measurements correspond to the hydrodynamic 
diameters of particles in a sample, whilst the PDI is a measure of the width of the particle size 
distribution. 
PDI values of 0.0-0.1 point to a narrow monodisperse distribution, 0.1-0.4 indicate a moderate 
polydisperse distribution system, whilst values greater than 0.4 indicate a broadly polydispersed 
system [NanoComposix, 2012]. Generally samples with mean particle sizes above 500 nm and 
PDIs greater than 0.5 are considered as “big and agglomerated” however, such data may not be 
given much consideration. This is because few large particles present in a sample usually dominate 
the light scattering signal in PCS and give rise to large PDI values, which could render the results 
unreliable.  
In addition, nanoparticles with ZP up to |10 mV| are considered to have a neutral charge, whereas 
those with ZP greater than |30 mV| are considered as being strongly charged [Clogston and Patri, 
2011]. 
Figure 3.1 shows the particle size distribution by intensity of drug-free SLNs before and after 
exposure to simulated GI fluids. Figures 3.2 and 3.3 illustrate the z-averages and PDIs, and ZPs of 
all the SLNs, respectively, before and after exposure to the simulated fluids. The z-average, PDI 
and ZP of drug-free SLNs in SGF-only were obtained as 737.4±41.8 nm, 1.00±0.00 and 2.4±0.3 
mV, respectively, however, the values for the freshly prepared particles were 195.4±3.1 nm, 
0.17±0.01 and -67.6±1.7 mV, respectively.  
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Figure 3.1 Particle size distribution by intensity of drug-free SLNs, before (fresh sample) and 
after their incubation in simulated GI fluids (n = 3) 
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The SGF contains approximately 2.0 g/L of NaCl and 2.917 g/L of HCl according to the 
specifications in the United States and European Pharmacopoeias. SGF is less complex as 
compared with in vivo gastric fluid; however, the dominant features of stomach fluid are its acidity 
and ionic content, and these properties of the simulated fluid match well with the in vivo condition. 
There was an approximately 3.8-fold increase in the z-average of the drug-free particles in SGF-
only, which points to massive aggregation of the particles in the medium. The marked drop in the 
magnitude of ZP, as well as the change in surface charge from negative to positive (-67.6±1.7 mV 
to 2.4±0.3 mV) were due to the presence of H+ ions in the SGF and their neutralisation of the 
negative charge on the fresh SLNs. This reduction in ZP favoured van der Waals inter-particle 
interactions and resulted in particle aggregation.  
SIF contains approximately 0.616 g/L of NaOH and 6.8 g/L of KH2PO4. In SIF-only, the z-average, 
PDI and ZP of the drug-free SLNs were 342.5±1.3 nm, 0.38±0.03 and -28.9±0.6 mV, respectively, 
indicating a 1.75-fold increase in particle size and a 2.33-fold decrease in the ZP after exposure of 
the particles to the medium. The PDI value indicates a relatively narrower size distribution of the 
particles in SIF-only than in SGF-only, and no aggregation of the SLNs due to retention of an 
adequate surface charge (-28.9 mV) above the threshold attendant for agglomeration of colloidal 
particles (|15 mV|) [Riddick, 1968].  
The composition and volume of fluid along the GI tract, the motility of the GI tract as well as the 
transit of dosage forms within it are highly variable [Roger et al., 2009]. As a result, there is no 
perfect representative model of GI fluid; however, the process of gastric contents being emptied 
into the small intestine is a consistent characteristic of the gut. Simulation of gastric emptying in 
respect of exposure to GI fluids was therefore replicated by exposing the SLNs to SGF and then 
to SIF. The z-average, PDI and ZP obtained were 517.0±113.0 nm, 0.54±0.22 and -0.4±0.1 mV, 
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respectively. Although the very low ZP magnitude is suggestive of maximum particle 
agglomeration and precipitation, the PDI and mean particle size are intermediate between the 
values obtained for the particles in SGF-only and SIF-only, which suggests that the aggregates of 
the SLNs in SGF are held loosely as floccules, which become deaggregated on exposure to SIF. If 
this was the case, then the same is to be expected in vivo. A high ZP value is essential for long-
term storage stability of colloidal formulations. After oral administration however, only a 
sufficient ZP magnitude is necessary to maintain electrostatic repulsion among the particles prior 
to their absorption. As a result, a low ZP of nanoparticles after contact with GI fluids is not crucial 
if their final size is optimum for absorption. 
A study by Shakweh et al. (2005) showed that the uptake of neutral and negatively charged nano-
and microparticles by Peyer’s patches in mice occurs to a greater extent as compared with 
positively charged particles. Their investigation also revealed that particle uptake by Peyer’s 
patches is highly size-dependent. They observed a much larger number of particles with mean 
diameters of approximately 300 to 1000 nm in the patches than larger-sized particles. Again, 
particles with negative or close to neutral ZP did not interact with the intestinal mucus gel layer 
due to electrostatic repulsion; this allowed such particles to reach the follicle-associated epithelium 
for uptake by M cells through endocytosis. Positively charged particles on the other hand were 
found to interact strongly with the mucus layer as the latter is negatively charged, thereby resulting 
in a delayed uptake [Shakweh et al., 2005]. 
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Figure 3.2 Z-averages and PDIs of the SLNs before (fresh sample) and after their incubation in simulated GI fluids (n = 3) 
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Figure 3.3 ZPs of the SLNs before (fresh sample) and after their incubation in simulated GI fluids (n = 3)
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The aforementioned results therefore suggest that after exposure to SGF+SIF, the drug-free 
particles still retained their integrity, as regards size and surface charge, for absorption via 
endocytosis as well as lymphatic transport [Jani et al., 1989; Jani et al., 1994; Shakweh et al., 
2005]. The increase in size observed after exposure of the particles to the media may be a result of 
either aggregation or ingress of the dissolution media into the particles or both.  
Figure 3.4 shows the particle size distribution by intensity of AmB SLNs before and after 
placement in simulated GI fluids. The z-averages of the AmB SLNs in SGF-only, SIF-only and 
SGF+SIF were 779.3±137.7 nm, 336.7±12.8 nm and 513.2±22.8 nm; the PDIs were 0.66±0.02, 
0.38±0.01 and 0.48±0.01; and the ZPs were 1.1±0.6 mV, -31.2±1.2 mV and -3.0±0.1 mV, 
respectively, as depicted in Figures 3.2 and 3.3. The size distribution profile of the particles in the 
SGF-only showed a bimodal distribution with the two particle populations having mean sizes of 
115.3 nm and 737.7 nm.  
As with the drug-free particles, it can be said that the AmB SLNs aggregated in SGF and after 
transfer from SGF into SIF, some deaggregation occurred. Prior to incubation, the AmB SLNs had 
z-average of 210.1±1.4 nm, PDI of 0.22±0.01 and ZP of -61.9±1.0 mV. According to the findings 
of Shakweh et al. (2005), the uptake of the AmB SLNs via endocytosis and M cells after oral 
delivery would not be significantly affected as the mean particle size after exposure to SGF+SIF 
remained below 1000 nm although there had been an increase of about 2.4-fold.  
There were no marked differences between the PCS results obtained for drug-free and AmB SLNs. 
Interestingly, both formulations showed the same pattern of size changes in the respective media; 
with size increase being highest in SGF-only, followed by SGF+SIF and then SIF-only. 
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Figure 3.4 Particle size distribution by intensity of AmB SLNs, before (fresh sample) and after 
their incubation in simulated GI fluids (n = 3) 
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The increase in particle size in SGF-only and SGF+SIF could be attributed mainly to aggregation 
while the comparatively less marked size increase in SIF-only could be the result of influx of 
dissolution medium into the particles. The aggregation of the SLNs in SGF is likely to result in a 
reduced release of AmB from the particles due to a decrease in effective surface area. It then 
follows that, aside from slow drug release from SLNs due to the hydrophobic nature of the lipid 
matrix, which retains most of the encapsulated drug within the matrix, particle aggregation in 
acidic medium as observed above may augment slow drug release in the stomach. This attribute is 
advantageous in view of the fact that the small intestine is the probable site for uptake of the SLNs 
and that it has a high expression of Peyer’s patches. 
Figure 3.5 shows the particle size distribution by intensity of PAR SLNs before and after their 
exposure to the simulated GI fluids. The z-averages of the fresh PAR SLNs and after exposure to 
SGF-only, SIF-only and SGF+SIF were 206.5±1.7 nm, 469.9±53.7 nm, 401.5±14.1 nm and 
362.8±139.1 nm; the PDIs were 0.16±0.03, 0.56±0.11, 0.54±0.01 and 0.64±0.06; and the ZPs were 
-71.9±0.9 mV, 4.9±1.1 mV, -35.7±0.5 mV and 3.4±1.0 mV, respectively, in each case (Figures 
3.2 and 3.3). The PAR SLNs also showed a bimodal distribution in SIF-only with mean sizes of 
156.07 nm and 596.5 nm. 
It was observed that the size of the PAR SLNs was highest in SGF-only, followed by SIF-only and 
then SGF+SIF. Generally, the increase in SLN size after incubation in the media was lower for 
PAR SLNs as compared with the drug-free and AmB SLNs. 
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Figure 3.5 Particle size distribution by intensity of PAR SLNs, before (fresh sample) and after 
their incubation in simulated GI fluids (n = 3)
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Figure 3.6 shows the particle size distribution by intensity of SSZ SLNs, before and after their 
incubation in the simulated fluids. Figures 3.2 and 3.3 show the z-averages obtained for the fresh 
SSZ SLNs and after their incubation in SGF-only, SIF-only and SGF+SIF, as 224.8±3.3 nm, 
569.4±224.7 nm, 471.2±75.5 nm and 431±44.6 nm; the PDIs were 0.19±0.08, 0.38±0.30, 
0.59±0.08 and 0.56±0.07; and the ZPs were -70.7±0.6 mV, 2.9±0.5 mV, -30.9±0.4 mV and 0.5±0.2 
mV, respectively. The SSZ SLNs also showed the same pattern of size increase as the PAR SLNs: 
fresh sample < SGF+SIF < SIF-only < SGF-only, and a bimodal distribution in SIF-only with 
mean sizes of 132.9 nm and 706.8 nm. 
Using DLS, and after a 2 hr-incubation period in SGF-only, Roger et al. (2009) found that the size 
of paclitaxel lipid nanoparticles which had an initial diameter of 51 nm was not affected as there 
was less than a 10 nm increment in the size of the particles. Laserra et al. (2015) also investigated 
lipoyl-memantine SLNs and found essentially no change in the size of the particles indicating no 
aggregation in SGF, both in the absence and presence of pepsin. Zhang et al. (2013) similarly 
observed an insignificant decrease (< 30 nm) in the size of triptolide SLNs in SGF-only. Gelatin-
coated polymer-lipid nanoparticles having an initial size of 253 nm have also been shown to 
decrease by 68 nm after incubation in SGF [Jain et al., 2012].  
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Figure 3.6 Particle size distribution by intensity of SSZ SLNs, before (fresh sample) and after 
their incubation in simulated GI fluids (n = 3) 
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On the other hand, in SIF-only, paclitaxel lipid nanoparticles have shown an increase in size of 
only up to 10 nm after 3 hr incubation with and without pancreatin in the medium [Roger et al., 
2009]. An increase in size by 192.6 nm has also been observed after incubating pegylated SLNs 
[Yuan et al., 2013] in SIF-only, while lipoyl-memantine SLNs after 2 hr of incubation had an 
increase in size of 157.4 nm and 221.8 nm in the absence and presence of pancreatin, respectively 
[Laserra et al., 2015]. Jain et al. (2012) on the other hand observed a 21 nm decrease in the size of 
gelatin lipid nanoparticles after 6 hr of incubation in SIF. On exposing the gelatin nanoparticles to 
SGF+SIF, a 36 nm decrease in size was observed. Only the data obtained by Yuan et al. (2013) 
and Laserra et al. (2015) are comparable with those obtained in the present study for the SLNs in 
SIF-only.  
From the foregoing, it appears that either a decrease or no change in the size of various lipid 
nanoparticulate formulations was observed in SGF-only while in SIF-only, either an increase or a 
decrease in size was observed. It is likely that the composition of the SLNs may contribute to their 
propensity to aggregate as a function of the GI media. In the present work, an increase in size or 
aggregation of both drug-free and drug-loaded SLNs was observed in the simulated GI fluids and 
this was manifested more in SGF-only.  
The hydrodynamic size obtained from DLS measurements can be affected by the salt concentration 
in the suspending medium, due to the electrical double layer (EDL) surrounding charged particles 
in an aqueous medium. The EDL is a layer of oppositely charged ions that moves with a 
nanoparticle having a net surface charge. Even at very low salt concentrations such as in 
demineralised water, an additional drag is induced by the salts through the extension of the double 
layer resulting in a decrease in diffusion coefficient and an increase in size [Hackley and Clogston, 
2011]. 
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One drawback of DLS is that the technique determines particle size from fluctuations in scattered 
light intensity, and is biased towards larger particles within a sample. The intensity of scattered 
light is proportional to the square of the particle diameter thus, larger particles or clusters of smaller 
particles scatter light more strongly than smaller particles. Again, in DLS the hydrodynamic 
diameter depends not only on the size of the particle core but also on any surface structures which 
may be present on the particles [Balog et al., 2015]. 
The marked increase in size of the SLNs observed in the present work as compared with the other 
studies could therefore be attributed to the few aggregated or large particles having approximate 
sizes of 5000 nm, as seen in each of the size distribution profiles for the fresh SLN samples 
(Figures 3.1, 3.4-3.6). These large particles or aggregates can perturb the light scattering signals 
and mask the presence of smaller particles, leading to biased and inaccurate size measurements.  
It is also noteworthy that z-average is only very useful for characterising particle size of 
monomodal (single peak), spherical or near-spherical and monodisperse (very narrow distribution 
width) samples. Consequently, for samples containing significant differences in size populations 
such as the bimodal distributions obtained for: the AmB SLNs in SGF-only, as well as the PAR 
and SSZ SLNs in SIF-only, the calculated z-averages do not convey very accurate size 
information. Although the DLS software has been designed to correct this aberration in multimodal 
distributions, the results may not reflect true particle size distributions as such, other particle sizing 
techniques can be used in addition to DLS in such instances [NanoComposix, 2012; Lim et al., 
2013]. 
Overall, ZP was highest for the fresh SLN samples as depicted in Figure 3.3. This is because the 
initial dispersion medium of the SLNs is deionised water. Additionally, the negative charge on the 
fresh particles is solely due to sodium cholate, which was the anionic surfactant used during 
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formulation of the SLNs. Incubating the SLNs in the simulated fluids caused a decrease in their 
ZPs owing to the pH changes caused by the electrolytes in SGF and SIF. However, the decrease 
was more marked in SGF-only and SGF+SGF media.  
The ZP of a particle is highly dependent on the pH and conductivity of the suspending medium; 
therefore, different ZP values will be obtained as the two parameters are varied [Clogston and 
Patri, 2011]. The change from negative to positive surface charge observed in SGF-only for all the 
samples and in SGF+SIF for PAR and SSZ SLNs was due to charge neutralisation by the high 
concentration of H+ ions in SGF. 
In SGF+SIF, all the three drug-loaded SLNs had sizes ranging from 362.8 nm to 513.2 nm. Their 
surface charges were also neutral as their ZPs ranged from -10 mV and +10 mV. These properties 
favour the absorption of the SLNs via the M cells of the Peyer’s patches [Shakweh et al., 2005; 
Clogston and Patri, 2011]. It may be concluded that the SLNs exhibit ideal physical properties 
necessary for absorption, following oral delivery and transit from the stomach to the intestines. 
 
3.4.2 NTA studies 
In order to investigate the size variation of the SLNs in simulated GI fluids, free from the bias of 
DLS, the particle-by-particle approach for determining size using NTA was used. Unlike DLS, 
NTA is not biased towards larger particles as such, the latter was used to estimate the stability of 
the SLN formulations in simulated GI fluids in order to obtain more accurate results. 
Figure 3.7 shows the size distribution by particle concentration of drug-free SLNs, before and after 
their incubation in the simulated GI fluids. Figure 3.8 shows the mean particle size for the drug-
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free and drug-loaded SLNs in the simulated GI fluids. The mean size of drug-free particles prior 
to and after incubation in SGF-only, SIF-only and SGF+SIF were 172.3±11.9 nm, 181.9±101.7 
nm, 232.5±15.0 nm and 266.4±12.4 nm, respectively. As with the DLS results, it can be observed 
that there was an increase in size after incubation in the simulated media however, the current 
results are suggestive of particle size increase due to ingress of the media into the particles than of 
particle aggregation. The largest increase recorded was 94.1 nm and observed in SGF+SIF. 
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Figure 3.7 Size distribution by particle concentration of drug-free SLNs, before (fresh sample) 
and after their incubation in simulated GI fluids (n = 3) 
[Red profile shows the range of the distributions of particle size and concentration 
from triplicate measurements; black line signifies the average distribution]
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Figure 3.8 Mean particle sizes (using NTA) of the SLNs, before (fresh sample) and after their incubation in simulated GI fluids (n 
= 3) 
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Figure 3.9 illustrates the size distribution by particle concentration of AmB SLNs, before and after 
incubation in the simulated GI fluids. The mean size of the SLNs prior to and after incubation in 
SGF-only, SIF-only and SGF+SIF were 236.9±19.4 nm, 283.8±19.7 nm, 249.6±26.5 nm and 
181.7±35.8 nm, respectively.  
There was an increase in size in SGF-only and SIF-only, and a decrease in SGF+SIF. AmB is 
insoluble in water at pH 6-7 but soluble at pH 2 or 11 due to its amphoteric nature. It seems the 
SGF+SIF, which has an approximate pH of 1.5,  served as a better dissolution medium for AmB 
thereby causing the decrease in particle size due to outward diffusion of dissolved drug, as opposed 
to the increase in size in the other media.  
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Figure 3.9 Size distribution by particle concentration of AmB SLNs, before (fresh sample) and 
after their incubation in simulated GI fluids (n = 3) 
[Red profile shows the range of the distributions of particle size and concentration 
from triplicate measurements; black line signifies the average distribution]
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Figure 3.10 shows the size distribution by particle concentration of fresh PAR SLNs and after their 
incubation in simulated GI fluids. The mean sizes of the SLNs prior to and after incubation in 
SGF-only, SIF-only and SGF+SIF were 227.2±16.9 nm, 185.4±53.9 nm, 182.7±27.2 nm and 
92.8±32.5 nm, respectively. There was a decrease in particle size in all three media and the highest 
observed in SGF+SIF. PAR is a hydrophilic drug that exhibits increasing aqueous solubility as 
temperature is raised. PAR is also weakly acidic and forms a salt in the presence of a strong acid 
(SGF) or base however, the solubility of this salt depends on the ionic content of the dispersion 
medium. Again, the dissolution of weakly acidic drugs is minimal in strong acids. It can be 
observed that the size of the PAR SLNs in SGF-only and SIF-only was similar (185.4 nm versus 
182.7 nm), possibly indicating similar solubility characteristics of the drug as a salt and in its 
unionised form at the two pHs respectively. The dissolved drug in the particles then freely diffused 
into the surrounding fluid resulting in the observed decrease in particle size.  
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Figure 3.10 Size distribution by particle concentration of PAR SLNs, before (fresh sample) and 
after their incubation in simulated GI fluids (n = 3) 
[Red profile shows the range of the distributions of particle size and concentration 
from triplicate measurements; black line signifies the average distribution]
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Figure 3.11 shows the size distribution by particle concentration of fresh SSZ SLNs and after their 
incubation in GI fluids. The mean SLN sizes prior to and after exposure to SGF-only, SIF-only 
and SGF+SIF were 212.2±50.0 nm, 249.1±19.9 nm, 308.3±38.4 nm and 337.3±28.4 nm, 
respectively.  
Of the three drugs, SSZ has the highest logP value (Section 2.4.13) and hence, it is the most 
hydrophobic; which could be the reason the SSZ SLNs showed a similar pattern of size change in 
the various media as the drug-free SLNs (Figure 3.8). This is because the two formulations have 
the most hydrophobic cores compared with the AmB and PAR SLNs. 
Comparing DLS and NTA, the latter is time-consuming and requires more operational skills but it 
clearly has benefits over DLS. NTA allows for sample visualisation, it gives an approximate 
concentration of the particles in a sample, and it produces size data based on the Brownian motion 
of individual particles. 
Furthermore, NTA is very accurate for sizing both monodisperse and polydisperse samples and 
has a considerably better resolution for different particle populations. The presence of few large 
particles in a sample also has little impact on the sizing accuracy of the NTA technique [Filipe et 
al., 2010]. This is evident in the present study as much larger particle sizes were obtained using 
DLS as compared with NTA, although all the samples were similarly treated in the various media. 
Additionally, NTA proved more suitable in the present study for analysing the stability of the SLN 
formulations in simulated GI fluids. 
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Figure 3.11 Size distribution by particle concentration of fresh SSZ SLNs, before (fresh sample) 
and after their incubation in simulated GI fluids (n = 3) 
[Red profile shows the range of the distributions of particle size and concentration 
from triplicate measurements; black line signifies the average distribution]
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In summary, contrasting patterns of size changes were observed for the drug-loaded SLNs in the 
various media. It appears that size changes were mainly based on the solubility of the incorporated 
drug in the simulated fluids such that, entry of the dissolution media into the SLNs caused some 
swelling of the particles, followed by drug dissolution in the fluid. The diffusion rate of the 
dissolved drug out of the particles then depended on the aqueous solubility of the drug, which 
resulted in the varying size changes as observed. Therefore, with PAR being the most hydrophilic, 
the PAR SLNs manifested a larger decrease in size due to the efflux of the drug from the SLN 
matrices. 
Particle size is a very important factor because uptake of particulates within the GI tract is governed 
by size, whereby smaller particles are taken to a greater extent compared to larger ones. Particles 
with sizes below 10 µm are well taken up in the GI tract but uptake occurs more favourably when 
sizes are below 1000 nm [Jani et al., 1989; Kreuter, 1991; Shakweh et al., 2005]. In addition, the 
mesh-pore spacing of the intestinal mucosal barrier is 50-1800 nm; however, nanoparticles with 
sizes below 200 nm diffuse more effectively through the mucus [Lai et al., 2010; Primard et al., 
2010].  
The three SLN formulations were found to be stable in the simulated GI fluids and can therefore 
be deemed to be stable in vivo as well. The mean particle sizes and ZPs for all three formulations 
in the simulated media were also optimal for GI absorption meaning that the different particles 
would respond similarly with GI mucus and epithelia. 
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3.4.3 ToF-SIMS analyses 
The negative and positive ion spectra of the pure drugs, drug-free and drug-loaded SLNs as well 
as the individual ingredients used for preparing the SLNs were subjected to ToF-SIMS analyses. 
However, only the negative ion spectra are presented as they gave data that are more meaningful. 
In addition, the spectra for the individual non-drug components of the SLNs are not presented as 
these constituted the drug-free SLNs. ToF-SIMS was used to analyse the relative drug intensities 
on the SLN formulations before and after their exposure to the simulated GI media in the present 
study because it is a surface sensitive technique. 
The molecular formula and mass of AmB are C47H73NO17 and 923.49 g/mol respectively. Figure 
3.12 illustrates the chemical structure of AmB showing the portions corresponding to the 
diagnostic peaks used to identify AmB on the SLNs: (a) [C20H27O2]- at m/z 299.20; (b) [C20H29O2]
- 
at m/z 301.22; and (c) [C17H21NO4]
- at m/z 303.23. The whole negative molecular ion of AmB 
which is [C47H72NO17]
- was not used as the diagnostic peak because the aforementioned ions (a, b 
and c) showed the most prominent peaks characteristic to the drug. 
 
 
 
 
 
 
 
(a, b) 
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Figure 3.12 The chemical structure of AmB with the portions representing the diagnostic peaks 
demarcated: (a) [C20H27O2]- at m/z 299.20; (b) [C20H29O2]
- at m/z 301.22; and (c) 
[C17H21NO4]
- at m/z 303.23 
 
Comparing pure AmB with AmB SLN, the peak intensities of the diagnostic ions in Figure 3.13 
indicate that the drug is present only in a small quantity on the surface of the freshly prepared 
SLNs. This is a reflection of the high encapsulation efficiency of 91.2±3.04% that was obtained 
for the formulation in Section 2.4.12, as more of the drug is encapsulated within the matrix. As 
there was no drug incorporated in the drug-free particles, it could be said that the peaks 
corresponding to the diagnostic ions in the spectrum for the drug-free SLNs are due to the other 
ingredients used in preparing the nanoparticles. As a result, the peaks at m/z 299.20, 301.22 and 
303.23 in the spectrum for the AmB SLNs could be due to the excipients in the formulation, 
especially since the peak intensities are higher for the drug-free particles. This further points to a 
very low or no AmB count on the surface of the particles untreated in the media. 
 
 
(c) 
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Figure 3.13 Negative ion ToF-SIMS spectra of pure AmB, drug-free SLNs, fresh AmB SLNs 
and AmB SLNs incubated in simulated GI fluids 
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Figure 3.14 compares the relative intensities of AmB on the surfaces of the fresh SLNs and after 
their exposure to the various media. It can be seen that higher drug counts were detected on the 
particles after their exposure to the media in the following order: SGF+SIF > SIF-only > SGF-
only. This trend is in reverse order for decrease in the particle size of the AmB SLNs in the 
corresponding media (Section 3.4.2). The higher intensities of the reference peaks for the media-
exposed SLNs compared to the fresh sample points to the diffusion of AmB towards the surfaces 
of the SLNs. It is apparent that this diffusion to the surface is most effective in SGF+SIF and least 
so in SGF-only. Furthermore, this observation is in concert with the assertion that the efflux of 
AmB from the SLN matrix results in size shrinkage. 
The SLNs were washed in deionised water prior to the ToF-SIMS analyses in order to remove any 
free drug residing on the surface of the particles. Therefore, the ToF-SIMS data represents AmB 
directly associated with the matrix of the SLNs at their surfaces. 
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Figure 3.14 Negative ion ToF-SIMS spectra showing AmB on the surface of AmB SLNs, 
before and after their incubation in simulated GI fluids 
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The molecular formula and mass of PAR are C8H9NO2 and 151.163 g/mol respectively. Figure 
3.15 shows the chemical structure of PAR outlining the portion representing the diagnostic peak 
[C7H7O]
- with m/z of 107.05. 
 
 
Figure 3.15 The chemical structure of PAR with a demarcation of the portion representing the 
diagnostic peak [C7H7O]
- at m/z 107.05 
 
Figure 3.16 also shows that very minimal amount of PAR was on the surface of the fresh PAR 
SLNs, just as was observed for the AmB SLNs. The peak at m/z 107.05 in the spectrum of the 
drug-free SLNs is attributable to the other ingredients within the formulation. The intensity of the 
diagnostic peak was higher on the PAR SLNs than on the drug-free particles; which indicates that 
the peak intensity observed on the fresh PAR SLNs is a combination of that for the drug itself, and 
that as a result of the excipients. This observation is the reverse of that detected in Figure 3.13 for 
AmB. Regardless, the results indicate that for the SLNs untreated in media, there is a minimal 
amount of PAR on the PAR SLNs unlike the AmB SLNs, which possibly had no AmB on them. 
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Figure 3.16 Negative ion ToF-SIMS spectra of pure PAR, drug-free SLNs, fresh PAR SLNs 
and PAR SLNs incubated in simulated GI fluids 
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Unlike the AmB SLNs, which presented a high drug count on the SLNs after exposure to the 
simulated media, the spectra in Figure 3.17 show a much intense PAR count on the fresh particles 
in comparison to those incubated in the media. The PAR SLNs had a lower encapsulation 
efficiency of 60.7±0.26% (Section 2.4.12), which may have resulted in saturation of the 
unencapsulated drug attached to the surface of the fresh SLNs and hence the high drug intensity 
seen in the spectrum. 
PAR is hydrolysed in acidic solutions to produce 4-aminophenol and acetic acid; however, these 
products have different masses and would therefore not contribute to the signal intensity at m/z 
107.05. This would manifest as low PAR intensity on the particles in SGF-only as compared with 
the fresh particles. PAR is very soluble at the pH of SIF, which favours drug release and dissolution 
in the medium resulting in an equally low drug count on the particles. As with the AmB SLNs, the 
highest drug intensity was detected on the PAR SLNs after incubation in SGF+SIF which indicates 
the latter as the best dissolution medium for both drugs, and also explains why the two SLNs had 
the smallest size in that medium (Figure 3.8).  
The mean size (based on the NTA data) of the PAR SLNs after exposure to the media decreased 
in the order, SGF-only > SIF-only > SGF+SIF, and drug intensity on the SLNs was in the order, 
SIF-only < SGF-only < SGF+SIF. From Figures 3.8 and 3.17, the mean sizes of the PAR 
nanoparticles in SGF-only and SIF-only are comparable (185.4±53.9 nm and 182.7±27.2 nm, 
respectively). In addition, the intensity of the diagnostic peak is similar in the two media albeit 
slightly lesser in SIF-only, unequivocally signifying that amount of drug released from the 
particles in a medium is inversely related to the ultimate size of the particles. 
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Figure 3.17 Negative ion ToF-SIMS spectra showing PAR on the surface of PAR SLNs, before 
and after their incubation in simulated GI fluids 
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In the case of SSZ, the entire molecular ion was used as the diagnostic anion as it was the most 
intense peak on observing the whole mass spectrum of the drug. The molecular formula and mass 
of SSZ are C18H14N4O5S and 398.393 g/mol, respectively, therefore its molecular ion is 
[C18H13N4O5S]
- and the peak location is m/z 397.09. The fresh SSZ SLNs showed minimal amount 
of drug on the particle surface as seen in Figure 3.18, just as was the case for the other formulations. 
After incubation in the media, it could be seen from Figure 3.19 that the SSZ diagnostic peak was 
absent in the mass spectrum for the particles in SIF-only, and there was a higher drug intensity on 
the particles in SGF+SIF than in SGF-only. The signal intensity was highest on the fresh SLNs 
pointing to a strong SSZ-lipid hydrophobic interaction after the particles were formulated. The 
absence of any burst release as evidenced in the in vitro release study in Section 2.4.13 further 
suggests that the drug was not loosely attached at the SLN surface. 
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Figure 3.18 Negative ion ToF-SIMS spectra of pure SSZ, drug-free SLNs, fresh SSZ SLNs and 
SSZ SLNs incubated in simulated GI fluids 
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In ToF-SIMS analyses, there could be suppression or enhancement of the signal of one molecule 
in a mixture due to the presence of other molecules or perhaps due to interactions among the 
compounds present. The ionisation of a molecule can therefore be affected to a large extent by its 
chemical environment, which is known as “the matrix effect” however, this is exploited in matrix-
enhanced SIMS (ME-SIMS).  
There are a number of techniques used to address signal suppression, with applications to film and 
cell preparations, such as washing samples with ammonium formate, ethanol or water prior to 
analyses. Samples could also be prepared and analysed in a frozen-hydrated state, which is the 
only procedure that has shown the most useful results [Jones et al., 2007; Jones et al., 2008; 
Piwowar et al., 2009]. In the present study, using ammonium formate was avoided to prevent the 
introduction of more ions into the samples. Ethanol was also not used because PAR is completely 
soluble in it and SSZ has partial solubility in it; which would negatively affect the signal intensities 
of the diagnostic ions. The samples could not be frozen-hydrated as well as that would have made 
incubation in the simulated media unfeasible, leaving washing with water as the only choice. In a 
study by Piwowar et al. (2009), washing with water or ammonium formate was however found to 
reduce secondary ion yield from arginine films which were not exposed to any chemical 
environment and did not therefore require washing (i.e. control samples), showing that washing 
may be deleterious and not suitable for all sample types. 
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Figure 3.19 Negative ion ToF-SIMS spectra showing SSZ on the surface of SSZ SLNs, before 
and after their incubation in simulated GI fluids  
[** - New peak appearing in spectrum possibly due to a “matrix effect”]   
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This “matrix effect” could be the reason the [C18H13N4O5S]- ion was not detected in the spectrum 
for the SSZ SLNs in SIF-only. SGF contains NaCl (2.0 g/L) and HCl (2.917 g/L), while SIF 
contains NaOH (0.616 g/L) and KH2PO4 (6.8 g/L). Since Na
+ ions are present in either medium 
and SGF+SIF contains some amount of KH2PO4, the massive suppression of the SSZ ion signal in 
SIF-only resulting in its absence in the spectrum could be due to the presence and high 
concentration of the K+ and H2PO4
- ions. 
In a study by Yang et al. (2013), none of the cluster primary ions [C60
+, Arn
+ or Bi3
+] used in 
sputtering Au/SiO2 nanoparticles produced SIMS profiles that were easily explicable. The authors 
observed the appearance of other structures; some of which were not related to any of the 
ingredients used to prepare the nanoparticles. A similar observation is recorded here for the SSZ 
SLNs in the simulated media where there is a peak occurring at m/z 396.7 in each spectrum (red 
asterisks), close to the position of the diagnostic peak but this is absent in the spectra for the pure 
drug and the drug-free and fresh SSZ SLNs (Figures 3.18 and 3.19). This could be the result of  a 
“matrix effect”. In the study by Yang et al. (2013), the main issue of concern was that melting of 
the nanoparticles occurred during ion bombardment as were also evident from the SEM images 
they took before and after sputtering. Meaningful ToF-SIMS analyses on heat sensitive samples 
therefore requires efficient interventions of controlling any heat (heat sinking) produced due to the 
kinetic energy of the ion beam, in order to prevent melting and thereby obtain more reliable  data 
[Yang et al., 2013].  
Depth profiling of samples is used to obtain ion concentration/intensity data as a function of depth 
within a sample. In this study, depth analyses were conducted on the fresh SLN formulations. 
Figure 3.20 shows the molecular ion depth profiles of the three diagnostic ions for AmB. All the 
three profiles are seen to generally decrease in concentration with increasing sputtering time, 
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which suggests that the drug is more concentrated closer to the shell of the particles, and decreases 
towards the core. For the [C20H29O2]
- and [C17H21NO4]
- ions however, a more random pattern in 
drug counts was observed. The intensity of [C20H27O2]
- was highest of the three diagnostic ions as 
was observed in the mass spectrum in Figure 3.13. Although the three ions are all representative 
of the drug, they did not exhibit the same profile because they represent different portions of the 
drug’s structure, corresponding to the ions from different functional groups, and are therefore 
likely to interact differently with the excipients in the formulation. In this case, the ingredients in 
the formulation aside the drug could be considered as causing artifacts in the data resulting in a 
“matrix effect”. 
 
 
 
 
 
 
 
 
 
Figure 3.20 Molecular ion depth profiles of [C20H27O2]
-, [C20H29O2]
- and [C17H21NO4]
- obtained 
from the AmB SLNs 
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Figure 3.21 depicts the profile for [C7H7O]
-, which also shows a random pattern in PAR 
concentration across the sample however, the trend is more of a decrease in drug intensity with 
sputtering.  
 
 
 
 
 
 
 
 
Figure 3.21 Molecular ion depth profile of [C7H7O]
- obtained from the PAR SLNs 
  
The depth profile of [C18H13N4O5S]
-, which is diagnostic of SSZ, as depicted in Figure 3.22 shows 
a different pattern as compared with those for AmB and PAR. The intensity of [C18H13N4O5S]
- 
initially decreases and rises  gradually, forming a crater-like appearance and this was followed by 
an irregular but increase in drug concentration till the end of the sputtering.  
The sputtering of particles occurs differently from that of films or bulk materials, and this is 
particularly true for smaller particles such as nanoparticles. As such, the sputter depth profiling 
did not seem to be the optimum approach to obtain layer or depth information on the SLNs. 
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Figure 3.22 Molecular ion depth profile of [C18H13N4O5S]
- obtained from the SSZ SLNs 
  
This is because nanoparticles and the bulk forms of their ingredients are different in terms of 
optical properties, reactivity and electrical conductivity among others, which are caused by the 
differences in size, shape or molecular arrangements, surface area, agglomeration state and surface 
or bulk chemistry [Baer et al., 2008; Yang et al., 2013]. This variation may be what accounts for 
the peak-trough phenomenon observed. The properties of nanoparticles may also be altered in a 
medium or during a particular process and result in unintended consequences [Grassian, 2008] for 
instance, the ion beam in SIMS could be destructive in analysing lipid nanoparticles because 
melting and resolidification may occur and cause significant structural changes [Yang et al., 2013]. 
In the depth profiling, it was expected that drug intensity counts would increase with sputtering 
time because in vitro studies had revealed a slow rate of drug release in PBS for all three SLNs, 
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especially for AmB and SSZ (Section 2.4.13). The AmB SLNs showed a high drug intensity on 
the surface after exposure to the simulated media, according to the ToF-SIMS spectra in Figure 
3.14; however, the depth profiles did not show increasing drug intensity with sputtering time. PAR 
and SSZ SLNs also showed higher drug intensities on the surface of their respective fresh SLNs 
as compared with after incubation in simulated media yet, both formulations showed different 
depth profile patterns. Again, for the PAR SLNs, drug count on the particles before and after 
incubation in SGF+SIF was similar and suggestive of a somewhat constant drug release; as well 
as a drug-concentrated particle core however, this was not reflected in the depth profile. 
The peak and trough pattern in drug intensity observed in the depth profiles is attributable to the 
roughness or non-uniform nature of the layer of deposited particles when a drop of SLN suspension 
was placed on the silicon wafer. As the dispersion medium evaporates prior to the analyses, the 
particles pack to form an uneven layer so that layer-by-layer scans give a variable expression of 
drug deposition. A depth profile similar to those obtained in the present study was reported by 
Cheng and Winograd (2005) for a peptide-trehalose film sample, which had an irregular surface 
due to crystallisation. 
As the top (a few nm) of the SLN samples were etched off in the depth analyses, different surfaces 
and heights of the packed particles were encountered, containing varying drug amounts that could 
have resulted in the profiles obtained. It could therefore be concluded that a single layer of particles 
tightly packed together to form a film-like layer and having a fairly flat surface would be more 
suitable for a depth profile study of nanoparticles. Notwithstanding, the depth profile analyses 
coupled with the spectral data have provided us with some indication of mass transfer of the drugs 
within the SLNs when these are placed in simulated GI media. 
160 
 
3.5 Conclusions 
The data obtained indicate that after placement of the SLNs in the simulated GI media, there was 
an inflow of the fluids into the SLNs followed by outward diffusion of the dissolved drug. The rate 
of the diffusion however depended on the solubility of the loaded-drug in the particular medium. 
As a result of this, there was an increase in the size (NTA) of the drug-free SLNs since the main 
mass transfer was the diffusion of the media into the SLNs and no drug diffusion out of the 
particles. In the case of the SLNs containing SSZ, which is the most hydrophobic drug, there was 
an increase in size due to a slow rate of dissolution and diffusion of the drug payload while the 
reverse was true for PAR, which has the highest aqueous solubility of the three drugs. The study 
showed NTA to be a more suitable technique for analysing the stability of the SLNs in the various 
media as compared with PCS, which was biased towards larger particles and produced data 
suggestive of high particle aggregation particularly in SGF-only. The data obtained indicate that 
the SLNs may aggregate in the stomach after oral ingestion; however, on reaching the small 
intestine, both size and surface charge of the particles would be optimal for absorption, which 
indicates good stability. 
The mass spectra coupled with the depth profiles obtained from the ToF-SIMS analyses indicated 
that drug loading into the SLNs possibly followed the core-shell model, and that the AmB SLNs 
may have a drug-enriched core. 
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CHAPTER 4 
DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY METHOD 
4.1 Introduction 
Validation of analytical methods is an important regulatory requirement in pharmaceutical 
analyses. High-performance liquid chromatography (HPLC) is commonly used as an analytical 
technique in developing and validating assay methods for drug products and drug substances 
[Shabir, 2004].  
HPLC is an advanced form of liquid chromatography that may be used in separating a mixture of 
compounds by passing a solution of the compounds through a column of very packed particles 
called the stationary phase, in order that the analytes are retained individually [Crawford Scientific, 
2015(b)]. Compound separation occurs because each constituent has a different affinity for the 
stationary phase. Stronger interactions result in longer retention times and hence, slower 
movement of an analyte through the column and vice versa. 
In reversed-phase HPLC (RP-HPLC), a mobile phase more polar than the stationary phase is used 
as opposed to normal phase HPLC in which a polar stationary phase is used with a less polar 
mobile phase [Crawford Scientific, 2015(b)]. Stationary phases for RP-HPLC are hydrophobic and 
usually chemically bonded to the surface of silica support particles. For neutral analytes, the 
mobile phase consists of water, and an organic solvent that is used to modify the retention of 
analytes by reducing the polarity of the mobile phase. Analysis of ionisable compounds requires 
the use of buffers and other additives in the aqueous phase to control retention and peak shape. 
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Increasing the water content in the mobile phase results in repulsion of hydrophobic analytes out 
of the mobile phase and onto the non-polar stationary phase, on which they reside until they 
partition out into the mobile phase again.    
The development of an analytical method comprises evaluation and optimisation of the various 
stages in the sample preparation, chromatographic separation, detection and quantification of the 
analytes [Shah et al., 1992]. On the other hand, validation of the method is essential as it serves as 
documented evidence that a specifically developed analytical method is suitable for its planned 
use, and involves a set of procedures for the collection, processing, storing and 
analysis/quantitative determination of an analyte or group of analytes in a matrix. Validation test 
methods have to basically document the accuracy, sensitivity, specificity, reproducibility, linearity 
and range among other attributes. Ideally, the sample extraction procedure has to be time-
economical and give the highest possible recovery with acceptable accuracy and precision. Method 
performance is determined primarily by the quality of the developed procedure itself [Shah et al., 
1992].  
An internal standard (IS) is usually employed in bioanalytical assays to compensate for losses 
during sample extraction and to eliminate the error caused by possible disparities in injection 
volumes; because variations in the latter significantly affect results especially when the injection 
volume is small [Jones, 2009]. A fixed volume of an IS of no critical concentration is usually added 
to all standards and samples with the principle that, if a smaller or larger injection volume is used, 
the ratio of the peak response of analyte to IS will be the same. Selection of a suitable IS is based 
on the following: it must be detected/excited at the same wavelength as the analyte, in the case of 
UV/fluorescence detection; it must be soluble in the same sample solvents; and it must not be a 
degradation product of the analyte [Jones, 2009]. 
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Data on the transit behaviour of dosage forms through the GI tract is essential in determining 
possible absorption windows of the drug payload. This information can in turn be used to optimise 
desirable properties from the dosage form with a view to improving drug bioavailability. The GI 
transit properties of dosage forms can be studied directly using gamma scintigraphy, nuclear 
magnetic resonance and other radiographic methods but all these require the use of expensive 
equipment or harmful radiation. An indirect means of studying GI transit properties of dosage 
forms using marker drugs provides a less costly alternative and has been used successfully by 
researchers [Peh and Yuen, 1996; Kondo et al., 2003(a,b); Rahman et al., 2005].  
A vital component in utilising the indirect GI transit estimation of dosage forms based on the use 
of marker drugs is that a suitable analytical method is developed and validated to be sufficiently 
sensitive to detect minute drug concentrations. A further desirable requirement is the simplicity of 
the method, given that several drugs would have to be analysed. This chapter focusses on the 
development of a simple and sensitive RP-HPLC method for the simultaneous assay of AmB, PAR 
SP and an IS in rat plasma, for use in a subsequent study to determine the GI transit and 
pharmacokinetic data of AmB following oral administration of AmB SLNs to rats. 
 
4.2 Materials  
Acetonitrile was purchased from Duksan Pure Chemicals Co. Ltd. (Ansan, Korea). Paracetamol, 
dimethyl sulphoxide (DMSO) and sulphapyridine were purchased from Sigma-Aldrich (St. Louis, 
MO, USA), and amphotericin B from Nacalai Tesque (Kyoto, Japan). Methanol and ethanol were 
purchased from Thermo Fisher Scientific. Water was Milli-Q 18.2 MΩ·cm at 25°C (Millipore 
Corp., Bedford, USA). Acetic acid and sodium acetate trihydrate were purchased from R & M 
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Chemicals (Essex, UK). All reagents and solvents used were of analytical and HPLC grades 
respectively. 
 
4.3 Methods 
4.3.1 HPLC instrumentation and conditions 
A Perkin Elmer HPLC system (Series 200 auto-sampler, Series 200 UV/VIS detector, Waltham, 
MA, USA) configured to TotalChrom® Navigator software was used to analyse drug samples in 
the rat plasma. Separation of peaks was achieved using a ZORBAX Eclipse Plus® C18 (250 x 4.6 
mm, 5 μm) column (Agilent Technologies, Santa Clara, CA, USA). The mobile phase comprised 
of: acetate buffer (pH 4) [A], prepared  by mixing 847 mL of 0.1 M acetic acid and 153 mL of 0.1 
M sodium acetate trihydrate [Lambert and Muir, 1955], and the resulting mix vacuum filtered with 
a 0.2 µm filter paper; and acetonitrile [B]. The mobile phase was run at a flow rate of 1 mL/min in 
gradient mode as follows: 100% A from 0-0.5 min; 60% A from 0.5-7 min; 20% A from 7-9 min; 
60% A from 9-12 min and 100% A from 12-15 min. The HPLC was run in a two-step injection 
mode to detect PAR and SP at 254 nm and then AmB at 405 nm. A 5-μg/mL piroxicam solution 
in a 1:1 methanol-ethanol mixture was used as internal standard (IS). The IS was detectable at both 
wavelengths. The methanol-ethanol mixture also served as the deproteinising agent for the plasma 
samples. 
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4.3.2 Plasma standards 
Stock rat plasma solutions containing AmB, PAR and SP at 100 µg/mL, 200 µg/mL and 1000 
µg/mL, respectively, were prepared by spiking the appropriate amounts of the respective drug 
solutions into the appropriate volumes of rat plasma. The stock solutions were further diluted with 
blank rat plasma to prepare the calibration standards for each drug. The samples were prepared at 
three concentration levels for each drug representing low (LC), mid-range (MC) and high (HC) 
concentrations. The LC, MC and HC for AmB were 0.05, 0.25 and 10 µg/mL; for PAR were 0.5, 
2.5 and 100 µg/mL; and for SP were 0.1, 0.5 and 20 µg/mL, respectively. 
 
4.3.3 Plasma sample preparation 
Samples for drug analyses were prepared by transferring 100 µL of plasma and 150 µL of the IS 
solution into microcentrifuge tubes. The tubes were vortex-mixed for 5 min and the extracts 
centrifuged at 14 000 rpm for 10 min. The clear supernatants were aspirated and filtered through 
a 0.20 µm syringe filter followed by direct injection onto the HPLC system. 
 
4.3.4 Specificity  
The specificity of the analysis was first performed by visually observing the chromatograms for 
individual as well as combined solutions (drug dissolved in solvent) of pure AmB, PAR, SP and 
the IS at their respective detection wavelengths. This was followed by examining chromatograms 
for blank plasma samples to detect any possible peak interferences at the retention times of the 
analytes. The final step of this procedure involved obtaining chromatograms of the analytes spiked 
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in plasma. These steps are necessary to ensure that the analytes, both as pure drug solutions or 
spiked into plasma elute at similar times and that the elution of one component is not affected by 
the other, to indicate that the method is specific for the analytes.   
 
4.3.5 Linearity and range 
Calibration curves for AmB, PAR and SP in drug spiked-plasma were obtained over the following 
concentration ranges: 0.05-10 µg/mL, 0.5-100 µg/mL and 0.1-20 µg/mL, respectively. The 
calibration curves were constructed using the ratio of the peak signal of each drug concentration 
to that of the internal standard, versus the corresponding drug concentration. Each analysis 
represents a replica of six runs. 
 
4.3.6 Precision  
The within-day and between-day precision of the analyses at each concentration for each drug was 
determined to investigate the repeatability and reproducibility of the method, as a measure of the 
percentage coefficient of variation (%CV) using the following relationship: 
%CV =  
Standard deviation (SD)
Mean concentration
× 100% … … … … … … Equation 4.1 
Each mean value represents a replica of six determinations. 
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4.3.7 Accuracy 
The within-day and between-day accuracy of the analyses is a measure of the disparity between 
the actual and measured concentrations of the drugs to estimate the reliability of the results 
obtained from using the assay method. This was determined as the relative error at each 
concentration for each drug using the following relationship:   
Relative error (Er) =  
x̅ −  xt
xt
 × 100% … … … … … Equation 4.2 
Where: x̅ = measured concentration (average) and xt = true concentration 
 
4.3.8 Recovery 
The recoveries of AmB, PAR and SP from spiked plasma following the extraction procedure were 
determined by comparing the peak signal of each drug from the prepared plasma samples with that 
of pure drug samples in a solvent mixture of DMSO and methanol. Six determinations were done 
for each drug covering the three concentration levels stated in Section 4.3.2. The percentage 
recovery was determined using the following relationship: 
%Recovery =  
Concentration of drug in spiked plasma
Concentration of pure drug solution 
× 100% … Equation 4.3 
 
4.3.9 Limits of detection and quantification  
The sensitivity of the method was estimated in terms of limit of detection (LOD) and limit of 
quantification (LOQ), which were determined as the lowest amount of each analyte at which the 
peak signal to noise ratios (S:N) were 3:1 and 10:1, respectively [Shabir, 2004]. 
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4.4 Results and discussion 
4.4.1 Selection of internal standard (IS) 
As previously mentioned, an IS must absorb UV light at the same wavelength as an analyte and 
have similar solvent solubility characteristics with the analyte [Jones, 2009]. This means that a 
compound with similar structural properties as the analyte may be the quickest choice. N-acetyl-
AmB was used as IS for AmB in an HPLC analysis by Granich et al. (1986) however, the former 
is costly and not readily available. Due to the absorption wavelengths of PAR and SP being 
different from that of AmB, N-acetyl-AmB or other compounds with structural similarities as 
AmB would be unsuitable for the present analyses because the ideal IS would be a compound 
detectable at both 254 and 405 nm.  
Internal standards that have been used in HPLC analysis of AmB as a single entity include 
natamycin [Lambros et al., 1996], piroxicam [Campanero et al., 1997; Echevarría et al., 1998], 1-
amino-4-nitronaphthalene [Eldem and Arican-Cellat, 2001], α-naphthol [Italia et al., 2009(b)] and 
lornoxicam [Chakrabarty and Pal, 2011]. Natamycin, lornoxicam and 1-amino-4-nitronaphthalene 
were excluded because they do not absorb UV light at 254 nm. Piroxicam and α-naphthol were 
therefore selected for analyses. HPLC chromatograms of piroxicam and α-naphthol showed the 
former to be a better choice as it produced more prominent peak responses. 
Figure 4.1 shows a representative chromatogram of a solution containing 125 µg/mL each of α-
naphthol and piroxicam. The peak response for piroxicam is 8.8-fold greater than that for α-
naphthol.  The retention times obtained were 8.8 and 9.7 min for piroxicam and α-naphthol, 
respectively. The chromatogram is representative of the peak responses of the compounds at both 
254 and 405 nm and clearly shows piroxicam to be a better IS option, as it has a better response 
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compared to α-naphthol at an equivalent concentration. Piroxicam was therefore selected as IS for 
the subsequent analyses. 
 
Figure 4.1 Chromatogram for piroxicam and α-naphthol (125 µg/mL each), showing 
piroxicam as the preferred IS for the HPLC analyses 
 
4.4.2 Mobile phase composition and elution method 
Isocratic elution is the term used if the composition of a mobile phase system in an HPLC analysis 
remains constant throughout the separation of the analytes, while the reverse is true for gradient 
elution [Barkovich, 2015]. In the latter, all the compounds in a sample mix can be eluted in a 
shorter time as compared with isocratic elution. This is because maintaining the same proportion 
of solvents in a mobile phase system for HPLC analysis of compounds with different solvent 
solubilities requires a long run time, sufficient to allow interaction of hydrophobic analytes with 
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the stationary phase prior to their elution or partitioning back into the mobile phase. On the other 
hand, by changing the ratio of polar to non-polar solvents in the mobile phase during a sample run, 
various compounds covering a wide range of polarities can interact faster with the stationary phase 
with shorter retention times. In general, isocratic or gradient elution can be used for separating a 
mix of analytes and provided that all other conditions are optimal, peak resolution can be 
maintained in both methods. This leaves the technique of choice to the results from preliminary 
studies as well as the polarity range of the analytes. As non-polar compounds interact strongly 
with the stationary phase resulting in long retention times, gradient elution is a better choice for 
HPLC analyses of polar and non-polar compounds since this has the capability of allowing for a 
shorter run time while ensuring that peaks are well resolved. 
A search through literature revealed an HPLC method using 1.8% tetrahydrofuran in 0.01 M 
sodium acetate buffer adjusted to pH 4.5 with glacial acetic acid as the mobile phase for analysing 
PAR and SP [Rahman and Niaz, 2004]. For AmB, organic solvents such as methanol and 
acetonitrile have been used together with aqueous solutions such acetate or phosphate buffers 
[Lambros et al., 1996; Campanero et al., 1997; Italia et al., 2009(b); Chakrabarty and Pal, 2011], 
or acetic acid and water [Echevarría et al., 1998] as the mobile phase. A study by Italia et al. 
(2009b) revealed acetonitrile to be better than methanol as the organic modifier in the mobile phase 
mix for HPLC analyses of AmB because acetonitrile produced peaks with better symmetry. 
Methanol was therefore excluded from the mobile phase system in the present study. 
Using the aforementioned studies as a guide, a solvent system of sodium acetate buffer (pH 4) as 
the aqueous phase [A] and acetonitrile as the organic phase [B] was selected as the mobile phase 
for the current study. Using this solvent mix in isocratic mode and varying the ratios of A to B, 
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from 90:10 to 10:90 over various ranges of run times, analyte peaks were either not properly 
resolved or absent from the resulting chromatograms.  
On running the mobile phase in gradient mode according to Table 4.1 and injecting a mixture of 
all the analytes onto the HPLC, the chromatograms in Figures 4.2(a) and (b) were obtained. In 
order to identify the peaks, each analyte was run separately.  
 
Table 4.1 Gradient elution method for analysing AmB, PAR, SP and IS  
Step Time          
(min) 
% A                             
(acetate buffer, pH 4) 
% B       
(acetonitrile) 
Equilibration 2 80 20 
1 2 80 20 
2 4 20 80 
3 2 20 80 
4 2 60 40 
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Figure 4.2 Chromatograms for (a) PAR and SP at 254 nm and (b) AmB at 405 nm, using the gradient method in Table 4.1 
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There was no peak corresponding to the IS in either of the chromatograms. The retention times 
were 7.5 and 8.8 min for PAR and SP, respectively, at 254 nm and 8.1 min for AmB at 405 nm. 
The run time of the method was therefore extended from 10 min to 15 min to allow for elution of 
the IS, and the gradient elution method was also revised so as to obtain more distinct retention 
times as those for SP and AmB were not well resolved although the compounds are detected at 
different wavelengths. 
The mobile phase gradient was modified by increasing the percentage and run time of the aqueous 
phase as shown in Table 4.2 to obtain the chromatograms in Figure 4.3. The retention times for 
the analytes were 7.5, 8.8 and 12.1 min for PAR, SP and the IS, respectively, at 254 nm, and 11.7 
and 12.2 min for AmB and the IS, respectively, at 405 nm. These results were an improvement on 
the previous method (Table 4.1) as it can be seen that the IS was eluted at both wavelengths at 
approximately the same time, and each analyte had a distinctive retention time. However, only the 
peaks for PAR and SP were of good symmetry while those for AmB and IS showed some splitting.  
The HPLC column was flushed with distilled water, methanol, acetonitrile, methanol and the 
mobile phase (in that order) to remove any particles such as salts that may have precipitated from 
the sodium acetate buffer and may have resulted in the split peaks. The gradient method was then 
again adjusted until the method shown in Table 4.3 was obtained, which resulted in chromatograms 
with well-resolved peaks for the analytes as are evident in the subsequent chromatograms (Figure 
4.5).  
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Table 4.2 Improved gradient elution method for HPLC analyses of AmB, PAR, SP and IS 
Step Time          
(min) 
% A                             
(acetate buffer, pH 4) 
% B       
(acetonitrile) 
Equilibration 2 60 40 
1 7 60 40 
2 2 20 80 
3 2 60 40 
4 4 100 0 
 
 
Table 4.3 Optimum gradient elution method for the HPLC analyses 
Step Time          
(min) 
% A                             
(acetate buffer, pH 4) 
% B       
(acetonitrile) 
Equilibration 2 100 0 
1 0.5 100 0 
2 6.5 60 40 
3 2 20 80 
4 3 60 40 
5 3 100 0 
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Figure 4.3 Chromatograms for (a) PAR, SP and IS at 254 nm; and (b) AmB and IS at 405 nm, using the gradient method in Table 
4.2
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4.4.3 Effect of deproteinising agent 
Proteins are usually removed from biological samples to allow for qualitative or quantitative 
analysis of drugs and their metabolites, as well as other non-protein compounds [Polson et al., 
2003]. In order to exclude responses due to proteins, deproteinising agents/protein precipitants are 
normally used to treat the samples prior to such analyses.  
Protein solubility in biological fluids is due to polar interactions with the aqueous solvent, ionic 
interactions with salts, and repulsive electrostatic forces between similar charged molecules. At 
the isoelectric point (pI), proteins have no net charge and hence they have minimum solubility in 
aqueous solvents. Above the pI, a protein has a net negative charge and vice versa. 
Protein precipitation is a simple purification method of denaturing proteins using strong acids or 
bases, heat, organic solvents, salts (e.g. ammonium sulphate) and metal ions to disrupt protein-
drug binding [Englard and Seifter, 1990; Kole et al., 2011; Oh and Lee, 2013]. The aforementioned 
agents facilitate protein precipitation differently: organic solvents lower the dielectric constant of 
the plasma protein solution, which increases the attraction between charged molecules. Organic 
solvents also displace water molecules around the protein surface, which results in attractive 
electrostatic interactions and then protein aggregation. Acids on the other hand form insoluble salts 
with the positively charged amino groups of protein molecules. Addition of high amounts of salts 
to proteins in solution draw water away from the proteins to become hydrated which in turn results 
in aggregation of protein molecules by enhancing protein-protein hydrophobic interactions. 
Positively charged metal ions on the other hand bind with proteins and reduce protein solubility 
by changing the pI. Metal ions in solution also compete with protons for binding sites on amino 
acids and displace bound protons thereby lowering the pH of the solution. The alteration of the 
pI and reduction in pH result in protein precipitation. Heating also alters intramolecular hydrogen 
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bonds in proteins, which are responsible for the secondary and tertiary structures of proteins 
thereby denaturing the proteins [Polson et al., 2003]. 
The use of salts, acids and heat result in trapping of analytes in protein aggregates and causes a 
reduction in analyte concentration in the supernatant leading to erroneous results. Acids and metal 
ions (e.g. zinc sulphate) also require a prior evaluation of an analyte’s stability in them in order to 
detect possible degradation and analyte loss through binding with the metal cations. As a result, 
most bioanalytical protein precipitation methods use water miscible organic solvents for protein 
denaturation, most of which achieve up to 90-96% protein precipitation [Chamberlain, 1995; 
Polson et al., 2003; Chang et al., 2007]. 
Organic solvents used as deproteinising agents include methanol, ethanol and acetonitrile. 
However, when acetonitrile was used both as deproteinising agent and solvent for the IS in the 
present study, distortions such as peak broadening, splitting and tailing (Figure 4.4(a)) were 
obtained on repeated analyses at 254 nm. On using methanol and ethanol in equal proportions as 
the deproteinising agent and maintaining acetonitrile as the solvent for the IS, the peaks for PAR 
and the IS became sharper with better symmetry while the SP peak remained distorted and off the 
baseline of the chromatogram as depicted in Figure 4.4(b).  
As a result of the peak improvements after using the methanol/ethanol mix for deproteinising, the 
latter was employed as the solvent for the IS as well. The chromatogram in Figure 4.4(c) shows 
all the analyte peaks to be well resolved, sharp and symmetrical without any splitting. As well, all 
the peaks were on the baseline, clearly indicating methanol/ethanol (1:1) as the optimal 
deproteinising agent for the plasma samples. Subsequent analyses were therefore conducted using 
methanol/ethanol (1:1) as both solvent for the IS and as deproteinising agent. In doing so, further 
dilution of analytes in the plasma samples was avoided, as would have been the case if different 
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solvents were used for both purposes, while ensuring that sufficient deproteinising solvent is used 
for effective protein precipitation. The peaks for AmB and the IS at 405 nm were largely unaffected 
by the choice of solvent for deproteinisation.  
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Figure 4.4 Chromatograms showing the effects of deproteinising agent on peak shape and symmetry at 254 nm 
(a) Using acetonitrile containing IS (10 µg/mL) for deproteinisation 
(b) Using acetonitrile containing IS (10 µg/mL) + methanol/ethanol (1:1) for deproteinisation 
(c) Using methanol/ethanol (1:1) containing IS (10 µg/mL) for deproteinisation 
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4.4.4 HPLC method validation 
A number of HPLC methods specific to the detection of AmB and suitable internal standards in 
biological fluids have been reported [Lambros et al., 1996; Campanero et al., 1997; Echevarría et 
al., 1998; Italia et al., 2009(b); Chakrabarty and Pal, 2011]. In the present study, a method for the 
simultaneous analyses of AmB, PAR and SP, which would be suitable for the GI transit monitoring 
and absorption of AmB, using PAR and SP as marker drugs was developed. Piroxicam was 
employed as the IS in the present study because it was found to absorb considerably at the two 
detection wavelengths used (254 and 405 nm). 
The results for the method validation parameters investigated for AmB, PAR and SP are 
summarised in Tables 4.4-4.6 respectively.  
 
4.4.4.1 Specificity 
Firstly, it had to be ensured that the method was specific for the drugs in the study so pure solutions 
of the individual drugs were injected onto the HPLC system separately to obtain the individual 
retention times of the analytes for the purpose of peak identification. The Eclipse Plus C18 column, 
mobile phase composition and the simple gradient elution method employed in the study were 
found to be suitable for the simultaneous analysis of AmB, SP, PAR and the IS. Figures 4.5(a) and 
(b) show the chromatograms obtained when pure drug solutions containing identical 
concentrations (22.22 µg/mL each) of PAR, SP and the IS were analysed at 254 nm; and AmB and 
the IS at 405 nm, respectively.  
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Figure 4.5 Chromatograms of a pure solution of the analytes showing (a) PAR, SP and IS at 254 nm; and (b) AmB and IS at 405 
nm 
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The retention times obtained were 7.1, 8.6 and 12.3 min for PAR, SP and the IS at 254 nm; and 
11.7 and 12.9 min for AmB and the IS at 405 nm, respectively. The chromatograms obtained 
clearly show no interfering peaks, which indicate the absence of degradation products or synthetic 
precursors, as well as the specificity of the method for the analytes. It is also clear from the 
chromatograms how different wavelengths affect an analyte’s signal [Harvey, 2015] as is seen for 
the IS. 
The hydrophobicity of a compound is the primary indicator of its retentivity in RP-HPLC; that is, 
retention time is higher for more hydrophobic compounds [Crawford Scientific, 2015(b)]. LogP 
is a measure of how an analyte in its unionised form partitions between two immiscible solvents 
(usually octanol and water) under standard conditions, and is used to express hdrophobicity. The 
higher the value of logP, the more hydrophobic a compound is. The order of elution of analytes is 
therefore governed by their chemical structures and hence, their solubility in water, as well as their 
carbon content in the case of an analogous series.   
In RP-HPLC, hydrophilic molecules adsorb less to the hydrophobic stationary phase and are eluted 
first while less polar and non-polar molecules are more strongly held by the hydrophobic stationary 
phase and are eluted later [Crawford Scientific, 2015(b)]. Polarity however is not the only factor 
involved in the order of elution. Analyte retention may also be affected by other conditions such 
as the mobile phase, stationary phase and column temperature.   
The logP values for PAR, SP, AmB and the IS are 0.48, 0.47, 1.16 and 2.67, according to the 
ACD/LogP model predictions. It is observed that the analytes eluted in the order of their logP 
values except that SP would have been expected to elute before PAR however, this is not 
concerning as the peaks are well resolved. 
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Separation of compounds varies for different mobile phases at various solvent ratios. This is 
because of differences in the chemical properties of organic solvent molecules [Shimadzu, 2015]. 
The elution order depends on which organic solvent is used in the mobile phase as well as the 
amount of water present or the pH of the aqueous solvent. The retention time for each analyte is 
therefore affected differently by the choice of organic solvent. For instance, changing from 
acetonitrile to tetrahydrofuran or methanol will result in different elution orders for a given set of 
analytes, leaving the choice of organic solvent to the one which gives the best peak resolution 
[Harvey, 2015; Shimadzu, 2015].  
From Figure 4.6 for instance, it is evident how the elution order of phenol and benzoic acid is 
reversed due to change in mobile phase composition. The order of elution could however remain 
the same for two different mobile phases for a given mixture of compounds however, each 
analyte’s retention time would be affected differently; some analytes would elute earlier or more 
slowly [Harvey, 2015]. 
 
Figure 4.6 Chromatograms showing the separation selectivity of phenol, benzoic acid and p-
toluic acid for acetonitrile and methanol [Shimadzu, 2015] 
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4.4.4.2 Effect of plasma (matrix effect) 
Injecting blank plasma onto the HPLC showed no interfering peaks at the retention times of all the 
analytes at both detection wavelengths as depicted in Figures 4.7(a) and (b), further indicating the 
specificity of the HPLC method for the analytes. The baselines also showed low noise at the same 
attenuation of the detector.  
Plasma samples spiked with the analytes and IS, treated according to the sample preparation 
procedure in Section 4.3.3 and injected onto the HPLC system produced the chromatograms shown 
in Figures 4.8(a) and (b). It can be seen that the peaks for all the drugs remained very well resolved 
and symmetrical in plasma, with slight increases in some of the retention times. At 254 nm, 
retention times increased from 7.1 to 8.5 min for PAR; from 8.6 to 9.9 min for SP; and from 12.3 
to 12.9 min for the IS, compared with the respective peaks obtained from the pure drug solutions 
in Figure 4.5. The peaks in Figure 4.8 were obtained by spiking the same solution used to obtain 
the chromatograms in Figure 4.5 into an equal volume of blank plasma. The differences in the 
relative peak signals/intensities are attributable to the effect of the plasma matrix; however, this 
effect remains constant as all subsequent analyses were conducted in plasma. The differences in 
the peak signals of the analytes relative to each other (i.e. PAR > SP > IS in Figure 4.5 as compared 
with IS > PAR > SP in Figure 4.8) further indicate that the matrix effects of plasma vary for 
different analytes. At 405 nm however, the retention times for AmB and the IS remained 
essentially unchanged.  
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Figure 4.7 Chromatograms of the methanol-ethanolic extract of blank rat plasma at (a) 254 nm and (b) 405 nm 
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Figure 4.8 Chromatograms of spiked plasma showing (a) PAR, SP and IS at 254 nm; and (b) AmB and IS at 405 nm
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HPLC is a useful analytical technique for quantifying drugs, their metabolites and endogenous 
compounds in biological samples however, “matrix” effects may be encountered [Hall et al., 
2012]. Matrix refers to all the constituents of a sample other than the analyte of interest. Plasma 
samples may contain unknown components however, the known components also vary in amounts 
in different subjects based on genetics and disease state, as well as the presence of any medications 
being taken and their metabolites. As a result, matrix effects may differ among subjects. Plasma 
comprises proteins, amino acids, peptides, glucose, carbohydrates, vitamins, electrolytes, 
hormones and lipids, all of which contribute to matrix effects. 
The Sprague-Dawley rats used in the present study were reared solely for the project and were not 
given any drug substances except food and water prior to the study. As a result, plasma matrix 
effects were minimised to the presence of endogenous biological components and metabolites such 
as phospholipids and carbohydrates, and to interactions such as covalent binding between analytes 
and plasma proteins [Hall et al., 2012]. 
A matrix effect can be detected if a peak co-elutes with an analyte and causes a suppression or 
enhancement in the chromatographic peak properties of the analyte [Polson et al., 2003]. Some 
matrix components are removed during sample “clean-up” processes such as protein precipitation, 
liquid-liquid extraction and solid-phase extraction. The use of internal standards also helps to 
minimise matrix effects. Organic solvent-based deproteinisation efficiently removes majority of 
proteins from plasma samples hence, further processing of plasma samples can be avoided to 
reduce analyte losses and ensure accuracy of results [Polson et al., 2003; Hall et al., 2012]. 
It has been reported that polar analytes are usually more affected by endogenous matrix effects 
than non-polar analytes, which is clearly manifested in the present study. After the analytes were 
spiked into plasma, a reduction in the relative peak heights for the polar analytes, PAR and SP, 
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was observed compared with the peak signal for the hydrophobic IS which remained unchanged 
(Figure 4.5 versus Figure 4.8). This is due to the fact that most of the constituents of biological 
matrices are water-soluble compounds. The latter are detectable within the UV range and usually 
elute early during RP-HPLC [Bonfiglio et al., 1999; Müller et al., 2002] as observed in the initial 
7 min of the chromatogram at 254 nm (Figure 4.8), and may affect peak properties of polar analytes 
as observed for PAR and SP. 
The results obtained however clearly showed that the developed HPLC method was suitable for 
the simultaneous assay of the three drugs and IS in the presence or absence of a biological matrix 
such as plasma. 
 
4.4.4.3 Linearity and range 
The linearity of the method was tested to establish proportionality between peak response and 
analyte concentration over the working drug concentration ranges. The calibration curves for 
AmB, PAR and SP in plasma as illustrated in Figures 4.9(a)-(c) were found to be linear over the 
concentration ranges of 0.05-10 µg/mL, 0.5-100 µg/mL and 0.1-20 µg/mL, respectively. The 
coefficients of determination were also found to be 0.9999, 0.9991 and 0.9999, respectively, 
indicating good linearity in each case.  
The concentration ranges were selected based on literature on the Cmax values obtained after oral 
administration of formulations of the analytes as single entities to rats. For AmB, doses of 4.5-200 
mg/kg resulted in Cmax values of 0.071-1.469 µg/mL [Risovic et al., 2003; Gershkovich et al., 
2009; Patel and Patravale, 2011; Jain et al., 2012]. For PAR, 10-30 mg/kg doses produced Cmax 
values ranging 3.5-16.9 µg/mL [García-López et al., 1997; Adzu et al., 2001; Qinna et al., 2014]. 
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Lastly, for SP, 20-60 mg/kg oral doses of SSZ resulted in Cmax values for SP in the range of 4.764-
37.6 µg/mL [Chungi et al., 1989; Zamek-Gliszczynski et al., 2012].  
In the present study, it was intended that 10 mg/kg doses of each of the three nanoparticle 
formulations containing AmB, PAR and SSZ, would be orally administered to rats, implying that 
the selected concentration ranges would be suitable to detect the plasma concentration levels of 
the analytes in rat plasma. 
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Figure 4.9 Standard calibration curve of the peak response ratios of (a) AmB to IS, (b) PAR to IS, and (c) SP to IS, each versus the 
corresponding concentration of AmB, PAR or SP (µg/mL) in rat plasma  
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4.4.4.4 Precision 
Precision is a measure of the degree of repeatability of the developed HPLC method [Shabir, 
2004]. The within-day assay is the results of the reproducibility of the HPLC method during a 
short time period, under the same conditions. The between-day runs on the other hand estimates 
the inter-day variation due to within-laboratory changes resulting from random events such as the 
effects of different days on performances by the same or different analysts or equipment. The 
within-day precision determination gave values of 4.39-7.17% for AmB, 2.54-4.28% for PAR and 
3.77-9.89% for SP. The variabilities for between-day run on the other hand were in the ranges of 
0.93-9.41% for AmB, 2.87-6.08% for PAR and 1.13-4.79% for SP. The precisions were found to 
be less than 10% in all cases indicating an acceptable degree of variation for all the analytes. To 
be acceptable, %CV values must be less than 15% at all concentration levels [Bressolle et al., 
1996; Campanero et al., 1997].  
Other precision values that have been obtained in HPLC analyses of AmB and PAR in rat plasma 
are 1.02-13.93% [Lambros et al., 1996; Echevarría et al., 1998; Italia et al., 2009(b); Chakrabarty 
and Pal, 2011] and 3.48-15% [Qinna et al. 2014; Alolga et al., 2015], respectively, for both intra- 
and inter-day assays. The data from the present study are therefore either comparable with those 
reported in the aforementioned studies or better. 
 
4.4.4.5 Accuracy 
The percentage accuracy of an analytical method estimates the closeness between observed/actual 
and expected/nominal concentrations [Shabir, 2004]. Accuracy was measured in terms of 
percentage relative error and was found to be as follows for the within-day run; 0.20-3.20% for 
192 
 
AmB, 0.27-1.44% for PAR and 0.08-1.60% for SP. For the between-day run, 0.27-3.90% was 
obtained for AmB, 1.81-5.06% for PAR and 1.29-7.50% for SP. Comparing the results for all the 
analytes, the maximum error obtained was 7.50%, which is very minimal. A relative error value 
less than 15% at all concentrations is an acceptable level of accuracy [Bressolle et al., 1996; 
Campanero et al., 1997] for an assay method, which indicates that the current HPLC method is 
accurate for the analysis of the analytes in rat plasma. The studies by Lambros et al. (1996) and 
Echevarría et al. (1998) produced maximum relative error levels of 4.4% and 6.4%, respectively, 
for AmB as a single entity in rat plasma/serum, which agree with the results obtained in the current 
study. An HPLC method developed by Alolga et al. (2015) to assay PAR produced a relative error 
value of up 13.4% for both intra- and inter-day assays over a concentration range of 0.03-15 
µg/mL, to which the current results are superior. A search through published studies revealed no 
recent data on the accuracy of an HPLC assay of SP in rat plasma.  
Precision and accuracy together estimate the error of an analytical method and are the primary 
criteria used to assess the quality of analytical methods [Bressolle et al., 1996]. The results 
therefore indicate that the developed HPLC method is of good quality, repeatable and reproducible. 
 
4.4.4.6 Recovery 
The percentage recoveries of the analytes from plasma estimate the efficiency of the plasma 
treatment procedure and the extraction of the drugs spiked in plasma for analysis. Recovery also 
serves as an indicator of the level of plasma matrix effect. The recovery values obtained were 
92.09-98.39% for AmB, 98.73-100.10% for PAR and 91.69-99.20% for SP. These values are all 
above 91%, indicating that the rat plasma matrix affected the extraction and quantitation of the 
analytes by 9% or less, which points to good analyte recovery from plasma. Recovery values of 
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AmB as a single entity from rat plasma/serum have been obtained to be up to 96%, 95%, 97%, 
108.5% and 96.5% in other studies by Lambros et al. (1996), Campanero et al. (1997), Echevarría 
et al. (1998), Italia et al. (2009b) and Chakrabarty and Pal (2011), respectively. Mean recovery 
values of 78.1%, 96.47% and 99.6% were obtained for PAR by Abu-Qare and Abou-Donia (2001), 
Alolga et al. (2015) and Qinna et al. (2014), respectively; however for the former, PAR was in an 
analyte mixture containing pyridostigmine bromide, acetylsalicylic acid and caffeine as well. The 
recoveries of AmB and PAR obtained in the current study are either superior to or comparable 
with those obtained in literature, which indicates a minimal matrix effect, as well as the suitability 
of the HPLC method for the simultaneous assay of the drugs in rat plasma.  
 
4.4.4.7 LOD and LOQ 
LOD can be defined as the lowest amount of an analyte that is detectable above the baseline noise, 
and is normally estimated to be three times the noise level while LOQ is the lowest amount of the 
analyte that can be reproducibly measured quantitatively above baseline noise [Shabir, 2004]. 
LOQ is normally estimated as ten times the noise level and at least twice the value of the LOD 
[Bressolle et al., 1996]. LOD and LOQ were 5.70 ng/mL and 19.05 ng/mL for AmB; 13.44 ng/mL 
and 44.82 ng/mL for PAR; and 15.30 ng/mL and 51.02 ng/mL for SP, respectively. Some LOD 
and LOQ values from published HPLC data are 1-5 ng/mL and 10 ng/mL, respectively, for AmB 
[Lambros et al., 1996; Echevarría et al., 1998; Italia et al., 2009(b); Chakrabarty and Pal, 2011], 
and 100-200 ng/mL and 150-199 ng/mL, respectively, for PAR [Abu-Qare and Abou-Donia, 2001; 
Qinna et al., 2014].  
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The LOQ values obtained for the analytes are lower than the respective plasma analyte 
concentrations, obtained at the first blood sampling times in pharmacokinetic studies after oral 
administrations of the following doses to rats: AmB at 4.5-200 mg/kg [Risovic et al., 2003; 
Gershkovich et al., 2009; Patel and Patravale, 2011; Jain et al., 2012], PAR at 10-30 mg/kg 
[García-López et al., 1997; Adzu et al., 2001; Qinna et al., 2014] or SSZ at 60 mg/kg [Chungi et 
al., 1989].  
The LOQ values are therefore sufficiently low to allow detection and quantification of expected 
plasma analyte concentrations following planned (discussed in the next chapter) oral 
administration of AmB, PAR and SSZ SLNs to rats, each at a dose of 10 mg/kg. It can be observed 
that the LOD and LOQ values obtained in this study are comparable with those in the stated reports 
however, for PAR and SP, better values were obtained in the present study.  
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Table 4.4 Summary of HPLC method validation parameters for AmB 
Parameter Concentration (µg/mL) Intra-day Inter-day 
 
Precision 
(% CV) 
Low 0.05 4.39 9.41 
Medium 0.25 7.17 2.36 
High 10.00 5.78 0.93 
 
Accuracy 
(%) 
Low 0.05 2.40 0.27 
Medium 0.25 3.20 3.90 
High 10.00 0.20 1.20 
 
Recovery 
(%) 
Low 0.05 97.77±3.15 
Medium 0.25 95.60±6.12 
High 10.00 92.09±0.58 
 
Sensitivity 
LOD 5.70 ng/mL 
LOQ 19.05 ng/mL 
Linearity range 0.05-10 µg/mL 
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Table 4.5 Summary of HPLC method validation parameters for PAR 
Parameter Concentration (µg/mL) Intra-day Inter-day 
 
Precision 
(% CV) 
Low 0.50 2.53 6.08 
Medium 2.50 4.01 2.87 
High 100.00 4.28 5.13 
 
Accuracy 
(%) 
Low 0.50 0.90 5.06 
Medium 2.50 1.44 1.81 
High 100.00 0.27 2.90 
 
Recovery 
(%) 
Low 0.50 98.73±1.53 
Medium 2.50 100.10±5.33 
High 100.00 99.35±1.34 
 
Sensitivity 
LOD 13.44 ng/mL 
LOQ 44.82 ng/mL 
Linearity range 0.5-100 µg/mL 
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Table 4.6 Summary of HPLC method validation parameters for SP 
 
 
 
 
 
 
Parameter Concentration (µg/mL) Intra-day Inter-day 
 
Precision 
(% CV) 
Low 0.10 7.31 1.13 
Medium 0.50 9.89 4.79 
High 20.00 3.77 3.16 
 
Accuracy 
(%) 
Low 0.10 1.55 1.29 
Medium 0.50 1.60 7.50 
High 20.00 0.08 1.67 
 
Recovery 
(%) 
Low 0.10 97.48±5.42 
Medium 0.50 99.20±4.76 
High 20.00 91.69±1.82 
 
Sensitivity 
LOD 15.30 ng/mL 
LOQ 51.02 ng /mL 
Linearity range 0.1-20 µg/mL 
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4.5 Conclusions 
The results show that the validated HPLC method has the advantage of a simple sample 
preparation procedure as compared to solid-phase extraction. It can be concluded that the 
HPLC method is simple, rapid, accurate and reliable for determining the concentrations of 
AmB, PAR and SP in plasma using piroxicam as the IS. In addition, the method produced data 
that were comparable with or better than those obtained in other studies. The peaks for all the 
analytes are well resolved and separated from each other and also, the 15 min run time is 
relatively short considering that four different compounds (including the IS) can be 
simultaneously analysed. Again, the volume of plasma used in the analyses is small, which is 
necessary for pharmacokinetic studies in rodents since only small blood volumes can be 
sampled for analyses due to their small size. 
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CHAPTER 5 
PILOT GASTROINTESTINAL TRANSIT STUDY 
5.1 Introduction 
The formulation of pharmaceutical products is carried out with the key aim of enhancing the 
bioavailability of the therapeutic agent, which presents a challenging prospect for poorly water-
soluble drugs. For dosage forms intended for oral delivery, the balance between a drug's 
solubility in gastrointestinal (GI) fluids and its permeation across the lipophilic membrane of 
the enterocytes determines its rate and extent of absorption [Pramod et al., 2010; Kalepu et al., 
2013]. 
Amphotericin B (AmB) is poorly absorbed from the GI tract when administered orally due to 
its low aqueous solubility. There is therefore growing interest by formulation scientists in 
developing alternative delivery systems to address this constraint. Lipid-based drug delivery 
systems (LBDDS) are a useful technology designed to address this challenge. This is because 
encapsulating or solubilising drugs in lipid excipients can promote absorption and improve 
bioavailability [Pouton, 2006]. In the past decade, researchers have focused their interest on 
lipids as carrier systems for hydrophobic drugs. 
One LBDDS that has received much attention lately is the solid lipid nanoparticle (SLN). After 
oral administration, lipids are digested by gastric and pancreatic lipases and then incorporated 
into micellar and vesicular colloidal structures. The presence of exogenous lipids in the small 
intestine also stimulates the secretion of bile salts which aid in solubilisation and absorption of 
the lipids. Lipids impact oral drug absorption and bioavailability in a variety of ways including: 
increasing membrane fluidity which enhances transcellular absorption; allowing paracellular 
transport via opening of tight junctions; increased intracellular concentration and residence 
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time by surfactants due to inhibition of P-gp and/or CYP450; and stimulation of 
lipoprotein/chylomicron production [Humberstone and Charman, 1997; Porter and Charman, 
1997; Driscoll, 2002]. LBDDS enhance drug transport into systemic circulation via the 
extensive drainage network of the intestinal lymphatic system when given orally. SLNs also 
have the potential to be taken up by Peyer’s patches along the GI tract, which drain into the 
lymph. Drug association with chylomicrons in enterocytes is the important step in lymphatic 
drug absorption. Advantages of lymphatic drug transport include avoidance of first-pass 
metabolism and targeting specific diseases that spread via the lymphatics [Charman et al., 
1997; Driscoll, 2002; Porter et al., 2007]. 
AmB is currently delivered intravenously but this route of administration is associated with 
adverse effects like fever, chills, rigors, malaise, headache, generalised aches, nausea, vomiting 
and hypoxia [Patel, 2000]. There is evidence that lipid-based AmB formulations present 
reduced renal toxicity [Risovic et al., 2003; Gershkovich et al., 2009; Jain et al., 2012] in 
addition to enhanced bioavailability when delivered orally [Patel and Patravale, 2011; Jain et 
al., 2012]. Aside the infusion-related side effects of AmB, other general drawbacks of 
intravenous administration include drug or blood extravasation, catheter infections and 
thrombosis, which makes oral delivery the most popular route of drug administration. 
However, oral delivery may be limited by drug properties such as poor solubility, low 
permeability, instability and rapid metabolism. 
Designing and developing pharmaceuticals aimed at achieving maximum oral bioavailability 
is best ascertained through monitoring the absorption profile of the drug payload, as well as 
assessing the GI transit properties of the dosage form. These are particularly crucial for 
hydrophobic drugs. 
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In this study, paracetamol (PAR) is used as a marker drug for estimating the gastric emptying 
rate of AmB SLNs based on the rate of appearance of PAR in the blood following oral 
administration [Heading et al., 1973; Clements et al., 1978]. Sulphasalazine (SSZ) is partially 
and irregularly absorbed after oral administration however, a larger proportion of the dose 
passes unchanged into the colon where it is metabolised by bacteria to produce sulphapyridine 
(SP) and 5-aminosalicylic acid [Moffat et al., 2005]. The SP is very rapidly and almost 
completely absorbed from the colon into the blood and can therefore serve as an estimate for 
the arrival time of an SSZ-containing formulation at the caecum [Kellow et al., 1986; Staniforth 
et al., 1987]. PAR and SP have been used as marker drugs to estimate gastric emptying and 
orocaecal transit times, respectively, of pellet-filled capsules in humans [Peh and Yuen, 1996; 
Rahman et al., 2005], liquids in monkeys [Kondo et al., 2003(a,b)], and provide a cheaper, 
safer and more appropriate alternative to direct methods such as gamma scintigraphy in 
experimental animals like rats. 
Prior to administration, AmB, PAR and SSZ were formulated into SLNs using identical 
methods. These were then characterised to ensure similarity in their physical disposition as 
reported in Chapter 2, with the assumption that when administered simultaneously, all three 
SLNs would respond similarly to the hydrodynamics within the GI tract. After this assumption 
was ascertained in vitro (Chapter 2), the stage was now set to conduct a GI transit study on the 
AmB SLNs.  
A pilot or background study is a small-scale version of a main study run to assess if the 
components and processes involved in the study can efficiently generate an outcome [FDA, 
2013]. Generally, pilot studies are conducted prior to full bioequivalence studies in order to 
obtain clinically relevant data. A pilot study can therefore be used to validate an analytical 
methodology, assess variability, optimise sample collection time intervals and obtain other 
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useful information. In the present study, a pilot GI transit investigation on the AmB SLNs was 
conducted using rat as the animal model. 
 
5.2 Materials and methods 
5.2.1 Preparation of AmB, PAR and SSZ SLN formulations 
AmB, PAR and SSZ SLNs were individually prepared according to the procedure stated in 
Section 2.3.3 and freeze-dried using trehalose (10%w/v). 
 
5.2.2 In vivo study 
5.2.2.1 Animals 
Pharmacokinetic studies on AmB, PAR and SSZ, and GI transit studies on the SLNs were 
performed using three 2-month-old disease-free male Sprague-Dawley rats (300-350 g), fasted 
overnight. The use of the animals, the protocol for their care, as well as the study protocol used 
were reviewed and approved by the Animal Ethics Committee of the University Sains 
Malaysia. The animals were obtained from the Animal Holding Unit of University Sains 
Malaysia and the study conducted at the School of Pharmaceutical Sciences of the same 
university. 
The rats were housed in ventilated cages, maintained under a 12/12 hr light/dark cycle at 
ambient temperature and humidity, and supplied with food and water ad libitum. The animals 
were acclimatised for 7 days before the study.  
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5.2.2.2 Procedural care of the rats 
The tail end of each rat was clipped once during the initial blood sampling time. The rats were 
allowed to move freely in their cages throughout the study period except for being restrained 
in metabolic cages during the blood sampling periods. After each sampling time, the wounds 
were monitored for approximately 3 min to ensure that there was no excessive bleeding.  
In addition, the wounded tails were swabbed with cotton wool rinsed with 70% ethanol to 
reduce infection upon completion of the study. Normal food and water supply were resumed 
to the rats after the study before they were euthanised.   
 
5.2.2.3 Drug administration and blood sampling 
The study commenced after a 12 hr overnight fast. Each rat in the treatment group received a 
dose containing an equivalent of 10 mg/kg each of the three SLNs dispersed in 1 mL of distilled 
water, which was administered by oral gavage. The control rat was given a suspension of pure 
AmB, PAR and SSZ in distilled water each at 10 mg/kg. Water and food were withdrawn from 
all the animals until 2 hr and 4 hr, respectively, post dose administration. Blood samples (300 
μL) were collected from the tail end of the rats before and at 1, 2, 4, 8, 12 and 24 hr post dose 
administration into heparinised microcentrifuge tubes.  
The first blood samples were taken by clipping the tail end of the rats while subsequent samples 
were collected by removing the clotted blood with cotton rinsed with 100 IU of heparin 
solution. Blood samples were centrifuged at 13 800 rpm for 15 min to obtain plasma, which 
was immediately harvested and frozen till analyses for drug content using the validated HPLC 
method described in Chapter 4. Plasma samples were treated and analysed using piroxicam as 
the internal standard as outlined in Sections 4.3.1 and 4.3.3.  
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5.2.3 Data and statistical analyses 
A plasma concentration (ng/mL) versus time (hr) curve was plotted for each drug, from which 
the peak plasma concentration (Cmax) and time of its occurrence (Tmax) were directly obtained. 
The area under the plasma drug concentration-time curve (AUC), which measures the extent 
of drug absorption was calculated according to the linear trapezoidal method using GraphPad 
Prism 5 software. 
Statistical analyses were also performed using the same software by means of analysis of 
variance (ANOVA). Statistical significance was set at p < 0.05. 
 
5.3 Results and discussion 
5.3.1 Selection of animal model 
Small laboratory animals such as rats, mice, guinea pigs and rabbits are mostly suitable for GI 
transit studies of drugs. They are used to obtain valuable data on the mechanisms of drug 
absorption and bioavailability of powder or solution formulations, while larger animals such 
as dogs, pigs and monkeys are used to determine drug absorption from other oral dosage forms. 
It is imperative to understand the physiological, anatomical and biochemical differences 
between the GI tracts of the aforementioned laboratory animals to aid the selection of the most 
suitable model to mimic the bioavailability of compounds in humans [Kararli, 1995]. 
A study by Cao et al. (2006) in human and rat small intestines revealed a correlation in oral 
drug bioavailability between the two species for drug intestinal permeability by carrier-
mediated absorption and passive diffusion. In general, passive diffusion is the main mechanism 
for the absorption of many lipophilic compounds or particulates, which means that rats are the 
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more suitable model for the present study. Furthermore, rats and humans exhibit similar drug 
absorption profiles and transporter expression patterns in the small intestine; therefore, rat 
models can be used to predict oral drug absorption in the small intestines of humans [Cao et 
al., 2006]. 
Another study by Zhao et al. (2003) on the absorption of 111 compounds showed that the extent 
of absorption of the drugs presented as tablets or capsules in humans was similar when these 
were presented as solutions or suspensions in rats; 94% of the drugs showed less than 20% 
difference in absorption between the two species while 98% of drugs showed a difference of 
less than 30%. The results strongly suggested that oral in vivo absorption studies in rats could 
be used to predict the extent of intestinal absorption in humans following oral administration 
[Zhao et al., 2003]. 
At the microscopic level, humans and rats have a strong morphological similarity in their 
intestinal tracts but for obvious reasons such as size difference, there is a gross anatomical 
dissimilarity in the relative absorptive surface areas [DeSesso and Jacobson, 2001]. This makes 
the human GI tract capable of absorbing materials relatively faster and to a greater extent than 
that of the rat. 
Adult male Sprague-Dawley rats were selected for the study as male rats are less susceptible 
to physiological changes than female rats, as exemplified by hormonal fluctuations during the 
oestrous cycle in female rats [Kulkarni et al., 2012]. Such physiological changes could affect 
the pharmacokinetics of drugs and induce more variables into a study. In addition, Sprague-
Dawley rats are a common rat species and are preferred over mice because of their bigger size. 
Due to the latter, a relatively higher dose of the test formulation can be administered and larger 
blood volumes can be sampled to produce quantifiable plasma drug concentrations to facilitate 
an oral absorption study [Ciccone and Holdcroft, 1999; Kulkarni et al., 2012].  
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5.3.2 Improved absorption of AmB after its incorporation into SLNs 
Figure 5.1 depicts the plasma concentration-time profile of AmB after simultaneous oral 
administration of AmB, PAR and SSZ SLNs to the rats. The figure also shows the profile for 
the control rat, which received only a suspension of the pure drugs in distilled water. Table 5.1 
shows the pharmacokinetic data as obtained from the plasma drug profiles.  
As can be seen in Figure 5.1, the plasma concentration of AmB was higher in rats given the 
SLNs at each time point. The AUC0-24 values were 7638.5±440.5 ng.hr/mL and 5649.0 
ng.hr/mL for the rats receiving the SLNs and suspension, respectively, which clearly shows the 
superior attribute of the SLNs in improving bioavailability. The Tmax values were obtained as 
8 hr for both the SLN and suspension however, a small peak at 2 hr was obtained in the SLN 
profile. The Cmax for the SLN formulation was 1.3 times higher than that of the suspension, 
446.8±23.5 ng/mL versus 332.9 ng/mL.  
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Figure 5.1 Mean plasma concentration-time curves of AmB after a single oral dose 
administration of AmB SLNs, PAR SLNs and SSZ SLNs; and a suspension of 
AmB, PAR and SSZ to fasted rats (n = 3) 
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Table 5.1 Pharmacokinetic data for AmB SLNs and AmB suspension in rat plasma 
Formulation Dose  
(mg/kg) 
Tmax      
(hr) 
Cmax    
(ng/mL) 
AUC0-24 
(ng.hr/mL) 
AmB SLNs 10 8 446.7±23.6 7638.5±440.5 
AmB control 10 8 332.9 5649.0 
 
Lymphatic transport of drug-loaded SLNs is highly supported as there have been several 
studies in which intact SLNs have been found circulating in lymph after oral or intraduodenal 
administration of SLNs. In these studies, lymph was sampled from cannulated lymph ducts of 
rats to assess the presence of the SLNs [Bargoni et al., 1998; Cavalli et al., 2003; Yuan et al., 
2007; Paliwal et al., 2009]. The presence of the second and main peak at 8 hr in the SLN profile 
could therefore be attributed to lymphatic absorption of the SLNs prior to drug release into the 
blood, which takes time to occur. Another reason for the second peak could be due to the 
prolonged absorption of AmB SLNs due to the possible mucoadhesion of the SLNs in the gut 
[Luo et al., 2011]. 
Some oral lipid-based AmB formulations which have been studied include the following: 
Risovic et al. (2003) prepared AmB lipid formulations by dispersing the drug in either Peceol® 
or Intralipid®, and conducted pharmacokinetic studies in male Sprague-Dawley rats weighing 
380-450 g. Peceol® is an oily vehicle containing glycerol and glyceryl monooleates and used 
in self-emulsifying lipid preparations, while Intralipid® is a fat emulsion prepared mainly for 
intravenous administration and contains soybean oil, egg yolk phospholipids and glycerin. At 
an AmB oral dose of 50 mg/kg, the AUC0-24, Cmax and Tmax obtained were 5984 ng.hr/mL, 769 
ng/mL and 2 hr for the Intralipid® formulation. For the Peceol® formulation, a 5 mg/kg dose 
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gave AUC0-24, Cmax and Tmax of 4415 ng.hr/mL, 1187 ng/mL and 2 hr; while for a 50 mg/kg 
dose, the values were 11 407 ng.hr/mL, 1469 ng/mL and 4 hr, respectively. 
Gershkovich et al. (2009) have prepared an AmB lipid formulation in Peceol®/ 
distearoylphosphatidylethanolamine-poly (ethylene glycol)2000 (DSPE-PEG2000). The authors 
administered the formulation by oral gavage to fasted male Sprague-Dawley rats (330-350 g) 
at two concentrations; 4.5 mg/kg and 10 mg/kg, and obtained AUC0-24 as 991 ng.hr/mL and 
1534 ng.hr/mL, Cmax as 71 ng/mL and 96 ng/mL and Tmax at 6.3 hr and 12.5 hr, respectively. 
Patel and Patravale (2011) used the microemulsion-based nanoprecipitation technique to 
formulate AmB SLNs and obtained AUC0-24, Cmax and Tmax as 1906.8 ng.hr/mL, 124.94 ng/mL 
and 9 hr, respectively, after administering an oral dose of 200 mg/kg to fasted male Wistar rats 
weighing 200-250 g. 
Jain et al. (2012) used a two-step desolvation method to prepare AmB polymer-lipid hybrid 
nanoparticles and obtained AUC0-72 to be 2813 ng.hr/mL, Cmax as 94.38 ng/mL and Tmax at 8 
hr after a dose of 10 mg/kg was orally administered to fasted male Sprague-Dawley rats 
weighing 200-250 g. 
In the study by Patel and Patravale (2011), a very high dose of AmB was administered to the 
rats which was 20 times what was used in the present work however, the Cmax obtained in the 
present study is 4.5-fold higher than that reported by the former. The AmB SLNs formulated 
in the present study is therefore superior in terms of bioavailability. Furthermore, the SLN 
preparation method utilised in the present work is much simpler and timesaving, employing 
cheap, readily available and natural lipids in the formulation. The formulation method reported 
by Patel and Patravale (2011) lasts over 6 hr. The same can be said of the method used by Jain 
et al. (2012) which requires more than 12 hr of preparation time. Gershkovich et al. (2009) on 
the other hand prepared a relatively simple formulation involving only three steps however, the 
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whole process lasts not less than 5 hr. Alternatively, the AmB lipid preparations by Risovic et 
al. (2003) required merely stirring the drug in Peceol® or Intralipid® with gentle heating if 
needed however, the two vehicles are very expensive. The authors obtained a better AmB 
bioavailability in the Peceol® vehicle.  
The Cmax values obtained by Risovic et al. (2003) for AmB in Peceol
® were higher than those 
obtained in the present study; the 5 mg/kg formulation for instance gave a value 2.7 times 
higher than that obtained in the present study. Again, for the AUC0-24, they obtained a value of 
4415 ng.hr/mL for the 5 mg/kg dose, and a value of 11 407 ng.hr/mL when the dose was 
increased 10-fold to 50 mg/kg, clearly depicting a lack of dose proportionality. The AUC0-24 
obtained in the present study however was 7638.5 ng.hr/mL for a 10 mg/kg AmB dose, which 
is in line with the values obtained in the former study. 
It can be observed that the aforementioned results show wide variations in the data from the 
various studies except for those obtained by Risovic et al. (2003), which showed somewhat 
comparable AUC0-24 values to that obtained in the present study. Although Risovic et al. (2003) 
and Gershkovich et al. (2009) dispersed AmB in Peceol®, the former group had higher AUC0-
20 and Cmax values, which could be attributed to the different methods they used to prepare the 
formulations. Risovic et al. (2003) merely dissolved AmB in the vehicle with gentle heating 
while Gershkovich et al. (2009) used DSPE-PEG2000 and ethanol in addition to the Peceol
® 
although the solvent was evaporated off in the last step of the procedure.  
In cross-study comparisons, where the blood concentration-time curve of a particular drug 
product in one study is compared with the blood concentration-time curve of the same drug in 
another study, misleading conclusions can be made. The credibility of any bioavailability study 
involving the assay of drug levels in plasma and urine is the analytical methodology used to 
determine the drug levels, in addition to the study design and subject controls. In the review of 
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the studies conducted on oral AmB lipid formulations on animals, it can be observed that there 
were sizable differences in the plasma AmB levels and hence AUC values from the different 
studies. Usually, such differences are attributable to different subject populations (species and 
gender), differences in the various study conditions, as well as the different assay methods or 
varying modifications of the same assay technique employed [Malinowski and Johnson, 2006]. 
 
5.3.3 Absorption of PAR from SLNs and suspension 
The encapsulation of hydrophilic drugs into the hydrophobic matrix of SLNs is challenging. 
This is because such drugs tend to quickly partition into the aqueous phase during and after 
production of the SLNs because of their low affinity for, and weak interaction with the lipids. 
With the emulsification solvent diffusion technique used in the present study however, an 
encapsulation efficiency of 60.7% was achieved for PAR (Section 2.4.12), which is a 
hydrophilic compound. 
Figure 5.2 shows the plasma concentration-time curves for PAR from SLNs and suspension. 
The curves show a higher concentration for the PAR suspension than the SLNs. Both curves 
however showed a similar pattern of absorption with Tmax occurring at 1 hr in both cases, 
followed by a decreasing concentration over the study period. The Cmax for the PAR suspension 
was obtained as 1337.0 ng/mL, being about 2.2 times higher than that obtained for the SLNs. 
The AUC0-24 however remained essentially unchanged for both formulations; 5146.0±356.4 
ng.hr/mL as against 5727.0 ng.hr/mL for the SLNs and suspension, respectively, albeit slightly 
higher for the latter. 
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Figure 5.2 Mean plasma concentration-time curves of PAR after a single oral dose 
administration of AmB SLNs, PAR SLNs and SSZ SLNs; and a suspension of 
AmB, PAR and SSZ to fasted rats (n = 3) 
  
Table 5.2 Pharmacokinetic data for PAR SLNs and PAR suspension in rat plasma 
Formulation Dose 
(mg/kg) 
Tmax       
(hr) 
Cmax    
(ng/mL) 
AUC0-24 
(ng.hr/mL) 
PAR SLNs 10 1 609.9±229.5 5146.0±356.4 
PAR control 10 1 1337.0 5727.0 
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The reason for the observed disparity of higher AmB absorption from SLNs than from the 
AmB suspension, as opposed to the reverse situation for PAR can be explained by the fact that 
PAR has much higher aqueous solubility than AmB, which is practically insoluble in water. In 
addition, PAR is favourably absorbed in the small intestine after oral delivery [Heading et al., 
1973; Clements et al., 1978], which was why a rapid absorption, reflected in a high Cmax was 
observed for the PAR suspension. In the in vitro release study (Section 2.4.13), more than 65% 
of the encapsulated PAR was released from the SLNs within 8 hr. This is reflected in the plasma 
PAR concentration profile which projects that majority of the drug had been absorbed into 
blood by 8 hr. Several authors have found intact SLNs circulating in blood; at 30 min and 21 
hr after intraduodenal administration [Bargoni et al., 1998; Cavalli et al., 2003], and at 2 hr 
after oral delivery [Yuan et al., 2007] of the SLNs to rats, using TEM analyses and fluorescence 
imaging, respectively. Since blood is an aqueous environment as well, PAR release from 
absorbed SLNs circulating in blood was a continuous process by passive diffusion.  
The Tmax for AmB SLNs occurred at a later time as compared with that for the PAR SLNs 
because of the very slow rate of AmB release from the SLNs into the surrounding aqueous 
medium so that, most of the AmB would be absorbed via uptake of the intact SLNs, which is 
a slow process. Furthermore, the presence of food (4 hr after dose administration) in the GI 
tract of the animals slowed down the uptake of the SLNs, resulting in increased release of PAR 
in the GI tract prior to its absorption as opposed to the AmB, which was preferentially 
encapsulated within the hydrophobic lipid matrix of the particles. As a result, a higher 
proportion of the AmB SLNs were likely to have been taken up intact and transported via 
lymph resulting in the longer Tmax. 
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5.3.4 Absorption of SP from SSZ   
SP is a product of the hydrolytic activity of azoreductase enzyme-producing bacteria in the 
colon, on the azo link in SSZ as depicted in Figure 5.3; and virtually all the SP produced is 
quickly absorbed [Peppercorn and Goldman, 1973]. Figure 5.4 shows representative HPLC 
chromatograms in one rat depicting the initial detection of SP at 2 hr, signalling the arrival at 
and hydrolysis of SSZ in the caecum, and also the peak plasma SP concentration obtained at 8 
hr.  
 
 
Figure 5.3 Splitting of the azo bond in SSZ by colonic bacteria to release SP and 5-
aminosalicylic acid 
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Figure 5.4 Representative HPLC chromatograms showing the appearance of SP in plasma 
at 2 hr and peaking at 8 hr post dosing in one rat 
 
The plasma concentration-time profiles for SP released from SSZ SLNs and suspension are 
depicted in Figure 5.5. The pharmacokinetic data in Table 5.3 show that the AUC0-24 for SP 
from the SLNs was higher than that for the suspension; 5095.0 ng.hr/mL as against 3307.0 
ng.hr/mL. The Cmax was however slightly higher for SP from the SSZ suspension; 362.4 ng/mL 
as opposed to 341.8 ng/mL, while Tmax was the same in both cases.  
Both plasma concentration-time profiles showed a similar pattern of increase in SP 
concentration followed by a decrease. The large error bars are indicative of a wide variation in 
SP production and absorption since the level of SP in the plasma mainly depends on the 
presence and amount of the azoreductase-producing bacteria in the colon, the rate of activity 
of the bacteria, as well as the variable arrival rates of the SSZ SLNs at the caecum. These 
factors are influenced by individual differences in the animals [Staniforth et al., 1987; Gramatte 
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and Terhaag, 1991]. Nonetheless, the use of SP in the present study is chiefly to mark the 
arrival of SSZ at the caecum using the initial detection of the former in plasma. 
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Figure 5.5 Mean plasma concentration-time curves for SP after a single dose oral 
administration of AmB SLNs, PAR SLNs and SSZ SLNs; and a suspension of 
AmB, PAR and SSZ to rats (n = 3) 
 
Table 5.3 Pharmacokinetic data for SP from SSZ SLNs and SSZ suspension in rat plasma 
Formulation Dose 
(mg/kg) 
Tmax 
(hr) 
Cmax    
(ng/mL) 
AUC0-24 
(ng.hr/mL) 
SP (from SSZ SLNs) 10 8 341.8±169.1 5095.0±3186.2 
SP (from SSZ suspension)  10 8 362.4 3307.0 
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5.3.5 Pilot GI transit study 
In order to test the viability of the indirect method for estimating the GI transit and absorption 
of AmB SLNs using PAR and SP as markers, this pilot GI study was conducted. The three 
SLNs exhibited identical physicochemical characteristics as discussed in Chapter 2. Figure 5.6 
shows the plasma drug concentration-time profiles for AmB, PAR and SP following 
simultaneous oral administration of AmB, PAR and SSZ SLNs to the rats.  
The Tmax of about 1 hr observed for PAR indicates a rapid PAR release and absorption in the 
small intestine and therefore serves as a good estimate of the gastric emptying time of the SLNs. 
AmB SLNs were slowly absorbed from the GI tract most likely via lymphatic transport and 
Peyer’s patches, which are located mainly in the ileum, prior to drug emptying into systemic 
circulation and reaching Tmax at 8 hr. 
There was a lag time of about 2 hr prior to appearance of SP in the plasma, which estimates the 
caecal arrival time (CAT) of the SLNs. The delay in the absorption of SP is due to a combined 
delay in the arrival of the SLNs at the colon, as well as the delay in the microbial degradation 
of SSZ, followed by SP absorption. It then follows that the estimated small intestinal transit 
time (SITT) of the SLNs is 1 hr, which is the difference between CAT and the time of initial 
detection of PAR in the plasma, which was also found to be 1 hr.  
The AUC0-24 for AmB SLNs was 1.6 times more than that for PAR, indicating a more 
favourable albeit slow uptake process as well as the suitability of using SLNs to improve the 
bioavailability of AmB. However, PAR had the highest magnitude of Cmax (609.9 ng/mL) 
among the three analytes, which is indicative of a rapid rate of absorption from the small 
intestine, and more likely to be as a result of released PAR than due to uptake of the PAR SLNs 
followed by drug emptying into blood. 
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Figure 5.6 Plasma drug concentration-time profiles for AmB, PAR, and SP following 
simultaneous administration of AmB SLNs, PAR SLNs and SSZ SLNs at a dose 
of 10 mg/kg each (n = 3) 
 
5.3.6 Considerations for the main GI transit study  
The plasma PAR profiles showed the Cmax of PAR for both the SLNs and suspension as the 
first point in the respective curves. As a result of this, more sampling points during the first 
hour post dose administration will be considered to ensure a more accurate estimate of Tmax 
and hence, gastric emptying. 
For the AmB SLN formulation, the 10 mg/kg dose used produced suitable plasma 
concentrations and the results obtained were comparable with or better than some published 
data. For PAR and SSZ as well, the 10 mg/kg dose seems favourable as PAR produced very 
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high plasma concentrations within the initial two hours of the study, and the SP from the SSZ 
was also quantifiable. The dose was therefore maintained in the main GI transit study. 
In the subsequent GI transit study (Chapter 6), the control rat group were given a dose of only 
AmB suspended in distilled water. Pure PAR and SSZ were excluded from the control dose as 
the pharmacokinetic data from PAR and SSZ were deemed not relevant in the control group.   
Lastly, since most of the studies conducted on the oral bioavailability of AmB in literature are 
in fasted rats, it was an objective to study the effect of food on the GI transit and absorption of 
the AmB SLNs in the subsequent study. As a result, the fasting period post dose delivery was 
extended as well in the fasted group. 
The results obtained in this pilot study strongly indicate that the HPLC method developed and 
validated in the preceding chapter is very suitable for the simultaneous assay of AmB, PAR 
and SP, using piroxicam as the internal standard. The HPLC method may therefore be 
employed in pharmacokinetic studies on these drugs as well as in the indirect estimation of the 
GI transit properties of oral dosage forms, using PAR and SP as marker drugs. 
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5.4 Conclusions 
Oral pharmaceuticals are more economical to formulate because they do not require sterile 
manufacturing conditions. Oral drug administration is most preferred for reasons such as 
patient convenience and compliance, which increase the therapeutic efficacy of a drug. The 
AmB SLNs therefore serve to produce a triple benefit of convenience of oral administration, 
improved bioavailability and potential for reduced renal toxicity.  
The pilot GI transit study indicates that AmB in SLNs is absorbed slowly but significantly from 
the small intestines. Therefore, development of dosage forms for delivery of AmB via the oral 
route may exploit this attribute.  
The previously validated HPLC method can potentially be applied to simultaneously assay 
AmB, PAR, SP and piroxicam in rat plasma, and the indirect approach of studying the GI 
transit properties and pharmacokinetics of AmB SLNs has been successfully applied in the 
present study. The data from this pilot study has been useful as a better study protocol can be 
developed to achieve a better outcome from the main transit study.  
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CHAPTER 6 
EFFECT OF FOOD STATUS ON THE GASTROINTESTINAL TRANSIT OF 
AMPHOTERICIN B-CONTAINING SOLID LIPID NANOPARTICLES 
6.1 Introduction 
The administration of drug products with food can alter drug bioavailability by either affecting 
the drug substance directly or indirectly, or by affecting the drug product, and may result in 
clinically important outcomes. In reality, the exact mechanism by which food changes 
bioavailability of drugs is difficult to determine without conducting specific mechanistic 
studies [FDA, 2002]. Generally, significant food effects on bioavailability occur less with most 
drug products containing BCS class I drugs (highly soluble/rapidly dissolving and highly 
permeable drugs). This is because the absorption of such drugs is usually pH and site-
independent and thus insensitive to differences in dissolution [FDA, 2002]. However, for some 
drugs in this class, food can influence bioavailability if the drug is unstable in the GI tract, or 
if the drug undergoes extensive first-pass metabolism, adsorption or complexation. The type of 
excipients used in a product, interactions between excipients, as well as food-induced changes 
in the physiology of the gut can also affect bioavailability. Drug-food interactions present 
problems particularly for oral controlled-release products that are single unit dosage forms 
because a significant effect by food on systemic availability may have serious and prolonged 
consequences [Welling, 1996; Singh, 1999; FDA, 2002].  
For drugs that show enhanced bioavailability with food intake, high fat meals are recommended 
as fatty meals affect GI physiology and maximise drug transfer into systemic circulation. For 
immediate-release drug products containing BCS class II, III and IV drugs, and modified-
release products, food effects most likely result from more complex combinations of factors 
that influence the in vivo dissolution of the drug product and/or absorption of the drug. In such 
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instances, the effect of type and magnitude of food on bioavailability are difficult, if not 
impossible to predict without conducting a fed study [FDA, 2002]. 
The effects of food on drug bioavailability may manifest due to changes in drug dissolution 
prior to absorption, changes in GI residence time of the dosage form, modification in membrane 
permeability of the drug and inhibition of efflux transporters. Furthermore, the type and 
quantity of food, as well as the time interval between food intake and dosing may reduce, delay, 
increase or accelerate drug absorption. In addition, different dosage forms of the same drug 
may be affected differently by food [Welling, 1996; Singh, 1999; Benet et al., 2004].  
It is important to know how orally administered drug products respond to GI physiology during 
their transit through the GI tract. The transit of dosage forms through the oesophagus is 
dependent on the dosage form type and the patient’s posture; however, most dosage forms 
administered in an upright position transit quickly through the oesophagus in less than 15 sec. 
Gastric residence time, gastric emptying time or gastric emptying rate are synonymous terms 
used to refer to the time it takes a dosage form to travel through the stomach. Gastric emptying 
(GE) of pharmaceutical products is highly variable depending on the dosage form and 
fed/fasted states. Normal gastric residence times in humans range from 5 min to 2 hr however, 
longer times have been observed for large single dosage units [Nimmo et al., 1973; Ashford, 
2001]. 
In the small intestine, there are propulsive and mixing movements; the former primarily 
determines the intestinal transit rate and hence the residence time of a dosage form. As this is 
the main site of absorption in the GI tract for most drugs, small intestinal transit time (SITT) 
(transit time between the stomach and the caecum) is an important factor with respect to drug 
bioavailability, and particularly important for dosage forms that slowly release the incorporated 
drug as they pass along GI tract [Ashford, 2001]. 
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Colonic transit of pharmaceuticals is long, variable and dependent on the type of dosage form 
as well as the diet, eating pattern and disease state of an individual. Contractile activity in the 
colon consists of propulsive contractions or mass movements away from the mouth and 
segmental or haustral contractions, which serve to mix the luminal contents. Segmental 
contractions are brought about by circular muscles and predominate whereas propulsive 
contractions, which are due to contractile activity of longitudinal muscles occur only 3-4 times 
daily in normal individuals. Colonic transit is therefore characterised by short bursts of activity 
followed by long periods of stasis and can vary from 2 to 48 hr. In most individuals, mouth-to-
anus transit times are longer than 24 hr [Ashford, 2001]. 
It has been shown in humans that SITT of dosage forms is more consistent than gastric transit 
time (GTT), and the former is less affected by the nature  (physical state or size) of the dosage 
form and the presence of food [Davis et al., 1986].  
The importance of the transit times of dosage forms in the various regions of the GI tract makes 
it necessary for investigations involving the effect of food on drug absorption from dosage 
forms to be conducted. This allows for appropriate assessment of the resulting pharmacokinetic 
data, which in turn can be used in optimising the fomulation to maximise bioavailability.  
Peh and Yuen (1996) have monitored the GI transit and absorption of theophylline pellets in 
human volunteers, applying the indirect estimation method using PAR and SP as markers. The 
results they obtained were consistent with the findings of Yuen et al. (1993), who monitored 
pellets of approximately similar size and density using gamma scintigraphy. The results were 
also in agreement with previous gamma scintigraphic studies [Christian et al. 1980; Davis et 
al. 1984; Devereux, 1987], which indicate the suitability of the indirect method for a harmless 
and less expensive GI transit study.  
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AmB has two important physicochemical characters: amphiphilic behaviour due to the apolar 
and polar sides of its lactone ring; and amphoteric behaviour due to the presence of ionisable 
carboxyl and amine groups. As a consequence of its amphiphilic and zwitterionic nature, and 
the asymmetrical distribution of hydrophobic and hydrophilic groups, AmB is poorly soluble 
in all aqueous solvents and in many organic solvents. Although it is water soluble at a pHs 2 
and 11, the solubilised drug tends to show a loss of activity with pronounced instability 
[Torrado et al., 2008]. AmB, a BCS class IV drug, is poorly absorbed not only orally but also 
after intramuscular and subcutaneous administrations as well. It is slowly excreted in the urine 
and traces are still detectable 2 months after cessation of treatment [Moffat et al., 2005]. 
The absorption of small oral doses of PAR occurs readily while that of larger doses varies 
considerably and is influenced by the rate of gastric emptying, the presence of food and the 
time of day. PAR is widely distributed throughout most body fluids and is present in saliva at 
concentrations paralleling those in plasma. PAR undergoes first-pass metabolism, and about 
70 to 90% of the admministered dose is bioavailable [Moffat et al., 2005]. 
SSZ is partially and irregularly absorbed after oral administration however, the absorbed 
amount is not metabolised but excreted unchanged in urine. The greater part of the dose passes 
unchanged into the colon and is metabolised by bacteria to SP and 5-aminosalicylic acid, which 
is thought to be the active moiety [Moffat et al., 2005]. 
In previous chapters, an AmB-containing SLN formulation has been successfully developed 
and subjected to extensive characterisation. A pilot GI transit study of the formulation has also 
been performed in fasted rats. In this chapter, the pharmacokinetics of AmB and the GI transit 
of AmB SLNs as a consequence of food status is described by means of the indirect estimation 
method, using PAR and SP as markers.  
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6.2 Methods 
6.2.1 Preparation of SLN formulations 
The proportions of ingredients described in the optimised procedure for formulating the SLNs 
in Section 2.3.3 were used for preparing individual lipid nanoparticle formulations containing 
AmB, PAR or SSZ.  
 
6.2.2 Animals 
Twelve (12) disease-free male Sprague-Dawley rats weighing 250±20 g were obtained from 
the Animal Holding Unit of the University Sains Malaysia and used for the study. The study 
protocol complied with the recommendations of and was approved by the Animal Ethics 
Committee of the University Sains Malaysia. The animals were maintained under a 12/12 hr 
dark/light cycle and housed in cages at ambient temperature and humidity. They were allowed 
free access to food and water and acclimatised for 7 days before the study. The procedural care 
of the animals was as described in Section 5.2.2.2.  
The rats were randomly divided into fasted-SLNs, fasted-control, fed-SLNs and fed-control 
groups. Water was withdrawn from all the animals until 2 hr post dose administration. The 
fasted group was fasted overnight and allowed access to food 8 hr after dosing with the SLNs. 
 
6.2.3 Drug administration and blood sampling 
The rats in the fasted-SLNs and fed-SLNs groups were given single-dose oral gavages 
containing 10 mg/kg of each SLN (AmB, PAR and SSZ) dispersed in distilled water. Blood 
samples (300 μL) were collected from the tail end of the rats before dosing and at 0.25, 0.5, 
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0.75, 1, 2, 4, 8, 12, 24 and 30 hr post dose administration into heparinised microcentrifuge 
tubes. Plasma was immediately separated from the blood samples by centrifugation and frozen 
till analysis using the HPLC method described in Sections 4.3.1 and 4.3.3. 
 
6.2.4 Estimation of gastric transit time (GTT) 
The parameters for estimating the time elapsed for GE or GTT were obtained from the plasma 
PAR absorption-time profiles and based on the assumption that the percentage of PAR 
absorbed is directly related to the percentage of PAR SLNs emptied from the stomach into the 
duodenum [Peh and Yuen, 1996]. This serves as a fairly good estimate for GE of the AmB and 
SSZ SLNs as well. This is because all three SLNs shared identical physical characteristics 
(Chapters 2 and 3) and were administered simultaneously to the rats; therefore, the assumption 
is that all three SLNs would transit similarly within the GI tract. The time for complete 
emptying of the SLNs (T90P) from the stomach was estimated using the time for 90% of PAR 
absorption in the small intestine, which was also considered the GTT. Another parameter 
obtained from the plasma PAR absorption-time profile was the time for 10% PAR absorption 
(T10P), which was used to signal the arrival of the SLNs at the small intestine. 
 
6.2.5 Estimation of small intestinal transit time (SITT) 
The SITT was estimated as the time difference between the caecal arrival time of the SLNs and 
the start of emptying of the SLNs into the small intestines (T10P). SITT was therefore 
approximately the difference between T10S (the time taken for 10% SP absorption in the 
caecum) and T10P. 
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6.2.6 Estimation of caecal arrival time (CAT) and colonic transit time (CTT) 
Data obtained from plasma SP concentration-time curves were used to determine the CAT of 
the AmB SLNs. The CAT by definition is the time taken for the SLNs to arrive at the caecum 
and has been estimated as the time for the initial detection of SP in the plasma using the indirect 
method of estimation [Staniforth, 1989]. Due to the time lapse in SP production from SSZ 
released from SSZ SLNs reaching the caecum, CAT was estimated to be approximately T10S. 
T10S serves as a better estimate for CAT of the SLNs than the first SP detection in plasma as 
the latter may be mainly due to free SSZ released from the SLNs prior to caecal arrival, rather 
than SSZ released from the intact SSZ SLNs within the caecum. The CTT was estimated as the 
time for 90% SP absorption (T90S). 
 
6.2.7 Estimation of AmB absorption in the stomach, small intestine and colon 
The percentage of AmB SLNs absorbed in the stomach, small intestine and the colon were 
estimated from the plasma AmB absorption-time profiles using the respective transit times 
(GTT and SITT). The percentage AmB absorbed during gastric transit or GTT was estimated 
from the time of dose administration to T10P. The time from T10P to T10S, or SITT was used to 
estimate the percentage absorption in the small intestine while the remaining percentage of 
AmB SLNs absorbed after this point was considered as summation of both colonic and 
progressed lymphatic absorption. 
 
6.2.8 Statistical analyses 
The data have been presented as mean ± standard deviation (SD) where indicated. Statistical 
analyses were performed using GraphPad Prism 5 software. The various parameters were 
227 
 
analysed using analysis of variance (ANOVA) which distinguishes effects due to subject/group 
and treatment. Statistical significance was considered when p value < 0.05.  
 
6.3 Results and discussion 
6.3.1 Improved oral bioavailability of AmB from the SLNs 
Figure 6.1 shows the plasma concentration versus time profiles of AmB suspension and freshly 
prepared AmB SLNs in fasted rats and Table 6.1 gives the pharmacokinetic parameters of AmB 
in both fasted and fed rats. The peak plasma concentration (Cmax) for AmB from the SLNs was 
564.7±122.5 ng/mL and the Tmax was 8 hr, both values being significantly higher (p < 0.05) 
than those obtained for the AmB suspension, 205.3±9.6 ng/mL and 1.50±0.71 hr, respectively, 
as shown in Table 6.1. Furthermore, the extent of absorption (AUC0-30) of AmB was 
significantly higher (p < 0.05) for the AmB SLNs compared to the suspension; 7953.0±551.2 
ng.hr/mL against 4412.5±376.9 ng.hr/mL.  
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Figure 6.1 The mean plasma concentration-time curve of AmB in fasted rats after a single 
10 mg/kg oral dose of AmB suspension; and 10 mg/kg dose each of AmB SLNs, 
PAR SLNs and SSZ SLNs 
 
Table 6.1 Pharmacokinetic data for AmB SLNs and AmB suspension in fasted and fed 
rats 
 
Group 
 
Dose 
(mg/kg) 
Tmax        
(hr) 
Cmax     
(ng/mL) 
AUC0-30 
(ng.hr/mL) 
 
Fasted 
AmB SLNs 10 8.00±0.00* 534.7±122.5* 7953.0±551.2* 
AmB suspension 10 1.50±0.71 205.3±9.6# 4412.5±376.9 
 
Fed 
AmB SLNs 10 9.33±4.62** 323.2±44.0 ** 7565.3±1390.6 ** 
AmB suspension 10 0.38±0.18 173.8±27.9 3343.0±209.3 
  * p < 0.05 - significantly different from AmB suspension in fasted rats 
** p < 0.05 - significantly different from AmB suspension in fed rats 
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  # p < 0.05 - significantly different compared with fed rats 
In the case of the SLNs however, a rate-limiting step defined by the rate of AmB diffusion 
within the SLN matrix followed by drug release precedes absorption. The significant 
improvement in the extent of AmB absorption from SLNs points to an alternative route of 
absorption into the systemic circulation, most likely through uptake of intact SLNs since the 
GI epithelium is capable of taking up submicron to micron-sized particulates.  
Figure 6.2 depicts plasma AmB concentration in the fed rats. A similar observation was made 
in the fed rats as in the fasted rats, where Cmax, Tmax and AUC0-30 obtained from the rats 
administered the AmB SLNs were significantly (p < 0.05) higher as compared with the 
corresponding values obtained from the rats administered the suspension of pure drug only.  
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Figure 6.2 The mean plasma concentration-time curve of AmB in fed rats after a single 10 
mg/kg oral dose of AmB suspension; and 10 mg/kg dose each of AmB SLNs, 
PAR SLNs and SSZ SLNs 
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For the fed rats, the Cmax, Tmax and AUC0-30 were 323.2±44.0 ng/mL, 9.33±4.62 hr and 
7565.3±1390.6 ng.hr/mL, respectively, for the SLN formulation; and for the suspension, the 
values were 173.8±27.9 ng/mL, 0.38±0.18 hr and 3343.0±209.3 ng.hr/mL, respectively. These 
results clearly indicate improved oral absorption and bioavailability of AmB after incorporation 
into SLNs in both the fasted and fed states. 
From Figures 6.1 and 6.2, two peaks in both the fasted (0.75 and 8 hr) and fed (4 and 12 hr) 
states are noted after administration of the AmB SLNs, with those in the fasted rats being more 
prominent. A similar observation was made by Yang et al. (1999), Luo et al. (2011) and Jain 
et al. (2012) who reported bi-phasic plasma peak concentrations for camptothecin SLNs, 
puerarin SLNs and AmB gelatin-lipid nanoparticles. The first peak was due to absorption of 
free AmB particles released from the AmB SLNs and loosely adsorbed AmB on the surface of 
the SLNs. Free AmB may also be contributed by digestion of the lipid component of the SLNs 
by lipases followed by the action of bile salts to produce mixed micelles and chylomicrons 
containing solubilised AmB [Müller et al., 2006; Porter et al., 2007]. However, contribution of 
free AmB by this mode is expected to be modest. A further contribution of free AmB would 
come from released drug from the SLNs. Finally, absorption of free AmB is buoyed by 
surfactant (sodium cholate) effects within the SLNs.  
The AUC0-30 and Cmax values obtained for the fasted rats in the main study were 7953.0±551.2 
ng.hr/mL and 534.7±122.5 ng/mL, respectively, and were slightly higher than those obtained 
in the pilot study, 7638.5±440.5 ng.hr/mL and 446.8±23.5 ng/mL, respectively, which was also 
conducted in fasted rats although the sampling period in the main study was 6 hr longer. The 
more prominent peaks in the plasma AmB profiles obtained in the main study seem to reflect 
the effect of length of fasting period post SLN dosing on AmB bioavailability. In the pilot 
study, the animals were fasted for 4 hr as opposed to the 8 hr fast in the main study. It can also 
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be observed that the initial peak at 0.75 hr in the main study is obviously masked in the pilot 
study due to fewer sampling times during the initial phase. The minor differences are solely 
due to the different blood sampling times and normal experimental variables in cross-study 
comparisons and not actually due to differences in bioavailability [Malinowski and Johnson, 
2006]. Although the rats used in the pilot study were slightly bigger (325±25 g versus 250±20 
g), the adjustments made in the administered doses as per weight of each animal corrected for 
this. Therefore, the data obtained from the pilot and the main studies are essentially identical 
and indicate the success and importance of the pilot study. 
 
6.3.2 Gastric transit of the AmB SLNs 
The mean plasma PAR concentration-time profiles in both fasted and fed rats are presented in 
Figure 6.3 and the pharmacokinetic data obtained from the profiles are presented in Table 6.2. 
In both fasted and fed states, a rapid PAR absorption was observed albeit a slower rate in the 
fed state. Furthermore, multiple peaks were observed within the first four hours of the PAR 
concentration-time profile for the fed rats, possibly due to the effect of food.  
A later peak occurred at 8 hr post dose administration in the fasted rats and can be attributed to 
possible uptake of intact SLNs by Peyer’s patches and via lymph [Bargoni et al., 1998; Yuan 
et al., 2007] followed by assimilation and PAR release into blood. This is a slow process and 
therefore expected to manifest late. In the fed rats however, no such late sharp peak is observed 
as the presence of food significantly slowed the absorption rate of the intact SLNs. The plasma 
PAR profile pattern in the fasted rats was very much similar to that for the AmB in the fasted 
rats, and seems to be an inherent feature of the SLNs formulated in this study.  
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Figure 6.3 Effect of food on the absorption of PAR SLNs in fasted and fed rats (n = 3) 
 
Table 6.2 Pharmacokinetic data for PAR SLNs and PAR suspension in fasted and fed rats 
 
Group Dose 
(mg/kg) 
Tmax       
(hr) 
Cmax     
(ng/mL) 
AUC0-30    
(ng.hr/mL) 
Fasted 10 0.50±0.25 3616.3±68.4* 21 786.0 ± 5879.8 
Fed 10 0.75±0.29 2383.3±747.9 18 135.7±5712.2 
* p < 0.05 - difference between fasted and fed groups is statistically significant 
 
The main difference between the two profiles was that the initial peak for PAR was much 
higher than the second peak unlike for the AmB curve. This higher initial peak observed for 
PAR SLNs is due to the fast release of PAR from the SLNs followed by rapid uptake in the 
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small intestine. Furthermore, the encapsulation efficiency of PAR was less than that for AmB 
so that a lower PAR payload is assimilated by the epithelia from uptake of the SLNs. The Cmax 
and AUC0-30 values for the PAR SLNs obtained in this study were 3616.3±68.4 ng/mL and 21 
786.0±5879.8 ng.hr/mL, which were significantly higher than the respective values obtained 
in the pilot study: 609.85±229.5 ng/mL and 5146.0±356.4 ng.hr/mL. This is because significant 
absorption of PAR SLNs occurred within the first hour of dose administration resulting in a 
Tmax at 0.50 hr, an observation that was absent in the pilot study because the first blood sample 
was taken at 1 hr. 
PAR has better aqueous solubility than AmB hence PAR favourably partitions out into the 
more aqueous GI fluids than into the hydrophobic lipid matrix of the SLNs, leaving a lower 
drug load within any absorbed SLNs in the rats: an effect that was more pronounced in the fed 
rats. The presence of food caused an insignificant reduction in Cmax (p = 0.05) and AUC0-30 (p 
> 0.05), and a delay in Tmax (p > 0.05) in the absorption of PAR from SLNs. It is clear from the 
mean values that a delayed Tmax was caused by the presence of food through a slowed gastric 
emptying process of the SLNs.  
In both fasted and fed groups, no lag time in PAR absorption was observed as can be seen from 
Figure 6.4; however, this phenomenon is most likely a result of the rapid emptying of PAR 
solution released from the SLNs within the administered dose and subsequent absorption in the 
small intestine. The absorption of this PAR solution therefore occurred almost instantly after 
dose administration to the rats and emptying of this solution into the small intestines occurred 
unobstructed. PAR absorption in patients with pyloric stenosis has been found to be hindered 
and may cause a delay in GE [Heading et al., 1973]; however, the data obtained in the present 
study suggest unimpeded emptying into the small intestine. The statistical analyses indicate 
that although the patterns of absorption of the PAR SLNs in fasted and fed states were different 
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according to the profiles in Figure 6.3, GE was not markedly slowed by food. This is in 
agreement with previous studies in which food did not affect the extent of absorption of PAR 
from tablets but slowed the rate of absorption [McGilveray and Mattok, 1972; Divoll et al., 
1982; Digenis and Sandefer, 1994]. 
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Figure 6.4 Mean PAR absorption versus time curves in the fasted and fed rats (n = 3) 
 
Due to significant lymphatic absorption of lipid-based formulations as evidenced by the two-
peak plasma profiles, only the initial four hours of the plasma concentration-time curves of the 
PAR SLNs were used in estimating T10P and T90P. On observing the profiles, it can be said that 
the second peak occurring at 8 hr in the fasted rats is due to drug emptying into systemic 
circulation from the lymphatic vessels, while the initial peak is likely due to direct PAR 
absorption into blood from the gut. Using the whole absorption profile for the PAR SLNs over 
the 30 hr study period to determine the values of T10P and T90P would therefore result in an 
overestimation. The first four hours of the profiles give a better approximation of uptake of 
intact and digested PAR SLNs by the enterocytes into blood, and excludes SLN absorption via 
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lymph as much as possible in order to obtain a better estimate of GE. A similar approximation 
was done by Peh and Yuen (1996) who used the first 10 hr of PAR absorption in estimating 
GE as opposed to the total 24 hr blood-sampling period they used in human subjects. T10P and 
T90P were calculated from Figure 6.4, which depicts the cumulative percentage absorption of 
PAR in the rats. 
Quini et al. (2012) employed magnetic monitoring using alternating current biosusceptometry 
as a direct method to estimate GE in rats (equivalent to T90P in the present study), and found it 
be approximately 1.67 hr and 2.34 hr after liquid (ferrofluid) and solid (ferrite powder pellets 
and laboratory chow) meals, respectively, were orally administered. These values are 
comparable with those observed in the present study, which were 1.71 hr and 2.25 hr for the 
fasted and fed rats, respectively, as presented in Table 6.3, and indicate the suitability of using 
PAR as an indirect marker for GE. 
 
Table 6.3 Individual values of T10P, T90P and GTT, estimated from plasma PAR profiles 
under fasted and fed states (n = 3) 
 
 
Rat  No. 
 
 
Fasted 
 
Fed 
T10P                
(hr) 
T90P (GTT)        
(hr) 
 T10P                   
(hr) 
T90P (GTT)        
(hr) 
1  0.16 1.56 0.08 1.74 
2  0.18 2.38 
 
0.16 2.38 
3  0.09 1.19  0.10 2.63 
Mean  0.14 1.71 0.11 2.25 
SD  0.04 0.61 
 
0.04 0.46 
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6.3.3 Small intestinal transit of the AmB SLNs 
The mean SITT of the SLNs in the fasted rats was 1.65±0.86 hr, and 1.79±1.29 hr in the fed 
group as shown in Table 6.4, giving a time difference of only about 0.14 hr and p > 0.05, 
indicating that the difference between the two values is not statistically significant. This shows 
that the transit of the SLNs in the small intestines was similar in both states. In the study 
conducted by Quini et al. (2012), an identical mean value of approximately 1.71 hr was 
obtained as SITT in both liquid-meal and solid-meal fed Wistar rats, using magnetic 
monitoring. In another study by Myagmarjalbuu et al. (2013), SITT in mice was found to be 
approximately 1.60 hr. In the latter study, the authors used fluoroscopic imaging to monitor the 
transit of radio-opaque markers in the form of 0.5 mm metal balls in the animals. The mice 
were deprived of food 1 hr before the experiment and allowed access to food 1 hr after 
administration of the markers. They also used barium to determine the anatomical locations in 
the GI tract.  
The similarities among the values obtained from the two studies and in the present work are in 
concert with the established notion that transit of liquids and solids [Quini et al., 2012], and 
suspensions of nano-sized (SLNs in the current work) or larger particles (0.5 mm) 
[Myagmarjalbuu et al., 2013], in the small intestine is identical. They also indicate that the 
indirect and inexpensive means of estimating SITT using PAR and SP as marker drugs is 
reliable, and produces data identical with direct techniques such as the magnetic and 
fluoroscopic imaging methods used by the other authors. These studies suggest that 
physiological discrimination between solids and liquids may exist in the stomach but not in the 
small bowel [Davis et al., 1986; Yuen et al., 1993; Peh and Yuen, 1996]. 
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Table 6.4 Individual values of Tmax, T10S, CAT and SITT, estimated from plasma SP 
profiles under fasted and fed states (n = 3) 
 
 
Rat 
No. 
 Fasted  Fed 
Tmax  
(hr) 
T10S (CAT)  
(hr) 
SITT 
(hr) 
CTT 
(hr) 
Tmax  
(hr) 
T10S (CAT) 
(hr) 
SITT 
(hr) 
CTT 
(hr) 
1  8 1.92 1.76 19.9  8 0.92 0.84 23.6 
2  12 0.93 0.75 13.9  12 1.42 1.26 22.7 
3  8 2.54 2.45 18.8  12 3.36 3.26 27.5 
Mean  9.30 1.80 1.65 15.50*  10.70 1.90 1.79 24.60 
SD  2.30 0.81 0.86 3.20  2.30 1.29 1.29 2.60 
* p < 0.05 - Difference between fasted and fed groups is statistically significant 
 
SITT values ranging from 2.70 to 4.58 hr have been obtained in humans using various direct 
techniques employing materials such as radiolabelled fibre particles [Malagelada et al., 1984] 
and dosage forms [Davis et al., 1986; Yuen et al., 1993; Billa et al., 2000], a magnetic pill 
[Worsøe et al., 2011] and a video capsule endoscope [Fischer and Fadda, 2015]. Using the 
indirect method, SITT has been obtained as approximately 4.1-6.0 hr in both fasted and fed 
subjects [Peh and Yuen, 1996; Rahman et al., 2005]. 
The above-mentioned studies in both humans and mice/rats appear to support the proposal of 
Hofmann et al. (1983) that drugs, whether as a molecular solution, micellar preparation or a 
particulate dispersion, may be considered to be moved along the small intestine at the same net 
propulsive rate as food particles.  
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6.3.4 CAT and CTT of the AmB SLNs 
The human colon has over 400 distinct species of bacteria as resident flora, with a possible 
population of up to 1010 bacteria per gram of colonic contents [Chien, 1992]. Among the 
reactions carried out by these floras are azoreduction and enzymatic cleavage. The distribution 
of azoreductase and glucuronidase activity in the GI tracts of rats and rabbits has been found 
to be comparable with that in humans [Mooter and Kinget, 1995]. Metabolism of azo 
compounds by intestinal bacteria is one of the most extensively studied bacterial metabolic 
processes [Friend and Chang, 1985]. Colon targeted drug delivery systems have attracted 
considerable attention in developing drug delivery systems that are able to release drugs 
specifically in the colon in a predictable and reproducible manner, based mainly on the activity 
of flora in the colon. This makes the colon a site for both local and systemic delivery of drugs 
[Philip and Philip, 2010]. 
A number of transit studies on pellets or suspensions have estimated caecal arrival time as the 
time for the initial detection of SP in plasma [Peh and Yuen, 1996; Kondo et al., 2003(a,b); 
Rahman et al., 2005]. In the present study, T10S was used to estimate CAT of the AmB SLNs 
instead of the time for the first appearance of SP in plasma, which with most certainty is a result 
of SSZ released from the SLNs as solution and arriving at the caecum ahead of the SLNs. The 
arrival of this SSZ solution would lead to the hydrolysis of free SSZ and not the SSZ released 
from intact SLNs reaching the caecum and therefore will underestimate the CAT. The most 
accurate CAT estimation using initial SP detection in plasma would require more frequent 
blood sampling during the first few hours of the study, which is the main constraint in the use 
of the indirect approach.  
Figure 6.5 and Table 6.4 show the mean SP concentration-time profiles in plasma and the 
individual data obtained from the profiles, respectively. Both curves showed a similar 
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absorption pattern. Initially, there was a slight drop in plasma SP concentrations in both food 
statuses after which the plasma SP level rose and attained a Tmax at 8 hr.  
The first concentration point in each food status is due to the absorption of SP after colonic 
bacteria activity on released SSZ, which arrives at the colon relatively earlier than the SSZ 
SLNs. The slight drop in SP concentration thereafter can be attributed to a depleted source of 
this dissolved SSZ that arrived ahead of the SLNs, as well as the time lapse required for the 
release of SSZ from the SSZ SLNs, followed by microbial action by colonic bacteria when the 
SLNs were resident in the colon. The mean CAT was obtained as 1.80±0.81 hr in the fasted 
rats, and found to be 0.10 hr shorter than in the fed rats (p > 0.05). 
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Figure 6.5 Effect of food on the absorption of SP from SSZ SLNs in rat colon (n = 3) 
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Figure 6.6 shows the percentage SP absorption versus time curves in the fasted and fed 
conditions, from which T10S and T90S were obtained. A number of methods have been employed 
in measuring CTT in humans including the use of radio-opaque markers [Evans et al., 1999; 
Pomerri et al., 2007] and gamma scintigraphy [Burton et al., 1997; Bonapace et al., 2000], 
which involve tracking the time it takes for ingested markers to travel along the large bowel. 
In a study by Enck et al. (1989), a mean CTT value of 15.5 hr was obtained in rats fed ad 
libitum. In that study, a carmine red solution was infused into the caecum of the rats and the 
time for the first discharge of a red coloured faecal pellet was considered as CTT. 
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Figure 6.6 Mean SP absorption versus time curves in the fasted and fed rats (n = 3) 
 
Usually in CTT determination, subjects or animals are allowed to maintain their usual dietary 
intake and medications if any, provided the latter do not interfere with intestinal motility. In 
the present study, the mean CTT in the fasted rats was found to be 15.50 hr, which was 
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statistically shorter (p < 0.05) than that observed for the fed rats, which was 24.60 hr. The 
difference in CTT values observed in the present study with those reported by Enck et al. 
(1989) can be attributed to differences in the markers/methods used. In the present study, a 
suspension of nanoparticles was studied whereas Enck et al. (1989) used faecal discharge from 
the digestion of food administered to the animals to estimate CTT. This confirms that CTT 
varies for solids and liquids, and physiological variability exists in the colonic movements in 
different individuals [Ashford, 2001]. 
 
6.3.5 Estimated AmB absorption in the stomach, small intestine and colon 
In a preliminary formulation study, it has been shown that AmB is molecularly dispersed within 
the lipid matrix of the SLNs [Tan et al., 2014]. The data presented in the preceding chapters 
also showed that the three SLNs (AmB, PAR and SSZ) share identical physical characteristics; 
therefore, they were expected to respond similarly to the hydrodynamics of the GI tract. A 
molecularly dispersed arrangement of AmB within the lipid matrix favours prior interaction of 
the lipid with the intestinal epithelia and assimilation of the SLNs in the enterocytes and Peyer’s 
patches for lymphatic absorption [Bargoni et al., 1998; Müller et al., 2006; Li et al., 2009].  
The mean plasma AmB concentration-time profiles in the fasted and fed rats are depicted in 
Figures 6.7 and 6.8, respectively, and the pharmacokinetic data obtained from them have 
already been presented in Table 6.1. The first and second boundaries demarcated in the figures 
represent T10P and T10S, respectively, and the various regions within the profiles correlate the 
extent of absorption of AmB within the respective regions.  
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Figure 6.7 Absorption of AmB SLNs in the stomach, small intestine and colon in fasted 
rats  
 
 
 
Figure 6.8 Absorption of AmB SLNs in the stomach, small intestine and colon in the fed 
rats 
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Using TEM analysis, intact SLNs have been observed circulating in lymph and blood 30 min 
post duodenal administration of SLNs to rats [Bargoni et al., 1998]. Lymph contents are 
transported via lymph vessels into lymph nodes prior to emptying through the subclavian veins 
into blood. SLNs or drug particles in lymph will therefore appear in blood later although they 
may be detected in both lymph and blood at the same time. This is the reason the appearance 
of the second peak in the drug plasma profiles after oral administration of the SLNs in the 
present study is attributed to the process of particle uptake by Peyer’s patches and lymph, prior 
to drug emptying into the blood. This process is thus slow and hence AmB only appears in 
blood after a finite time. The latter is the basis for the “colon++” designated in Figures 6.7 and 
6.8. 
Absorption of the AmB SLNs in the colon++ regions is therefore attributable to a combination 
of absorption processes in the colon per se as well as the continued absorption process via 
lymph in the small intestines explained earlier. This means that plasma AmB concentration 
post CAT is not attributed solely to colonic drug absorption. At the present time, the proportion 
of AmB absorption occurring only in the colon against the same via lymph has not been 
established.  
The Cmax for AmB obtained from the fasted rats was well defined and significantly higher (p < 
0.05) than that in the fed group, signifying a more rapid rate of absorption of AmB from SLNs 
in the fasted state. There was no significant difference (p > 0.05) between the AUC0-30 values 
in the two groups. The absence of sharp peaks in the AmB absorption profile for the fed rats, 
and the relatively steady plasma concentration during the study period is a feature that can be 
exploited for controlled AmB delivery. 
Table 6.5 shows the estimated percentage absorptions of AmB from the SLNs in the various 
GI regions during the fasted and fed conditions, as obtained from Figure 6.9. In both cases, the 
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highest percentage absorption occurred in the colon++ region, indicating major colonic and 
lymphatic absorption. There was no statistically significant difference (p > 0.05) between the 
fasted and fed groups with regard to percentage absorptions in the respective GI regions (pair-
wise comparisons), confirming that although the presence of food slowed the rates of 
absorption of AmB SLNs, the extent of AmB absorption remained unchanged in either food 
status. The stomach presented the poorest percentage absorption of AmB albeit slightly higher 
in the fasted state. A significantly higher level of absorption occurred in the small intestines 
compared to the stomach; and slightly higher in the fasted state (44.1±10.7% and 37.2±16.0% 
obtained for the fasted and fed rats respectively). These findings agree with those obtained by 
Li et al. (2009) who indicated that the ileum and colon were the main GI segments where the 
absorption of quercetin-containing SLNs occurred. 
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Figure 6.9 Cumulative percentage absorption of AmB under fasted and fed conditions  
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Table 6.5 Estimated percentage absorption of AmB from SLNs in the stomach, small 
intestine and colon (n = 3) 
 
 
Rat    
No. 
 
 
Fasted 
 
Fed 
Stomach 
(%) 
Small 
intestine 
(%) 
Colon++ 
(%) 
 Stomach 
(%) 
Small 
intestine 
(%) 
Colon++ 
(%) 
1  3.4 53.5 43.1 1.9 19.8 78.3 
2  3.4 32.4 64.2 
 
3.8 40.4 55.8 
3  1.5 46.4 52.1  4.0 51.3 44.7 
Mean  2.8 44.1 53.1 3.2 37.2 59.6 
SD  1.1 10.7 10.6 
 
1.2 16.0 17.1 
 
Generally, little drug absorption occurs in the stomach due to its relatively smaller surface area 
however, gastric emptying can be rate limiting to the onset of drug absorption from the small 
intestine [Ashford, 2001]. The small intestine has a very large surface area provided by the villi 
and microvilli, and the intestinal wall is enriched with a network of blood and lymphatic 
vessels, all of which aid in absorption. The lymphatic system is important in the absorption of 
fats from the GI tract. Blood leaving the small intestine flows into the hepatic portal vein and 
into systemic circulation via the liver; therefore, drugs that are metabolised by the liver reach 
systemic circulation in lower concentrations. The colon, unlike the small intestine has no 
specialised villi; however, the microvilli of the absorptive epithelial cells, the presence of 
crypts, and the irregularly folded mucosae serve to increase the surface area of the colon. The 
surface area nevertheless remains approximately 1/30th that of the small intestine. 
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In addition, because of the high water absorption capacity of the colon, colonic contents are 
considerably viscous and their mixing is not efficient, thus availability of most drugs to the 
absorptive membrane is low [Chien, 1992]. As a result of these anatomical differences, the 
small intestine is generally better suited for drug absorption. 
As previously mentioned, the “colon++ absorption” is a summation of AmB absorption in the 
colon and lymphatic absorption from the small intestine. From the late detection of AmB that 
resulted in the second peak in the plasma profiles, it could be inferred that further AmB SLN 
absorption via lymphatic tissue in the colon may lead to significant blood levels of AmB after 
the 30th hour sampling time. 
Lymphatic tissues in the colon, rectum and appendix vermiformis are fewer and not discrete 
like the Peyer’s patches and isolated lymphoid follicles in the small intestine but rather, they 
occur diffusely in aggregated masses at irregular intervals, with the exception of the proximal 
colonic patches in rodents [Owen et al., 1991]. Uchida et al. (1988) observed the presence of 
M cells in the colon, which suggests that particles that are micron-sized or smaller may also be 
absorbed in this region of the GI tract.  
Although the absorption of particulates is mostly investigated in the small intestine, there are 
a few reports documenting lymphatic uptake of particulate material from the large intestine. 
Earlier studies have shown the absorption of colloidal gold in normal and inflamed colonic 
tissues of patients as well as in the rectal area [D’Addabbo et al., 1969; Fukai et al., 1987].  
Other studies on particulate absorption further suggest that while micron-sized particles cannot 
breach the intestinal barrier effectively, once in the sub-mucosal tissue, they are able to enter 
both capillaries and lymphatics leading to systemic dissemination. Some studies in rats have 
shown colonic absorption of both uncoated and surface-modified nanoparticles to also be a 
size-dependent process [Jani et al., 1990; Jani et al., 1994; Hillery et al., 1994].   
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These studies indicate that the high percentage of AmB SLN absorption of more than 53% that 
was observed in the colon++ in both fasted and fed conditions may be inclusive of particulate 
absorption via lymphoid tissues in the colon. 
 
6.4 Conclusions 
An indirect method was used to study the GI transit of AmB SLNs and the data obtained 
indicate that, the presence of food slowed the rate of absorption of AmB from SLNs but the 
extent of absorption remained essentially unchanged as AUC was not significantly different in 
fasted and fed rats. Furthermore, the percentage AmB absorption was lowest in the stomach 
region but significantly higher in the small intestine, and this process was slow to manifest but 
continued post caecal arrival of the SLNs. Some absorption of AmB appears to occur in the 
colon however, this amount is masked by the continued lymphatic absorption process in the 
small intestine resulting in late AmB appearance in the plasma. 
Specifically, the percentage AmB absorption during the fasted state in the stomach, small 
intestine and colon were not significantly different from absorption within the respective 
regions in the fed state. In both states however, absorption was highest in the colon and 
appeared to be a combination of lymphatic absorption from the small intestine plus absorption 
proper within the colon. Absorption of the SLNs via lymphoid tissues in the colon is also 
postulated. 
The study suggests that AmB SLNs irrespective of food status are slowly but well taken up in 
lymph, making the small intestine the most favourable site for the delivery of the AmB SLNs. 
As a result, a formulation process aimed at slowing down the transit time of the AmB SLNs in 
the small intestine would be beneficial to obtain a higher oral bioavailability. 
248 
 
CHAPTER 7 
SUMMARY AND GENERAL CONCLUSIONS 
Presently, there is no oral AmB product for clinical use, which makes research into oral AmB 
formulations as alternatives to the currently available yet costly intravenous formulations a 
growing interest. This is because AmB is a very useful antifungal agent but with serious side 
effects and as a result, is only used in severely ill patients who are usually 
immunocompromised. AmB is practically insoluble in water therefore, studies using lipid-
based delivery systems to make the drug orally bioavailable with better tolerability are 
developing. In this project, AmB has been formulated into SLNs to achieve the aforementioned 
benefit. There is limited research on the GI transit behaviour of oral AmB preparations, a need 
that has been met in the present study. SLN formulations containing either AmB, PAR or SSZ 
were successfully formulated using an identical method based on the emulsification solvent 
diffusion technique, with the aim of using the latter two drugs as indirect markers to investigate 
the transit of the AmB SLNs. The effectiveness of the preparation method resulted in good 
encapsulation efficiencies (> 60%), with AmB having the highest of 91.2±3.04%. The z-
average diameters of the freshly made particles ranged from 206.5 to 224.8 nm and the PDI 
values were 0.161-0.218. All three SLNs showed very good colloidal stability evident from the 
high zeta potential values which were > |60 mV|. The SLNs had other matching physical 
characteristics as regards shape and morphology, investigated using SEM and AFM. The 
mobility propensities of the particles were also determined using their migration time in a gel 
electrophoresis study, in which all three SLNs were observed to move similarly through the 
gel. The images obtained from the study showed that all the three SLNs travelled a similar 
distance of 22.2-22.4 mm after voltage application. This together with other similarities in 
physical properties was a clear indication of the suitability of employing the markers in 
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investigating the GI transit and absorption of the AmB SLNs. DSC studies showed that the 
drugs were in their amorphous forms in the lipid matrices and no polymorphic transitions had 
occurred. These further pointed to the stability of the systems. Storage of the SLNs at 4-8°C 
for 24 months, and freeze-drying did not significantly change the physical characteristics of 
the SLNs as their final properties as regards size, PDI and zeta potential were optimum for 
absorption via the oral route. The data obtained from in vitro release studies showed the AmB 
SLNs exhibited the lowest drug release (< 20% over 8 hr) among the three formulations. Such 
low drug release was very favourable in the quest for an AmB formulation with improved oral 
bioavailability via absorption of intact SLNs containing a high drug load, improved tolerability, 
and reduced or no systemic toxicity. The SLNs were subjected to tests in simulated 
gastrointestinal media in order to assess the stability of the particles after contact with GI fluids 
following oral administration. Using PCS, NTA and ToF-SIMS in the analyses, the data 
obtained indicated an inflow of the fluids into the SLNs followed by outward diffusion of the 
dissolved drug from the particles. The study showed NTA as a more suitable technique for 
analysing the stability of the SLNs in the various media as compared with PCS, as the latter 
showed bias towards larger particles and produced data suggestive of high particle aggregation. 
Overall, the data obtained indicated that the SLNs after oral ingestion may aggregate or 
increase in size after contact with GI fluids particularly in the stomach, possibly due to the low 
pH. However, on reaching the small intestine, both size and surface charge of the particles 
would be optimal for absorption indicating good stability; this is because the formulations had 
mean sizes < 350 nm and were either neutral or negatively charged after exposure to simulated 
gastric fluid followed by simulated intestinal fluid, which mimics GE. The mass spectra 
obtained from the ToF-SIMS analyses indicated that drug loading into the SLNs possibly 
followed the core-shell model, and that the AmB SLNs may have a drug-enriched core. 
Generally, the spectra corroborated the data obtained from the NTA, in that, a higher drug 
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count was observed on particles which had decreased in size as a result of drug diffusion from 
within the particles to the surfaces after incubation in a medium and vice versa, demonstrating 
that particle size is proportional to drug load. A two-step HPLC method that was developed 
and validated for the simultaneous assay of AmB, PAR and SP in rat plasma was found to be 
simple, rapid, accurate and reliable. Piroxicam was found to be a suitable internal standard for 
the analyses. Significantly, the method required a small volume of plasma, which is important 
for pharmacokinetic studies in rats, which were used as the animal model. A pilot study was 
conducted to validate the HPLC method and optimise sample collection time intervals. The 
data obtained indicated that AmB in SLNs was absorbed slowly but significantly from the small 
intestine. In the main study, the effect of food on the GI transit and absorption of the AmB 
SLNs was studied. The results from both fasted and fed rats showed a significant increase in 
bioavailability after incorporating AmB into SLNs as Cmax and AUC values from the SLNs 
were statistically higher than the respective values for AmB suspended in water only. Food 
slowed the rate of AmB absorption from the SLNs; however, it was observed that the extent of 
absorption remained essentially unchanged as it was not significantly different in fasted and 
fed rats. It was also noted that percentage AmB absorption in the fasted state in the stomach, 
small intestine and colon were not significantly different from absorption in the respective 
regions in the fed state. In both states however, absorption was highest in the colon and 
appeared to be a combination of lymphatic absorption from the small intestine plus absorption 
proper within the colon. Absorption of the SLNs via lymphoid tissues in the colon was also 
postulated. The study suggested that AmB SLNs, irrespective of food status, are slowly but 
well taken up via lymph, making the small intestine the most favourable site for the delivery 
of the AmB SLNs. As a result, a formulation process aimed at slowing the transit time of the 
SLNs in the small intestine would result in a higher oral bioavailability. It could be concluded 
that the use of SLNs eliminated any variabilities in AmB absorption due to fasted and fed states. 
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CHAPTER 8 
SUGGESTIONS FOR FUTURE WORK 
The research on improving the oral bioavailability of amphotericin B (AmB) using lipid-based 
drug delivery systems is gaining a lot of interest. The solid lipid nanoparticulate formulation 
of AmB presented herein shows a lot of promise for use in clinical settings as such, listed below 
are some suggestions for future work: 
 
 Effect of the AmB SLN formulation on renal toxicity in rats 
The nephrotoxicity caused by AmB manifests as renal vasoconstriction with substantial 
decrease in glomerular filtration rate and renal blood flow, and also renal potassium and 
magnesium wasting [Barton et al., 1984; Sawaya et al., 1995]. Some lipid-based AmB 
preparations have already been shown to exhibit less or no nephrotoxicity when compared with 
the free drug or AmB deoxycholate [Risovic et al., 2003; Gershkovich et al., 2009; Jain et al., 
2012] however, future work aimed at evaluating the AmB SLNs in reducing renal toxicity 
caused by AmB has to be conducted. 
Blood urea nitrogen and plasma creatinine levels can be used as biochemical markers to 
evaluate the nephrotoxicity. Risovic et al. (2003) have used a 50% increase in plasma creatinine 
concentration from the baseline as the criterion for detecting renal toxicity; however, a 
statistically significant increment in plasma creatinine after dose administration may signify 
renal toxicity.  
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 Modifications in the formulation procedure to further improve oral bioavailability 
The encapsulation efficiency of the AmB SLNs obtained in this study (91.2%) was a significant 
improvement on the lipid formulation previously prepared, which was less than 50%. This 
indicates that further modifications in the nanoparticle production parameters could result in a 
higher encapsulation efficiency, which with most certainty will translate to a higher oral 
bioavailability. 
It was observed in this study that the transit of the SLNs in the GI tract was similar to that of 
food particles and other dosage forms. It has also been shown that there is major lymphatic 
absorption of the SLNs. These indicate that slowing down the transit of the SLNs in the GI 
tract is likely to result in a higher lymphatic uptake. The addition of mucoadhesive agents to 
the formulation, preferably as a coating around the SLNs, could be used to achieve this. 
 
 Studies to ascertain the proportion of AmB SLNs absorbed in the colon only 
The results from the present study indicate significant absorption of the AmB SLNs after arrival 
of the particles in the colon, pointing to a combination of continuous lymphatic absorption and 
colonic absorption itself. It would therefore be valuable to investigate the proportion of SLN 
absorption that occurs only in the colon using rats as the animal model. 
Monitoring plasma AmB levels after dose administration into the duodenum [A], followed by 
a suitable washout period, and then a separate pharmacokinetic study after caecal delivery of 
the SLNs [B] would give useful data on colonic absorption. A suitable protocol has to be 
developed for surgery in the animals to aid dose administration and also, the blood sampling 
period in study A should be a summation of the sampling time in study B and the caecal arrival 
time of the SLNs, in order to obtain accurate results. 
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 Bioequivalent studies with commerciably available formulations 
As an alternative to the currently available formulations of AmB are being sought due to the 
associated side effects, cost and the general inconvenience of intravenous drug delivery, it 
would be worthwhile to conduct bioequivalence studies to compare the bioavailability of the 
oral AmB SLNs with those of the parenteral products which are presently in clinical use. 
 
 Investigating the long term effects of the AmB SLNs 
The treatments of fungal infections such as aspergillosis, severe invasive candidiasisis and 
other mycoses, as well as leishmaniasis often last several days to several months. AmB is 
usually the drug of choice for treating these systemic infections. It is therefore necessary that 
possible toxic effects of the AmB SLNs due to long-term use be investigated. 
 
 Improving the storage stability of the AmB SLNs 
The AmB SLN suspension was found to be stable over a 24-month storage period at 4-8°C, 
and the freeze-dried product was also found to possess similar physical properties as the freshly 
prepared formulation. These two situations indicate that an optimised freeze-dried SLN product 
will have a reasonably long shelf life if a careful study of the variables in the freeze-drying 
process is done, and an appropriate cryoprotectant is selected for use. Trehalose has been found 
in many studies to be the most suitable cryoprotectant for several SLN formulations [Cavalli 
et al, 1997; Schwarz and Mehnert, 1997; Heiati et al., 1998; Mehnert and Mäder, 2001] 
therefore, preliminary studies may be conducted using trehalose. 
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